U.S. patent application number 14/901617 was filed with the patent office on 2016-10-13 for dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis.
The applicant listed for this patent is Baylor Research Institute. Invention is credited to SangKon Oh, Gerard Zurawski.
Application Number | 20160296609 14/901617 |
Document ID | / |
Family ID | 52142738 |
Filed Date | 2016-10-13 |
United States Patent
Application |
20160296609 |
Kind Code |
A1 |
Oh; SangKon ; et
al. |
October 13, 2016 |
DENDRITIC CELL ASGPR TARGETING IMMUNOTHERAPEUTICS FOR MULTIPLE
SCLEROSIS
Abstract
Methods and compositions for treating multiple sclerosis using
dendritic cell anti-ASGPR antibodies fused to myelin basic protein
or myelin oligodendrocyte glycoprotein provided.
Inventors: |
Oh; SangKon; (Baltimore,
MD) ; Zurawski; Gerard; (Midothian, TX) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Baylor Research Institute |
Dallas |
TX |
US |
|
|
Family ID: |
52142738 |
Appl. No.: |
14/901617 |
Filed: |
June 27, 2014 |
PCT Filed: |
June 27, 2014 |
PCT NO: |
PCT/US14/44711 |
371 Date: |
December 28, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61841094 |
Jun 28, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 16/28 20130101;
A61K 2039/577 20130101; A61P 25/00 20180101; C07K 2319/33 20130101;
A61P 25/28 20180101; A61P 37/02 20180101; C07K 14/46 20130101; A61K
2039/505 20130101; A61K 39/0008 20130101 |
International
Class: |
A61K 39/00 20060101
A61K039/00; C07K 14/46 20060101 C07K014/46; C07K 16/28 20060101
C07K016/28 |
Claims
1. A method of inducing immune tolerance to at least one myelin
sheath protein in a patient comprising administering to the patient
an effective amount of a composition comprising a dendritic cell
targeting complex comprising a dendritic cell antibody, or
targeting fragment thereof, attached to the at least one myelin
sheath protein, or antigenic fragment thereof.
2. The method of claim 1, wherein at least one myelin sheath
protein is myelin basic protein (MBP), myelin oligodendrocyte
glycoprotein (MOG), proteolipid protein (PLP), or myelin associated
glycoprotein (MAG).
3. The method of claim 2, wherein at least one myelin sheath
protein is MBP.
4. The method of claim 2, wherein at least one myelin sheath
protein is MOG.
5. The method of any of claims 1-4, wherein the dendritic cell
antibody specifically binds asialoglycoprotein receptor
(ASGPR).
6. The method of any of claims 1-5, wherein the composition
comprises multiple dendritic cell targeting complexes.
7. The method of claim 6, wherein the multiple dendritic cell
targeting complexes comprise different myelin sheath proteins or
different antigenic fragments of one or more myelin sheath
proteins.
8. The method of claim 6 or 7, wherein each myelin sheath protein
or antigen fragment is separately attached to a dendritic cell
antibody, or a targeting fragment thereof.
9. The method of any of claims 1-8, wherein the dendritic cell
antibody is attached to the myelin sheath protein using a peptide
linker.
10. The method of any of claims 1-9, wherein the composition
further comprises at least one tolerogenic adjuvant.
11. The method of claim 10, wherein the tolerogenic adjuvant is
attached to the dendritic cell targeting complex.
12. The method of claim 11, wherein the tolerogenic adjuvant is
conjugated to the dendritic cell targeting complex.
13. The method of claim 11, wherein the tolerogenic adjuvant is
fused to the dendritic cell antibody, or targeting fragment
thereof, and/or to the at least one myelin sheath protein.
14. The method of any of claims 10-13, wherein the tolerogenic
adjuvant is selected from IL-10, dexamethasone, FK506 (Tacrolimus),
cholera toxin B subunit, Escherichia coli heat-labile enterotoxin B
subunit, IFN-beta, glucocorticoids, vitamin D3, and vitamin D3
analogues.
15. The method of any of claims 1-14, wherein the dendritic cell
antibody is attached to at least one myelin sheath protein through
binding polypeptides.
16. The method of claim 15, wherein the binding polypeptides are
dockerin and cohesin.
17. The method of any of claims 1-16, comprising more than one
administration of the composition.
18. The method of any of claims 1-16, wherein the composition is
administered orally, intravenously, subcutaneously, intradermally,
intramuscularly, nasally, by injection, by inhalation, mucosally,
and/or using a nebulizer.
19. The method of any of claims 1-18, wherein the subject exhibits
one or more symptoms of a demyelinating disease.
20. The method of any of claims 1-19, wherein the subject has been
diagnosed with a demyelinating disease.
21. The method of any of claims 1-20, wherein the subject is at
risk for a demyelinating disease.
22. The method of any of claims 19-21, wherein the demyelinating
disease affects the central nervous system.
23. The method of claim 22, wherein the demyelinating disease is an
idiopathic inflammatory demyelinating disease.
24. The method of claim 22, wherein the demyelinating disease is
multiple sclerosis, neuropathy, central pontine myelinolysis, tabes
dorsalis, transverse myelitis, Devic's disease, progressive
multifocal leukoencephalopathy, optic neuritis, or
leukodystrophy.
25. The method of claim 24, wherein the demyelinating disease is
multiple sclerosis.
26. The method of any of claims 19-21, wherein the demyelinating
disease affects the peripheral nervous system.
27. The method of claim 26, wherein the demyelinating disease is
Guillain-Barre syndrome, chronic inflammatory demyelinating
polyneuropathy, anti-MAG peripheral neuropathy, Charcot-Marie-Tooth
Disease, copper deficiency, or progressive inflammatory
neuropathy.
28. The method of any of claims 1-24, further comprising preparing
the composition.
29. The method of any of claims 1-28, further comprising measuring
antibodies against the at least one myelin sheath protein in the
subject after administering the composition.
30. A method for treating a demyelinating disease in a subject
comprising administering to the subject a pharmaceutically
acceptable vaccine composition comprising at least a first ASGPR
antibody, or binding fragment thereof, attached to myelin basic
protein (MBP) and/or myelin oligodendrocyte glycoprotein (MOG), or
antigenic fragment thereof.
31. The method of claim 30, wherein the ASGPR antibody, or binding
fragment thereof, is fused to MBP or MOG, or an antigenic fragment
thereof.
32. The method of claim 30 or 31, wherein the subject is
administered the vaccine composition multiple times.
33. The method of claim 32, wherein the composition is administered
orally, intravenously, subcutaneously, intradermally,
intramuscularly, nasally, by injection, by inhalation, muscosally,
and/or using a nebulizer.
34. The method of any of claims 30-33, wherein the subject exhibits
one or more symptoms of a demyelinating disease.
35. The method of any of claims 30-33, wherein the subject has been
diagnosed with a demyelinating disease.
36. The method of any of claims 30-33, wherein the subject is at
risk for a demyelinating disease.
37. The method of any of claims 34-36, wherein the demyelinating
disease affects the central nervous system.
38. The method of claim 37, wherein the demyelinating disease is an
idiopathic inflammatory demyelinating disease.
39. The method of claim 38, wherein the demyelinating disease is
multiple sclerosis, neuropathy, central pontine myelinolysis, tabes
dorsalis, transverse myelitis, Devic's disease, progressive
multifocal leukoencephalopathy, optic neuritis, or
leukodystrophy.
40. The method of claim 39, wherein the demyelinating disease is
multiple sclerosis.
41. The method of any of claims 34-36, wherein the demyelinating
disease affects the peripheral nervous system.
42. The method of claim 41, wherein the demyelinating disease is
Guillain-Barre syndrome, chronic inflammatory demyelinating
polyneuropathy, anti-MAG peripheral neuropathy. Charcot-Marie-Tooth
Disease, copper deficiency, or progressive inflammatory
neuropathy.
43. The method of any of claims 30-42, further comprising preparing
the composition.
44. The method of any of claims 30-43, further comprising measuring
antibodies against the at least one myelin sheath protein in the
subject after administering the composition.
45. A composition comprising at least a first ASGPR antibody, or
binding fragment thereof, attached to myelin basic protein (MBP)
and/or myelin oligodendrocyte glycoprotein (MOG), or antigenic
fragment thereof.
46. The composition of claim 45, wherein the dendritic cell
antibody is attached to the myelin sheath protein or antigenic
fragment thereof using a peptide linker.
47. The composition of any of claims 45-46, wherein the composition
further comprises at least one tolerogenic adjuvant.
48. The composition of claim 47, wherein the tolerogenic adjuvant
is attached to the dendritic cell targeting complex.
49. The composition of claim 48, wherein the tolerogenic adjuvant
is conjugated to the dendritic cell targeting complex.
50. The composition of claim 48, wherein the tolerogenic adjuvant
is fused to the dendritic cell antibody, or targeting fragment
thereof, and/or to the at least one myelin sheath protein.
51. The composition of any of claims 47-50, wherein the tolerogenic
adjuvant is selected from IL-10, dexamethasone, FK506 (Tacrolimus),
cholera toxin B subunit, Escherichia coli heat-labile enterotoxin B
subunit, IFN-beta, glucocorticoids, vitamin D3, and vitamin D3
analogues.
52. The composition of any of claims 45-51, wherein the dendritic
cell antibody is attached to at least one myelin sheath protein or
antigenic fragment thereof through binding polypeptides.
53. The composition of claim 52, wherein the binding polypeptides
are dockerin and cohesin.
Description
[0001] This application claims the benefit of priority to U.S.
Provisional Patent Application Ser. No. 61/841,094, filed Jun. 28,
2013, which is hereby incorporated by reference in its
entirety.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention relates generally to the field of
medicine. More particularly, it concerns methods and compositions
for treating multiple sclerosis using dendritic cell anti-ASGPR
antibodies fused to myelin basic protein or myelin oligodendrocyte
glycoprotein.
[0004] 2. Description of Related Art
[0005] The inappropriate immune response of the body against
substances and tissues normally present in the body is thought to
give rise to autoimmune diseases (autoimmunity).
[0006] Autoimmunity may be restricted to certain organs or involve
a particular tissue in different places. While the treatment of
autoimmune diseases is typically with immunosuppression--medication
that decreases the immune response, the repertoire of these drugs
can be limited and in some instances is insufficient to treat the
underlying condition. As a large number of autoimmune diseases are
recognized, treatment of these represents a substantial human
health issue. Multiple sclerosis (MS), also known as disseminated
sclerosis or encephalomyelitis disseminata, is an inflammatory
disease in which myelin sheaths around axons of the brain and
spinal cord are damaged, leading to loss of myelin and scarring. In
some instances, the underlying mechanism is thought to be either
destruction by the immune system. These changes affect the ability
of nerve cells to communicate resulting in a wide range of signs
and symptoms.
SUMMARY OF THE INVENTION
[0007] Methods and compositions are provided that can be used to
induce immune tolerance in autoimmune diseases or conditions.
Specifically contemplated are immunotherapeutic compositions and
methods of administering these compositions to patients.
Embodiments are focused on compositions that target myelin sheath
proteins or components to dendritic cells (DC) through receptor
mediated endocytosis by targeting specific DC receptors with
specific antibodies.
[0008] In some embodiments, a method of inducing immune tolerance
to at least one myelin sheath protein in a patient is provided. In
certain embodiments, the method comprises administering to the
patient an effective amount of a composition comprising a dendritic
cell targeting complex comprising a dendritic cell antibody, or
targeting fragment thereof, attached to the at least one myelin
sheath protein, or antigenic fragment thereof. In other
embodiments, the myelin sheath protein is myelin basic protein
(MBP), myelin oligodendrocyte glycoprotein (MOG), proteolipid
protein (PLP), or myelin associated glycoprotein (MAG). In certain
aspects the composition comprising a dendritic cell targeting
complex comprising a dendritic cell antibody, or targeting fragment
thereof, attached to the at least one myelin sheath protein, or
antigenic fragment thereof is considered an immunotherapeutic.
[0009] In some embodiments, the immunotherapeutic comprises
multiple myelin sheath proteins or myelin sheath components. In
certain embodiments at least one myelin sheath protein of the
immunotherapeutic is MBP. In other embodiments at least one myelin
sheath protein of the immunotherapeutic is MOG.
[0010] In certain embodiments the dendritic cell antibody or
fragment thereof of the dendritic cell targeting complex
specifically binds asialoglycoprotein receptor (ASGPR). In yet
other embodiments, dendritic cell targeting complex composition
comprises multiple dendritic cell targeting complexes. In other
aspects the multiple dendritic cell targeting complexes comprise
different myelin sheath proteins or different antigenic fragments
of one or more myelin sheath proteins. In still other aspects the
myelin sheath protein or antigen fragment is separately attached to
a dendritic cell antibody, or a targeting fragment thereof In
certain aspects dendritic cell antibody is attached to the myelin
sheath protein using a peptide linker. There are different ways in
which the antibody or antigenic fragment is attached to the myelin
sheath protein. In some embodiments, they are attached directly. In
certain embodiments, the antibody or antigenic fragment is attached
to the myelin sheath protein through one or more covalent bonds. It
is specifically contemplated that there may be a single polypeptide
that includes the antibody or antigenic fragment and one or more
myelin sheath proteins (or fragments thereof). Such a polypeptide
may be described as a fusion protein if the two parts are attached
covalently through peptide bonds (with or without a peptide
linker). Such a fusion protein with an ASGPR antibody (or antibody
fragment) and a myelin sheath protein (or fragment thereof) would
not be naturally occurring.
[0011] Certain embodiments include an immunogenic composition
comprising an isolated polypeptide comprising at least or at most
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,
38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103,
104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,
117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129,
130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142,
143, 144, 145, 146, 147, 148, 149, 150 or more amino acids of SEQ
ID NO: 42-53, including all values and ranges there between. In a
further aspect the isolated polypeptide is a fusion protein. The
composition can comprise an adjuvant. In certain aspects the
isolated polypeptide is a fusion protein and/or a lipopeptide.
[0012] Embodiments include compositions that include a polypeptide,
peptide, or protein that is or is at least 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, or 99% identical or similar to any of SEQ ID
NO: 42-53. Similar polypeptides, peptides and proteins, in some
embodiments, are limited to those proteinaceous compounds whose
substitutions are only with conservative amino acids. In other
embodiments, only conservative substitutions are contemplated,
while in others, deletions of nonessential amino acids or the
addition of other amino acids in an area that is not involved in
the compound's function are contemplated. In a further embodiment,
a composition may include a polypeptide, peptide, or protein that
is or is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or
99% identical or similar to a ASGPR binding polypeptide, such as
mAnti-ASGPR_49C11_7H (heavy chain) SEQ ID NO:42,
mAnti-ASGPR_49C11_7K (light chain) SEQ ID NO:43,
manti-hASGPR_6.3H9.1D11H (heavy chain) SEQ ID NO: 44,
manti-hASGPR_6.3H9.1D11K (light chain) SEQ ID NO: 45,
manti-hASGPR_5H8.1D4H (heavy chain) SEQ ID NO: 46,
manti-hASGPR_5H8.1D4K (light chain) SEQ ID NO: 47,
mAnti-ASGPR_4G2.2_(heavy chain) SEQ ID NO: 48,
mAnti-ASGPR_4G2.2_(light chain) SEQ ID NO: 49,
mAnti-ASGPR-5F10H(heavy chain) SEQ ID NO: 50,
mAnti-ASGPR-5F10H(light chain) SEQ ID NO: 51, mAnti-ASGPR1H11
(heavy chain) SEQ ID NO: 52, or mAnti-ASGPR1H11(light chain) SEQ ID
NO: 53.
[0013] The ASGPR binding polypeptides described herein may include
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36,
37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53,
54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,
88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more variant
amino acids within at least, or at most 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78,
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,
96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109,
110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122,
123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135,
136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148,
149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161,
162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174,
175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187,
188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,
201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213,
214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226,
227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239,
240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 300, 400,
500, 550, 1000 or more contiguous amino acids, or any range
derivable therein, of any of SEQ ID NO: 42-53.
[0014] In particular embodiments, the immunotherapeutic, DC
targeting complex or ASGPR binding polypeptide is purified, which
may be accomplished with or without minimal denaturation. In some
aspects, the immunotherapeutic, DC targeting complex or ASGPR
binding polypeptide is active, meaning the immunotherapeutic, DC
targeting complex or ASGPR binding polypeptide retains some
detectable level of function or activity, such as those described,
including binding ability. It is contemplated that the
immunotherapeutic, DC targeting complex or ASGPR binding
polypeptide may be purified to about, at least about, or at most
about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 100%
purity or homogeneity (with respect to other proteinaceous
molecules and/or cellular macromolecules), or any range derivable
therein. In additional embodiments, the recombinant
immunotherapeutic, DC targeting complex or ASGPR binding
polypeptide may be isolated. The term "isolated" can refer to a
nucleic acid or polypeptide that is substantially free of cellular
material, bacterial material, viral material, or culture medium
(when produced by recombinant DNA techniques) of their source of
origin, or chemical precursors or other chemicals (when chemically
synthesized). Moreover, an isolated compound refers to one that can
be administered to a subject as an isolated compound; in other
words, the compound may not simply be considered "isolated" if it
is adhered to a column or embedded in an agarose gel. Moreover, an
"isolated nucleic acid fragment" or "isolated peptide" is a nucleic
acid or protein fragment that is not naturally occurring as a
fragment and/or is not typically in the functional state.
[0015] Furthermore, in certain embodiments of the current methods,
methods may involve compositions containing about, at least about,
or at most about 0.1, 0.2, 0.3, 0.4, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0,
3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5,
10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0,
15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0. 19.5, 20.0, 21, 21,
22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,
73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140,
150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270,
280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400,
410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520,
530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650,
660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780,
790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910,
920, 930, 940, 950, 960, 970, 980, 990, or 1000 .mu.g or mg of
protein (or any range derivable therein). The protein may be in
about, at least about, or at most about 0.1, 0.2, 0.3, 0.4, 0.5,
0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8,
1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1,
3.2, 3.3, 3.4, 3.5, 3.6, 3.7. 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4,
4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7,
5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0,
7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3,
8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 10, 11, 12, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,
51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,
68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100,
110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230,
240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360,
370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480,
490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610,
620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740,
750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870,
880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000
.mu.l or ml (or any range derivable therein). In certain aspects,
one or more immunotherapeutics, DC targeting complexes or ASGPR
binding polypeptides can be administered as a dose of 0.1, 0.2,
0.3, 0.4, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5,
6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5,
12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0,
17.5, 18.0, 18.5, 19.0. 19.5, 20.0, 21, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78,
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,
96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190,
200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320,
330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441,
450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570,
580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700,
710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830,
840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960,
970, 980, 990, or 1000 mg per kg of body weight.
[0016] In particular embodiments, the immune tolerance response
elicited by the immunotherapeutic or dendritic cell targeting
complex may be complemented, supplemented, increased or augmented.
In certain aspects the immune tolerance response elicited by the
immunotherapeutic or dendritic cell targeting complex may be
complemented, supplemented, increased or augmented by an adjuvant.
In certain aspects the adjuvant is a tolerogenic adjuvant. In
certain embodiments the immunotherapeutic or dendritic cell
targeting complex composition further comprises at least one
tolerogenic adjuvant. In certain aspects the tolerogenic adjuvant
is attached to the dendritic cell targeting complex. In other
aspects, the tolerogenic adjuvant is conjugated to the dendritic
cell targeting complex. In still other aspects, the tolerogenic
adjuvant is fused to the dendritic cell antibody, or targeting
fragment thereof, and/or to the at least one myelin sheath protein.
In specific embodiments, the tolerogenic adjuvant is selected from
IL-10, dexamethasone, FK506 (Tacrolimus), cholera toxin B subunit,
Escherichia coli heat-labile enterotoxin B subunit, IFN-beta,
glucocorticoids, vitamin D3, and vitamin D3 analogues.
[0017] In particular embodiments, the use of binding polypeptides
is contemplated to fuse, conjugate or bring together separate
polypeptides, portions or modules of the immunotherapeutic or
dendritic cell targeting complex. In certain aspects, the dendritic
cell antibody or fragment thereof is attached to at least one
myelin sheath protein through binding polypeptides. In specific
embodiments, the binding polypeptides are dockerin and cohesin.
[0018] In certain aspects, administering to the patient an
effective amount of a composition comprising a dendritic cell
targeting complex comprises more than one administration of the
composition. In certain aspects, the composition is administered
orally, intravenously, subcutaneously, intradermally,
intramuscularly, nasally, by injection, by inhalation, and/or using
a nebulizer.
[0019] In particular aspects, the methods and compositions
described are aimed at treating, preventing, ameliorating,
suppressing, resolving, improving or otherwise addressing the
symptoms of a subject or patient with an autoimmune disorder,
disease or condition. In certain aspects, the subject exhibits one
or more symptoms of a demyelinating disease. In other embodiments,
the subject has been diagnosed with a demyelinating disease. In
still other embodiments, the subject is at risk for a demyelinating
disease. In specific embodiments, the demyelinating disease affects
the central nervous system. In other specific embodiments, the
demyelinating disease is an idiopathic inflammatory demyelinating
disease. In certain aspects the demyelinating disease is multiple
sclerosis, neuropathy, central pontine myelinolysis, tabes
dorsalis, transverse myelitis, Devic's disease, progressive
multifocal leukoencephalopathy, optic neuritis, or leukodystrophy.
In some embodiments, the demyelinating disease is one of the
borderline forms of multiple sclerosis. In some aspects, the
borderline form of multiple sclerosis is standard multiple
sclerosis, Remitent-Recidivant multiple sclerosis (RRMS), Secondary
Progressive multiple sclerosis (SPMS), Primary progressive multiple
sclerosis (PPMS), KIR4.1 multiple sclerosis, Optic-spinal multiple
sclerosis, Opticospinal multiple sclerosis, Devic's disease, acute
disseminated encephalomyelitis (ADEM), acute hemorrhagic
leukoencephalitis, Balo concentric sclerosis, Schilder disease,
diffuse myelinoclastic sclerosis, Marburg multiple sclerosis,
malignant multiple sclerosis, fulminant multiple sclerosis, acute
multiple sclerosis, Tumefactive multiple sclerosis, or Solitary
sclerosis. In yet other embodiments the demyelinating disease is
Susac's syndrome, myalgic encephalomyelitis or leukoaraiosis.
[0020] In other specific embodiments, the demyelinating disease is
multiple sclerosis. In certain aspects the demyelinating disease
affects the peripheral nervous system. In additional embodiments
the demyelinating disease is Guillain-Barre syndrome, chronic
inflammatory demyelinating polyneuropathy, anti-MAG peripheral
neuropathy, Charcot-Marie-Tooth Disease, copper deficiency, or
progressive inflammatory neuropathy.
[0021] In certain aspects, the methods described comprising a
dendritic cell targeting complex and/or immunotherapeutic further
comprise preparing the composition. In other embodiments, the
methods further comprise measuring antibodies against the at least
one myelin sheath protein in the subject after administering the
composition.
[0022] In some aspects, a method for treating a demyelinating
disease in a subject comprising administering to the subject a
pharmaceutically acceptable vaccine composition comprising at least
a first ASGPR antibody, or binding fragment thereof, attached to
myelin basic protein (MBP) and/or myelin oligodendrocyte
glycoprotein (MOG), or antigenic fragment thereof is contemplated.
In some embodiments, the ASGPR antibody, or binding fragment
thereof, is fused to MBP or MOG, or an antigenic fragment thereof.
In other embodiments, the subject is administered the vaccine
composition multiple times. In still other embodiments, the
composition is administered orally, intravenously, subcutaneously,
intradermally, intramuscularly, nasally, by injection, by
inhalation, and/or using a nebulizer. In certain aspects, the
subject exhibits one or more symptoms of a demyelinating disease.
In additional aspects, the subject has been diagnosed with a
demyelinating disease. In some embodiments, the subject is at risk
for a demyelinating disease. In other embodiments, the
demyelinating disease affects the central nervous system. In
additional embodiments, the demyelinating disease is an idiopathic
inflammatory demyelinating disease. In certain aspects, the
demyelinating disease is multiple sclerosis, neuropathy, central
pontine myelinolysis, tabes dorsalis, transverse myelitis, Devic's
disease, progressive multifocal leukoencephalopathy, optic
neuritis, or leukodystrophy. In specific embodiments, the
demyelinating disease is multiple sclerosis. In some embodiments,
the demyelinating disease is one of the borderline forms of
multiple sclerosis. In some aspects, the borderline form of
multiple sclerosis is standard multiple sclerosis,
Remitent-Recidivant multiple sclerosis (RRMS), Secondary
Progressive multiple sclerosis (SPMS), Primary progressive multiple
sclerosis (PPMS), KIR4.1 multiple sclerosis, Optic-spinal multiple
sclerosis, Opticospinal multiple sclerosis, Devic's disease, acute
disseminated encephalomyelitis (ADEM), acute hemorrhagic
leukoencephalitis, Balo concentric sclerosis, Schilder disease,
diffuse myelinoclastic sclerosis, Marburg multiple sclerosis,
malignant multiple sclerosis, fulminant multiple sclerosis, acute
multiple sclerosis, Tumefactive multiple sclerosis, or Solitary
sclerosis. In yet other embodiments the demyelinating disease is
Susac's syndrome, myalgic encephalomyelitis or leukoaraiosis. In
other aspects, the demyelinating disease affects the peripheral
nervous system. In specific embodiments, the demyelinating disease
is Guillain-Barre syndrome, chronic inflammatory demyelinating
polyneuropathy, anti-MAG peripheral neuropathy, Charcot-Marie-Tooth
Disease, copper deficiency, or progressive inflammatory neuropathy.
In certain embodiments, the methods further comprise preparing the
composition. In further embodiments still, the methods further
comprise measuring antibodies against the at least one myelin
sheath protein in the subject after administering the
composition.
[0023] In some embodiments, a composition comprises at least a
first ASGPR antibody, or binding fragment thereof, attached to
myelin basic protein (MBP) and/or myelin oligodendrocyte
glycoprotein (MOG), or antigenic fragment thereof. In other
embodiments, the dendritic cell antibody is attached to the myelin
sheath protein or antigenic fragment thereof using a peptide
linker. In some embodiments, the composition further comprises at
least one tolerogenic adjuvant. In still other embodiments, the
tolerogenic adjuvant is attached to the dendritic cell targeting
complex. In additional embodiments, the tolerogenic adjuvant is
conjugated to the dendritic cell targeting complex. In some
aspects, the tolerogenic adjuvant is fused to the dendritic cell
antibody, or targeting fragment thereof, and/or to the at least one
myelin sheath protein. In specific aspects, the tolerogenic
adjuvant is selected from IL-10, dexamethasone, FK506 (Tacrolimus),
cholera toxin B subunit, Escherichia coli heat-labile enterotoxin B
subunit, IFN-beta, glucocorticoids, vitamin D3, and vitamin D3
analogues. In still other aspects, the dendritic cell antibody is
attached to at least one myelin sheath protein or antigenic
fragment thereof through binding polypeptides. In some embodiments,
the binding polypeptides are dockerin and cohesin.
[0024] As used herein the specification, "a" or "an" may mean one
or more. As used herein in the claim(s), when used in conjunction
with the word "comprising", the words "a" or "an" may mean one or
more than one.
[0025] The use of the term "or" in the claims is used to mean
"and/or" unless explicitly indicated to refer to alternatives only
or the alternatives are mutually exclusive, although the disclosure
supports a definition that refers to only alternatives and
"and/or." As used herein "another" may mean at least a second or
more.
[0026] Throughout this application, the term "about" is used to
indicate that a value includes the inherent variation of error for
the device, the method being employed to determine the value, or
the variation that exists among the study subjects.
[0027] Other objects, features and advantages of the embodiments
will become apparent from the following detailed description. It
should be understood, however, that the detailed description and
the specific examples, while indicating preferred embodiments, are
given by way of illustration only, since various changes and
modifications within the spirit and scope of the embodiments will
become apparent to those skilled in the art from this detailed
description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] The following drawings form part of the present
specification and are included to further demonstrate certain
aspects of the embodiments. Certain embodiments may be better
understood by reference to one or more of these drawings in
combination with the detailed description of specific embodiments
presented herein.
[0029] FIG. 1A-B: (A) Experimental method schematic. (B)
Anti-DC-ASGPR-PSA vaccine can prime PSA-specific IL-10-producing
CD4+ T cells in NHPs.
[0030] FIG. 2A-B: (A) Experimental method schematic. (B)
Anti-DC-ASGPR-HA1 promotes IL-10-producing HA1-specific CD4.sup.+ T
cells in vivo.
[0031] FIG. 3A-B: Monoclonal antibody selection. (A) RT-PCR assay.
(B) Luminex assay. 3/7 clones induce DCs to express IL-10, other
clones induce less than 10 pg/ml IL-10. Levels of IL-10 expression
are variable among donors, IL-6 and TNFa are in background levels
in Luminex assay.
[0032] FIG. 4: Monoclonal antibody selection. 49C11 binds to
CD11c.sup.+ blood DCs in MS patients and healthy donors.
[0033] FIG. 5: Generation of anti-DC-ASGPR-MBP and
anti-DC-ASGPR-MOG fusion proteins. Expression product of
anti-DC-ASGPR (49C11) mAb fused to MBP and MOG.
[0034] FIG. 6A-B: (A) Experimental method schematic. (B) In vitro
validation of anti-DC-ASGPR (49C11)-MBP proteins. Anti-DC-ASGPR
(49C11)-MBP binds to CD11c.sup.+ DCs in PBMCs and promotes
MBP-specific Treg responses.
[0035] FIG. 7A-B: In vitro validation of anti-DC-ASGPR (49C11)-MOG
proteins. (A) CD11c+ DC staining. (B) MS patient PBMC loading
assay. Anti-DC-ASGPR-MOG binds to DCs and promotes MOG-specific
Treg response.
[0036] FIG. 8: Effectiveness of anti-ASGPR-hMOG in EAE Model in
Cynomolgus Macaque--Experimental Design.
[0037] FIG. 9: Anti-DC-ASGPR-MOG treatment suppresses EAE
development progression
[0038] FIG. 10: Anti-DC-ASGPR-MOG treatment results in enhanced
survival of animals
[0039] FIG. 11: Magnetic resonance images of AM637 animal brain on
day 22.
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
I. Multiple Sclerosis Immunotherapeutic Technology
[0040] Methods and compositions are provided to generate immune
tolerance in a subject against one or more myelin sheath antigens
in order to protect against or treat for autoimmune disorders such
as multiple sclerosis. Dendritic cells (DCs) are antigen-presenting
cells that play a key role in regulating antigen-specific immunity
(Mellman and Steinman 2001), (Banchereau, Briere et al. 2000),
(Cella, Sallusto et al. 1997). DCs capture antigens, process them
into peptides, and present these to T cells. Therefore delivering
antigens directly to DC is a focus area for developing
immunotherapeutics.
[0041] Provided herein are immunotherapeutics compositions
containing myelin sheath antigens for delivery to DC in order to
generate an immune tolerance response to myelin sheath protein or
components or to suppress an immune response to myelin sheath
protein or components. In some embodiments the myelin sheath
protein or component is myelin basic protein (MBP). In other
embodiments the myelin sheath protein or component is myelin
oligodendrocyte glycoprotein (MOG). In yet other embodiments, the
myelin sheath protein or component is proteolipid protein (PLP). In
still other embodiments the myelin sheath protein or component is
myelin associated glycoprotein. In additional embodiments, the
myelin sheath protein or component is any one of peripheral myelin
protein (PMP-22), P.sub.0 protein, connexin 32 protein, Schwann
cell myelin protein, or oligodendrocyte-myelin glycoprotein (OMgp).
In still additional embodiments, the immunotherapeutic comprises
multiple different myelin sheath components as stated above.
[0042] The type of immune response that is generated after delivery
of an immunotherapeutic may be modulated by the type of receptor
that is targeted by said therapeutic. In some embodiments of the
present methods, asialoglycoprotein receptor (ASGPR) is targeted by
ASGPR binding antibodies. In some aspects the antibodies are
monoclonal antibodies. In yet other aspects, the antibodies are
mouse monoclonal antibodies. In still other aspects, the antibodies
are human/mouse chimeras. In further aspects, the antibodies are
humanized monoclonal antibodies.
[0043] In certain aspects, the type of receptor that is targeted by
the immunotherapeutic is DEC-205. DEC-205 is a type I cell surface
protein expressed primarily by dendritic cells (DC). In some
embodiments of the present methods, DEC-205 is targeted by DEC-205
binding antibodies. In some aspects the antibodies are DEC-205
monoclonal antibodies. In yet other aspects, the antibodies are
DEC-205 mouse monoclonal antibodies. In still other aspects, the
antibodies are DEC-205 mouse/human chimeras. In further aspects,
the antibodies are humanized DEC-205 mouse monoclonal
antibodies.
[0044] Such technology and embodiments are described in the
following U.S. Patent Publications 20120282281 (Agents that Engage
Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein
Receptor (DC-ASGPR)); 20120244155 (Dendritic Cells (DCs) Targeting
for Tuberculosis (TB) Vaccine); 20120237513 (Vaccines Based on
Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells);
20120231023 (Novel Vaccine Adjuvants Based on Targeting Adjuvants
to Antibodies Directly to Antigen-Presenting Cells); 20120213768
(Diagnostic and Therapeutic Uses for B Cell Maturation Antigen);
20120128710 (Enhancement of Pathogen-Specific Memory Th17 Cell
Responses); 20120121592 (Targeting Antigens to Human Dendritic
Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10
Regulatory T-Cells; 20120039916 (NOVEL VACCINE ADJUVANTS BASED ON
TARGETING ADJUVANTS TO ANTIBODIES DIRECTLY TO ANTIGEN-PRESENTING
CELLS); 20120035240 (CONSERVED HBV AND HCV SEQUENCES USEFUL FOR
GENE SILENCING); 20120020990 (ISOLATED MAMMALIAN MONOCYTE CELL
GENES; RELATED REAGENTS); 20120004643 (Vaccines Based on Targeting
Antigen to DCIR Expressed on Antigen-Presenting Cells); 20110274653
(DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF
HUMAN CD8+ T CELLS); 20110081343 (VACCINES DIRECTED TO LANGERHANS
CELLS); 20100330115 (Multivariable Antigens Complexed with
Targeting Humanized Monoclonal Antibody); 20100322929 (ANTIGEN
PRESENTING CELL TARGETED CANCER VACCINES); 20100297114 (ANTIGEN
PRESENTING CELL TARGETED VACCINES); 20100291082 (ANTIGEN PRESENTING
CELL TARGETED ANTI-VIRAL VACCINES); 20100239575 (ANTI-CD40
ANTIBODIES AND USES THEREOF); 20100209907 (ISOLATED MAMMALIAN
MONOCYTE CELL GENES; RELATED REAGENTS); 20100135994 (HIV VACCINE
BASED ON TARGETING MAXIMIZED GAG AND NEF TO DENDRITIC CELLS);
20080267984 (Activation of Human Antigen-Presenting Cells Through
Dendritic Cell Lectin-Like Oxidized LDL Receptor-1 (LOX-1));
20080254047 (Activation of Human Antigen-Presenting Cells Through
CLEC-6); 20080254044 (Multivariable Antigens Complexed with
Targeting Humanized Monoclonal Antibody); 20080241170 (Vaccines
Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting
Cells); 20080233140 (Therapeutic Applications of Activation of
Human Antigen-Presenting Cells Through Dectin-1); 20080206262
(Agents That Engage Antigen-Presenting Cells Through Dendritic Cell
Asialoglycoprotein Receptor (DC-ASGPR)); 20080070854 (Conserved Hbv
and Hcv Sequences Useful for Gene Silencing); 20050287582
(Antibodies that specifically bind to FDF03); 20050059808 (Isolated
mammalian monocyte cell genes; related reagents); 20040143858
(Isolated mammalian monocyte cell genes; related reagents);
20030105303 (Isolated mammalian monocyte cell genes; related
reagents); and, 20020161218 (Hepatitis C virus vaccine), all of
which are hereby incorporated by reference.
II. Nucleic Acids
[0045] In certain embodiments, there are recombinant nucleic acids
encoding the proteins, polypeptides, or peptides described herein.
Polynucleotides contemplated for use in methods and compositions
include those encoding antibodies against DC receptors (also
referred to as anti-DC antibodies and DC targeting antibodies) or
binding portions thereof
[0046] As used in this application, the term "polynucleotide"
refers to a nucleic acid molecule that either is recombinant or has
been isolated free of total genomic nucleic acid. Included within
the term "polynucleotide" are oligonucleotides (nucleic acids 100
residues or fewer in length), recombinant vectors, including, for
example, plasmids, cosmids, phage, viruses, and the like.
Polynucleotides include, in certain aspects, regulatory sequences,
isolated substantially away from their naturally occurring genes or
protein encoding sequences. Polynucleotides may be single-stranded
(coding or antisense) or double-stranded, and may be RNA, DNA
(genomic, cDNA or synthetic), analogs thereof, or a combination
thereof. Additional coding or non-coding sequences may, but need
not, be present within a polynucleotide.
[0047] In this respect, the term "gene," "polynucleotide," or
"nucleic acid" is used to refer to a nucleic acid that encodes a
protein, polypeptide, or peptide (including any sequences required
for proper transcription, post-translational modification, or
localization). As will be understood by those in the art, this term
encompasses genomic sequences, expression cassettes, cDNA
sequences, and smaller engineered nucleic acid segments that
express, or may be adapted to express, proteins, polypeptides,
domains, peptides, fusion proteins, and mutants. A nucleic acid
encoding all or part of a polypeptide may contain a contiguous
nucleic acid sequence encoding all or a portion of such a
polypeptide. It also is contemplated that a particular polypeptide
may be encoded by nucleic acids containing variations having
slightly different nucleic acid sequences but, nonetheless, encode
the same or substantially similar protein (see above).
[0048] In particular embodiments, there are isolated nucleic acid
segments and recombinant vectors incorporating nucleic acid
sequences that encode a polypeptide (e.g., an antibody or fragment
thereof) that binds to DC receptors. The term "recombinant" may be
used in conjunction with a polypeptide or the name of a specific
polypeptide, and this generally refers to a polypeptide produced
from a nucleic acid molecule that has been manipulated in vitro or
that is a replication product of such a molecule.
[0049] The nucleic acid segments, regardless of the length of the
coding sequence itself, may be combined with other nucleic acid
sequences, such as promoters, polyadenylation signals, additional
restriction enzyme sites, multiple cloning sites, other coding
segments, and the like, such that their overall length may vary
considerably. It is therefore contemplated that a nucleic acid
fragment of almost any length may be employed, with the total
length preferably being limited by the ease of preparation and use
in the intended recombinant nucleic acid protocol. In some cases, a
nucleic acid sequence may encode a polypeptide sequence with
additional heterologous coding sequences, for example to allow for
purification of the polypeptide, transport, secretion,
post-translational modification, or for therapeutic benefits such
as targeting or efficacy. As discussed above, a tag or other
heterologous polypeptide may be added to the modified
polypeptide-encoding sequence, wherein "heterologous" refers to a
polypeptide that is not the same as the modified polypeptide.
[0050] In certain embodiments, there are polynucleotide variants
having substantial identity to the sequences disclosed herein;
those comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,
98%, or 99% or higher sequence identity, including all values and
ranges there between, compared to a polynucleotide sequence
provided herein using the methods described herein (e.g., BLAST
analysis using standard parameters). In certain aspects, the
isolated polynucleotide will comprise a nucleotide sequence
encoding a polypeptide that has at least 90%, preferably 95% and
above, identity to an amino acid sequence described herein, over
the entire length of the sequence; or a nucleotide sequence
complementary to said isolated polynucleotide.
[0051] Vectors
[0052] Polypeptides may be encoded by a nucleic acid molecule. The
nucleic acid molecule can be in the form of a nucleic acid vector.
The term "vector" is used to refer to a carrier nucleic acid
molecule into which a heterologous nucleic acid sequence can be
inserted for introduction into a cell where it can be replicated
and expressed. A nucleic acid sequence can be "heterologous," which
means that it is in a context foreign to the cell in which the
vector is being introduced or to the nucleic acid in which is
incorporated, which includes a sequence homologous to a sequence in
the cell or nucleic acid but in a position within the host cell or
nucleic acid where it is ordinarily not found. Vectors include
DNAs, RNAs, plasmids, cosmids, viruses (bacteriophage, animal
viruses, and plant viruses), and artificial chromosomes (e.g.,
YACs). One of skill in the art would be well equipped to construct
a vector through standard recombinant techniques (for example
Sambrook et al., 2001; Ausubel et al., 1996, both incorporated
herein by reference). Vectors may be used in a host cell to produce
an antibody that binds a dendritic cell receptor.
[0053] The term "expression vector" refers to a vector containing a
nucleic acid sequence coding for at least part of a gene product
capable of being transcribed. In some cases, RNA molecules are then
translated into a protein, polypeptide, or peptide. Expression
vectors can contain a variety of "control sequences," which refer
to nucleic acid sequences necessary for the transcription and
possibly translation of an operably linked coding sequence in a
particular host organism. In addition to control sequences that
govern transcription and translation, vectors and expression
vectors may contain nucleic acid sequences that serve other
functions as well and are described herein.
[0054] Host Cells
[0055] As used herein, the terms "cell," "cell line," and "cell
culture" may be used interchangeably. All of these terms also
include their progeny, which is any and all subsequent generations.
It is understood that all progeny may not be identical due to
deliberate or inadvertent mutations. In the context of expressing a
heterologous nucleic acid sequence, "host cell" refers to a
prokaryotic or eukaryotic cell, and it includes any transformable
organism that is capable of replicating a vector or expressing a
heterologous gene encoded by a vector. A host cell can, and has
been, used as a recipient for vectors or viruses. A host cell may
be "transfected" or "transformed," which refers to a process by
which exogenous nucleic acid, such as a recombinant
protein-encoding sequence, is transferred or introduced into the
host cell. A transformed cell includes the primary subject cell and
its progeny.
[0056] Some vectors may employ control sequences that allow it to
be replicated and/or expressed in both prokaryotic and eukaryotic
cells. One of skill in the art would further understand the
conditions under which to incubate all of the above described host
cells to maintain them and to permit replication of a vector. Also
understood and known are techniques and conditions that would allow
large-scale production of vectors, as well as production of the
nucleic acids encoded by vectors and their cognate polypeptides,
proteins, or peptides.
[0057] Expression Systems
[0058] Numerous expression systems exist that comprise at least a
part or all of the compositions discussed above. Prokaryote- and/or
eukaryote-based systems can be employed for use with an embodiment
to produce nucleic acid sequences, or their cognate polypeptides,
proteins and peptides. Many such systems are commercially and
widely available.
[0059] The insect cell/baculovirus system can produce a high level
of protein expression of a heterologous nucleic acid segment, such
as described in U.S. Pat. Nos. 5,871,986, 4,879,236, both herein
incorporated by reference, and which can be bought, for example,
under the name MAXBAC.RTM. 2.0 from INVITROGEN.RTM. and BACPACK.TM.
BACULOVIRUS EXPRESSION SYSTEM FROM CLONTECH.RTM..
[0060] In addition to the disclosed expression systems, other
examples of expression systems include STRATAGENE.RTM.'s COMPLETE
CONTROL Inducible Mammalian Expression System, which involves a
synthetic ecdysone-inducible receptor, or its pET Expression
System, an E. coli expression system. Another example of an
inducible expression system is available from INVITROGEN.RTM.,
which carries the T-REX.TM. (tetracycline-regulated expression)
System, an inducible mammalian expression system that uses the
full-length CMV promoter. INVITROGEN.RTM. also provides a yeast
expression system called the Pichia methanolica Expression System,
which is designed for high-level production of recombinant proteins
in the methylotrophic yeast Pichia methanolica. One of skill in the
art would know how to express a vector, such as an expression
construct, to produce a nucleic acid sequence or its cognate
polypeptide, protein, or peptide.
III. Proteinaceous Compositions
[0061] Substitutional variants typically contain the exchange of
one amino acid for another at one or more sites within the protein,
and may be designed to modulate one or more properties of the
polypeptide, with or without the loss of other functions or
properties. Substitutions may be conservative, that is, one amino
acid is replaced with one of similar shape and charge. Conservative
substitutions are well known in the art and include, for example,
the changes of: alanine to serine; arginine to lysine; asparagine
to glutamine or histidine; aspartate to glutamate; cysteine to
serine; glutamine to asparagine; glutamate to aspartate; glycine to
proline; histidine to asparagine or glutamine; isoleucine to
leucine or valine; leucine to valine or isoleucine; lysine to
arginine; methionine to leucine or isoleucine; phenylalanine to
tyrosine, leucine or methionine; serine to threonine; threonine to
serine; tryptophan to tyrosine; tyrosine to tryptophan or
phenylalanine; and valine to isoleucine or leucine. Alternatively,
substitutions may be non-conservative such that a function or
activity of the polypeptide is affected. Non-conservative changes
typically involve substituting a residue with one that is
chemically dissimilar, such as a polar or charged amino acid for a
nonpolar or uncharged amino acid, and vice versa.
[0062] Proteins may be recombinant, or synthesized in vitro.
Alternatively, a non-recombinant or recombinant protein may be
isolated from bacteria. It is also contemplated that bacteria
containing such a variant may be implemented in compositions and
methods. Consequently, a protein need not be isolated.
[0063] The term "functionally equivalent codon" is used herein to
refer to codons that encode the same amino acid, such as the six
codons for arginine or serine, and also refers to codons that
encode biologically equivalent amino acids (see Table, below).
TABLE-US-00001 Codon Table Amino Acids Codons Alanine Ala A GCA GCC
GCG GCU Cysteine Cys C UGC UGU Aspartic acid Asp D GAC GAU Glutamic
acid Glu E GAA GAG Phenylalanine Phe F UUC UUU Glycine Gly G GGA
GGC GGG GGU Histidine His H CAC CAU Isoleucine Ile I AUA AUC AUU
Lysine Lys K AAA AAG Leucine Leu L UUA UUG CUA CUC CUG CUU
Methionine Met M AUG Asparagine Asn N AAC AAU Proline Pro P CCA CCC
CCG CCU Glutamine Gln Q CAA CAG Arginine Arg R AGA AGG CGA CGC CGG
CGU Serine Ser S AGC AGU UCA UCC UCG UCU Threonine Thr T ACA ACC
ACG ACU Valine Val V GUA GUC GUG GUU Tryptophan Trp W UGG Tyrosine
Tyr Y UAC UAU
[0064] It also will be understood that amino acid and nucleic acid
sequences may include additional residues, such as additional N- or
C-terminal amino acids, or 5' or 3' sequences, respectively, and
yet still be essentially as set forth in one of the sequences
disclosed herein, so long as the sequence meets the criteria set
forth above, including the maintenance of biological protein
activity where protein expression is concerned. The addition of
terminal sequences particularly applies to nucleic acid sequences
that may, for example, include various non-coding sequences
flanking either of the 5' or 3' portions of the coding region.
[0065] The following is a discussion based upon changing of the
amino acids of a protein to create an equivalent, or even an
improved, second-generation molecule. For example, certain amino
acids may be substituted for other amino acids in a protein
structure without appreciable loss of interactive binding capacity
with structures such as, for example, antigen-binding regions of
antibodies or binding sites on substrate molecules. Since it is the
interactive capacity and nature of a protein that defines that
protein's biological functional activity, certain amino acid
substitutions can be made in a protein sequence, and in its
underlying DNA coding sequence, and nevertheless produce a protein
with like properties. It is thus contemplated by the inventors that
various changes may be made in the DNA sequences of genes without
appreciable loss of their biological utility or activity.
[0066] In making such changes, the hydropathic index of amino acids
may be considered. The importance of the hydropathic amino acid
index in conferring interactive biologic function on a protein is
generally understood in the art (Kyte and Doolittle, 1982). It is
accepted that the relative hydropathic character of the amino acid
contributes to the secondary structure of the resultant protein,
which in turn defines the interaction of the protein with other
molecules, for example, enzymes, substrates, receptors, DNA,
antibodies, antigens, and the like.
[0067] It also is understood in the art that the substitution of
like amino acids can be made effectively on the basis of
hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by
reference, states that the greatest local average hydrophilicity of
a protein, as governed by the hydrophilicity of its adjacent amino
acids, correlates with a biological property of the protein. It is
understood that an amino acid can be substituted for another having
a similar hydrophilicity value and still produce a biologically
equivalent and immunologically equivalent protein.
[0068] As outlined above, amino acid substitutions generally are
based on the relative similarity of the amino acid side-chain
substituents, for example, their hydrophobicity, hydrophilicity,
charge, size, and the like. Exemplary substitutions that take into
consideration the various foregoing characteristics are well known
and include: arginine and lysine; glutamate and aspartate; serine
and threonine; glutamine and asparagine; and valine, leucine and
isoleucine.
[0069] It is contemplated that in compositions there is between
about 0.001 mg and about 10 mg of total polypeptide, peptide,
and/or protein per ml. Thus, the concentration of protein in a
composition can be about, at least about or at most about 0.001,
0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0,
1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5,
8.0, 8.5, 9.0, 9.5, 10.0 mg/ml or more (or any range derivable
therein). Of this, about, at least about, or at most about 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,
73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% may be an antibody
that targets DC, and may be used in combination with other
proteins, antibodies or protein-binding antibodies described
herein.
[0070] Polypeptides and Polypeptide Production
[0071] Embodiments involve polypeptides, peptides, and proteins and
immunogenic fragments thereof for use in various aspects described
herein. For example, specific antibodies are assayed for or used in
binding to DC receptors and presenting myelin sheath protein or
components as antigens. In specific embodiments, all or part of
proteins described herein can also be synthesized in solution or on
a solid support in accordance with conventional techniques. Various
automatic synthesizers are commercially available and can be used
in accordance with known protocols. See, for example, Stewart and
Young, (1984); Tam et al., (1983); Merrifield, (1986); and Barany
and Merrifield (1979), each incorporated herein by reference.
Alternatively, recombinant DNA technology may be employed wherein a
nucleotide sequence that encodes a peptide or polypeptide is
inserted into an expression vector, transformed or transfected into
an appropriate host cell and cultivated under conditions suitable
for expression.
[0072] One embodiment includes the use of gene transfer to cells,
including microorganisms, for the production and/or presentation of
proteins. The gene for the protein of interest may be transferred
into appropriate host cells followed by culture of cells under the
appropriate conditions. A nucleic acid encoding virtually any
polypeptide may be employed. The generation of recombinant
expression vectors, and the elements included therein, are
discussed herein. Alternatively, the protein to be produced may be
an endogenous protein normally synthesized by the cell used for
protein production.
[0073] In a certain aspects a DC receptor fragment comprises
substantially all of the extracellular domain of a protein which
has at least 85% identity, at least 90% identity, at least 95%
identity, or at least 97-99% identity, including all values and
ranges there between, to a sequence selected over the length of the
fragment sequence.
[0074] Also included in immunogenic compositions are fusion
proteins composed of myelin sheath protein or components, or
immunogenic fragments of myelin sheath protein or components (e.g.,
myelin basic protein, proteolipid protein, myelin-associated
glycoprotein, myelin oligodendrocyte glycoprotein, peripheral
myelin protein (PMP-22), P.sub.0 protein, connexin 32 protein,
Schwann cell myelin protein, oligodendrocyte-myelin glycoprotein
(OMgp)). Alternatively, embodiments also include individual fusion
proteins of myelin sheath protein or components or immunogenic
fragments thereof, as a fusion protein with heterologous sequences
such as a provider of T-cell epitopes or purification tags, for
example: .beta.-galactosidase, glutathione-S-transferase, 6xHis,
green fluorescent proteins (GFP), epitope tags such as FLAG, myc
tag, poly histidine, or viral surface proteins such as influenza
virus haemagglutinin, or bacterial proteins such as tetanus toxoid,
diphtheria toxoid, CRM197.
[0075] Antibodies and Antibody-Like Molecules
[0076] In certain aspects, one or more antibodies or antibody-like
molecules (e.g., polypeptides comprising antibody CDR domains) may
be obtained or produced which have a specificity for a DC receptor.
These antibodies may be used in various diagnostic or therapeutic
applications described herein.
[0077] As used herein, the term "antibody" is intended to refer
broadly to any immunologic binding agent such as IgG, IgM, IgA, IgD
and IgE as well as polypeptides comprising antibody CDR domains
that retain antigen binding activity. Thus, the term "antibody" is
used to refer to any antibody-like molecule that has an antigen
binding region, and includes antibody fragments such as Fab', Fab,
F(ab')2, single domain antibodies (DABs), Fv, scFv (single chain
Fv), and polypeptides with antibody CDRs, scaffolding domains that
display the CDRs (e.g., anticalins) or a nanobody. For example, the
nanobody can be antigen-specific VHH (e.g., a recombinant VHH) from
a camelid IgG2 or IgG3, or a CDR-displaying frame from such camelid
Ig. Production and use of camelid antibodies is described in
EP1118669 A9 and EP1414858 B1, both of which are incorporated
herein by reference. The techniques for preparing and using various
antibody-based constructs and fragments are well known in the art.
Means for preparing and characterizing antibodies are also well
known in the art (See, e.g., Antibodies: A Laboratory Manual, Cold
Spring Harbor Laboratory, 1988; incorporated herein by
reference).
[0078] "Mini-antibodies" or "minibodies" are also contemplated for
use with embodiments. Minibodies are sFv polypeptide chains which
include oligomerization domains at their C-termini, separated from
the sFv by a hinge region (Pack et al., 1992). The oligomerization
domain comprises self-associating .alpha.-helices, e.g., leucine
zippers, that can be further stabilized by additional disulfide
bonds. The oligomerization domain is designed to be compatible with
vectorial folding across a membrane, a process thought to
facilitate in vivo folding of the polypeptide into a functional
binding protein. Generally, minibodies are produced using
recombinant methods well known in the art. See, e.g., Pack et al.
(1992); Cumber et al. (1992).
[0079] Antibody-like binding peptidomimetics are also contemplated
in embodiments. Liu et al.(2003) describe "antibody like binding
peptidomimetics" (ABiPs), which are peptides that act as pared-down
antibodies and have certain advantages of longer serum half-life as
well as less cumbersome synthesis methods.
[0080] Alternative scaffolds for antigen binding peptides, such as
CDRs are also available and can be used to generate DC
receptor-binding molecules in accordance with the embodiments.
Generally, a person skilled in the art knows how to determine the
type of protein scaffold on which to graft at least one of the CDRs
arising from the original antibody. More particularly, it is known
that to be selected such scaffolds must meet the greatest number of
criteria as follows (Skerra, 2000): good phylogenetic conservation;
known three-dimensional structure (as, for example, by
crystallography, NMR spectroscopy or any other technique known to a
person skilled in the art); small size; few or no
post-transcriptional modifications; and/or easy to produce, express
and purify.
[0081] The origin of such protein scaffolds can be, but is not
limited to, the structures selected among: fibronectin and
preferentially fibronectin type III domain 10, lipocalin, anticalin
(Skerra, 2001), thioredoxin A or proteins with a repeated motif
such as the "ankyrin repeat" (Kohl et al., 2003), the "armadillo
repeat", the "leucine-rich repeat" and the "tetratricopeptide
repeat". For example, anticalins or lipocalin derivatives are a
type of binding proteins that have affinities and specificities for
various target molecules; such proteins are described in US Patent
Publication Nos. 20100285564, 20060058510, 20060088908,
20050106660, and PCT Publication No. WO2006/056464, incorporated
herein by reference.
[0082] Scaffolds derived from toxins such as, for example, toxins
from scorpions, insects, plants, mollusks, etc., and the protein
inhibiters of neuronal NO synthase (PIN) may also be used in
certain aspects.
[0083] Monoclonal antibodies (MAbs) are recognized to have certain
advantages, e.g., reproducibility and large-scale production.
Embodiments include monoclonal antibodies of the human, murine,
monkey, rat, hamster, rabbit and chicken origin.
[0084] "Humanized" antibodies are also contemplated, as are
chimeric antibodies from mouse, rat, or other species, bearing
human constant and/or variable region domains, bispecific
antibodies, recombinant and engineered antibodies and fragments
thereof. As used herein, the term "humanized" immunoglobulin refers
to an immunoglobulin comprising a human framework region and one or
more CDR's from a non-human (usually a mouse or rat)
immunoglobulin. The non-human immunoglobulin providing the CDR's is
called the "donor" and the human immunoglobulin providing the
framework is called the "acceptor". A "humanized antibody" is an
antibody comprising a humanized light chain and a humanized heavy
chain immunoglobulin. In order to describe antibodies of some
embodiments, the strength with which an antibody molecule binds an
epitope, known as affinity, can be measured. The affinity of an
antibody may be determined by measuring an association constant
(Ka) or dissociation constant (Kd). Antibodies deemed useful in
certain embodiments may have an association constant of about, at
least about, or at most about 10e6, 10e7, 10e8,10e9 or 10e10 M or
any range derivable therein. Similarly, in some embodiments
antibodies may have a dissociation constant of about, at least
about or at most about 10e-6, 10e-7, 10e-8, 10e-9 or 10e-10. M or
any range derivable therein. These values are reported for
antibodies discussed herein and the same assay may be used to
evaluate the binding properties of such antibodies.
[0085] In certain embodiments, the antibodies are recombinant
antibodies. A recombinant antibody differs from an
endogenously-produced antibody. For example, recombinant antibodies
differ with respect to their glycosylation status (see, for
example, Jefferis, R. "Glycosylation of Recombinant Antibody
Therapeutics" Biotechnol. Prog. 2005, 21:11-16 which is herein
incorporated by reference).
[0086] In certain embodiments, a polypeptide that specifically
binds to DC receptors is able to bind a DC receptor on the surface
of the cells and present a myelin sheath protein or component that
allows the generation of a robust immune tolerance to that myelin
sheath protein or component. Moreover, in some embodiments, the
polypeptide that is used can provide immune tolerance against a
myelin sheath protein or component and protect against multiple
sclerosis.
[0087] 1. Methods for Generating Antibodies
[0088] Methods for generating antibodies (e.g., monoclonal
antibodies and/or monoclonal antibodies) are known in the art.
Briefly, a polyclonal antibody is prepared by immunizing an animal
with a DC receptor polypeptide or a portion thereof in accordance
with embodiments and collecting antisera from that immunized
animal.
[0089] A wide range of animal species can be used for the
production of antisera. Typically the animal used for production of
antisera is a rabbit, a mouse, a rat, a hamster, a guinea pig or a
goat. The choice of animal may be decided upon the ease of
manipulation, costs or the desired amount of sera, as would be
known to one of skill in the art. It will be appreciated that
antibodies can also be produced transgenically through the
generation of a mammal or plant that is transgenic for the
immunoglobulin heavy and light chain sequences of interest and
production of the antibody in a recoverable form therefrom. In
connection with the transgenic production in mammals, antibodies
can be produced in, and recovered from, the milk of goats, cows, or
other mammals. See, e.g., U.S. Pat. Nos. 5,827,690, 5,756,687,
5,750,172, and 5,741,957.
[0090] As is also well known in the art, the immunogenicity of a
particular immunogen composition can be enhanced by the use of
non-specific stimulators of the immune response, known as
adjuvants. Suitable adjuvants include any acceptable
immunostimulatory compound, such as cytokines, chemokines,
cofactors, toxins, plasmodia, synthetic compositions or vectors
encoding such adjuvants. Adjuvants may be chemically conjugated to
antibodies or antigen-delivering antibody fusions proteins.
Alternatively adjuvants may be recombinantly fused to antibodies or
antigen-delivering antibody fusions proteins. In certain aspects,
adjuvants may be chemically conjugated or recombinantly fused to
Cohesin or Dockerin to allow for binding to any other molecule
containing a corresponding Dockerin or Cohesin binding domain.
[0091] Adjuvants that may be used in accordance with embodiments
include, but are not limited to, IL-1, IL-2, IL-4, IL-7, IL-12,
-interferon, GMCSP, BCG, aluminum hydroxide, Poly ICLC, MDP
compounds, such as thur-MDP and nor-MDP, CGP (MTP-PE), lipid A, and
monophosphoryl lipid A (MPL). RIBI, which contains three components
extracted from bacteria, MPL, trehalose dimycolate (TDM) and cell
wall skeleton (CWS) in a 2% squalene/Tween 80 emulsion is also
contemplated. MHC antigens may even be used. Exemplary adjuvants
may include complete Freund's adjuvant (a non-specific stimulator
of the immune response containing killed Mycobacterium
tuberculosis), incomplete Freund's adjuvants and/or aluminum
hydroxide adjuvant.
[0092] In addition to adjuvants, it may be desirable to
coadminister biologic response modifiers (BRM), which have been
shown to upregulate T cell immunity or downregulate suppressor cell
activity. Such BRMs include, but are not limited to, Cimetidine
(CIM; 1200 mg/d) (Smith/Kline, PA); low-dose Cyclophosphamide (CYP;
300 mg/m2) (Johnson/Mead, N.J.), cytokines such as -interferon,
IL-2, or IL-12 or genes encoding proteins involved in immune helper
functions, such as B-7.
[0093] The amount of immunogen composition used in the production
of antibodies varies upon the nature of the immunogen as well as
the animal used for immunization. A variety of routes can be used
to administer the immunogen including but not limited to
subcutaneous, intramuscular, intradermal, intraepidermal,
intravenous and intraperitoneal. The production of antibodies may
be monitored by sampling blood of the immunized animal at various
points following immunization.
[0094] A second, booster dose (e.g., provided in an injection), may
also be given. The process of boosting and titering is repeated
until a suitable titer is achieved. When a desired level of
immunogenicity is obtained, the immunized animal can be bled and
the serum isolated and stored, and/or the animal can be used to
generate MAbs.
[0095] For production of rabbit polyclonal antibodies, the animal
can be bled through an ear vein or alternatively by cardiac
puncture. The removed blood is allowed to coagulate and then
centrifuged to separate serum components from whole cells and blood
clots. The serum may be used as is for various applications or else
the desired antibody fraction may be purified by well-known
methods, such as affinity chromatography using another antibody, a
peptide bound to a solid matrix, or by using, e.g., protein A or
protein G chromatography, among others.
[0096] MAbs may be readily prepared through use of well-known
techniques, such as those exemplified in U.S. Pat. No. 4,196,265,
incorporated herein by reference. Typically, this technique
involves immunizing a suitable animal with a selected immunogen
composition, e.g., a purified or partially purified protein,
polypeptide, peptide or domain, be it a wild-type or mutant
composition. The immunizing composition is administered in a manner
effective to stimulate antibody producing cells.
[0097] The methods for generating monoclonal antibodies (MAbs)
generally begin along the same lines as those for preparing
polyclonal antibodies. In some embodiments, Rodents such as mice
and rats are used in generating monoclonal antibodies. In some
embodiments, rabbit, sheep or frog cells are used in generating
monoclonal antibodies. The use of rats is well known and may
provide certain advantages (Goding, 1986, pp. 60 61). Mice (e.g.,
BALB/c mice)are routinely used and generally give a high percentage
of stable fusions.
[0098] The animals are injected with antigen, generally as
described above. The antigen may be mixed with adjuvant, such as
Freund's complete or incomplete adjuvant. Booster administrations
with the same antigen or DNA encoding the antigen may occur at
approximately two-week intervals. As discussed in the Examples, the
antigen may be altered compared to an antigen sequence found in
nature.
[0099] Following immunization, somatic cells with the potential for
producing antibodies, specifically B lymphocytes (B cells), are
selected for use in the MAb generating protocol. These cells may be
obtained from biopsied spleens, tonsils or lymph nodes, or from a
peripheral blood sample. Generally, spleen cells are a rich source
of antibody-producing cells that are in the dividing plasmablast
stage. Typically, peripheral blood cells may be readily obtained,
as peripheral blood is easily accessible.
[0100] In some embodiments, a panel of animals will have been
immunized and the spleen of an animal with the highest antibody
titer will be removed and the spleen lymphocytes obtained by
homogenizing the spleen with a syringe. Typically, a spleen from an
immunized mouse contains approximately 5.times.10.sup.7 to
2.times.10.sup.8 lymphocytes.
[0101] The antibody producing B lymphocytes from the immunized
animal are then fused with cells of an immortal myeloma cell,
generally one of the same species as the animal that was immunized.
Myeloma cell lines suited for use in hybridoma producing fusion
procedures preferably are non-antibody producing, have high fusion
efficiency, and enzyme deficiencies that render then incapable of
growing in certain selective media which support the growth of only
the desired fused cells (hybridomas).
[0102] Any one of a number of myeloma cells may be used, as are
known to those of skill in the art (Goding, pp. 65 66, 1986;
Campbell, pp. 75 83, 1984). cites). For, example, where the
immunized animal is a mouse, one may use P3 X63/Ag8, X63 Ag8.653,
NS1/1.Ag 4 1, Sp210 Ag14, FO, NSO/U, MPC 11, MPC11 X45 GTG 1.7 and
S194/5XX0 Bul; for rats, one may use R210. RCY3, Y3 Ag 1.2.3,
IR983F and 4B210; and U 266, GM1500 GRG2, LICR LON HMy2 and UC729 6
are all useful in connection with human cell fusions. See Yoo et
al. (2002), for a discussion of myeloma expression systems.
[0103] One murine myeloma cell is the NS-1 myeloma cell line (also
termed P3-NS-1-Ag4-1), which is readily available from the NIGMS
Human Genetic Mutant Cell
[0104] Repository by requesting cell line repository number GM3573.
Another mouse myeloma cell line that may be used is the 8
azaguanine resistant mouse murine myeloma SP2/0 non producer cell
line.
[0105] Methods for generating hybrids of antibody producing spleen
or lymph node cells and myeloma cells usually comprise mixing
somatic cells with myeloma cells in a 2:1 proportion, though the
proportion may vary from about 20:1 to about 1:1, respectively, in
the presence of an agent or agents (chemical or electrical) that
promote the fusion of cell membranes. Fusion methods using Sendai
virus have been described by Kohler and Milstein (1975; 1976), and
those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by
Gefter et al., (1977). The use of electrically induced fusion
methods is also appropriate (Goding pp. 71 74, 1986).
[0106] Fusion procedures usually produce viable hybrids at low
frequencies, about 1.times.10-6 to 1.times.10-8. However, this does
not pose a problem, as the viable, fused hybrids are differentiated
from the parental, unfused cells (particularly the unfused myeloma
cells that would normally continue to divide indefinitely) by
culturing in a selective medium. The selective medium is generally
one that contains an agent that blocks the de novo synthesis of
nucleotides in the tissue culture media. Exemplary and preferred
agents are aminopterin, methotrexate, and azaserine. Aminopterin
and methotrexate block de novo synthesis of both purines and
pyrimidines, whereas azaserine blocks only purine synthesis. Where
aminopterin or methotrexate is used, the media is supplemented with
hypoxanthine and thymidine as a source of nucleotides (HAT medium).
Where azaserine is used, the media is supplemented with
hypoxanthine.
[0107] A selection medium is HAT. Only cells capable of operating
nucleotide salvage pathways are able to survive in HAT medium. The
myeloma cells are defective in key enzymes of the salvage pathway,
e.g., hypoxanthine phosphoribosyl transferase (HPRT), and they
cannot survive. The B cells can operate this pathway, but they have
a limited life span in culture and generally die within about two
weeks. Therefore, the only cells that can survive in the selective
media are those hybrids formed from myeloma and B cells.
[0108] This culturing provides a population of hybridomas from
which specific hybridomas are selected. Typically, selection of
hybridomas is performed by culturing the cells by single-clone
dilution in microtiter plates, followed by testing the individual
clonal supernatants (after about two to three weeks) for the
desired reactivity. The assay should be sensitive, simple and
rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity
assays, plaque assays, dot immunobinding assays, and the like.
[0109] The selected hybridomas would then be serially diluted and
cloned into individual antibody producing cell lines, which clones
can then be propagated indefinitely to provide MAbs. The cell lines
may be exploited for MAb production in two basic ways. First, a
sample of the hybridoma can be injected (often into the peritoneal
cavity) into a histocompatible animal of the type that was used to
provide the somatic and myeloma cells for the original fusion
(e.g., a syngeneic mouse). Optionally, the animals are primed with
a hydrocarbon, especially oils such as pristane
(tetramethylpentadecane) prior to injection. The injected animal
develops tumors secreting the specific monoclonal antibody produced
by the fused cell hybrid. The body fluids of the animal, such as
serum or ascites fluid, can then be tapped to provide MAbs in high
concentration. Second, the individual cell lines could be cultured
in vitro, where the MAbs are naturally secreted into the culture
medium from which they can be readily obtained in high
concentrations.
[0110] Further, expression of antibodies (or other moieties
therefrom) from production cell lines can be enhanced using a
number of known techniques. For example, the glutamine synthetase
and DHFR gene expression systems are common approaches for
enhancing expression under certain conditions. High expressing cell
clones can be identified using conventional techniques, such as
limited dilution cloning and Microdrop technology. The GS system is
discussed in whole or part in connection with European Patent Nos.
0 216 846, 0 256 055, and 0 323 997 and European Patent Application
No. 89303964.4.
[0111] MAbs produced by either means may be further purified, if
desired, using filtration, centrifugation and various
chromatographic methods such as HPLC or affinity chromatography.
Fragments of the monoclonal antibodies can be obtained from the
monoclonal antibodies so produced by methods which include
digestion with enzymes, such as pepsin or papain, and/or by
cleavage of disulfide bonds by chemical reduction. Alternatively,
monoclonal antibody fragments can be synthesized using an automated
peptide synthesizer.
[0112] It is also contemplated that a molecular cloning approach
may be used to generate monoclonal antibodies. In one embodiment,
combinatorial immunoglobulin phagemid libraries are prepared from
RNA isolated from the spleen of the immunized animal, and phagemids
expressing appropriate antibodies are selected by panning using
cells expressing the antigen and control cells. The advantages of
this approach over conventional hybridoma techniques are that
approximately 10e4 times as many antibodies can be produced and
screened in a single round, and that new specificities are
generated by H and L chain combination which further increases the
chance of finding appropriate antibodies.
[0113] Another embodiment concerns producing antibodies, for
example, as is found in U.S. Pat. No. 6,091,001, which describes
methods to produce a cell expressing an antibody from a genomic
sequence of the cell comprising a modified immunoglobulin locus
using Cre-mediated site-specific recombination is disclosed. The
method involves first transfecting an antibody-producing cell with
a homology-targeting vector comprising a lox site and a targeting
sequence homologous to a first DNA sequence adjacent to the region
of the immunoglobulin loci of the genomic sequence which is to be
converted to a modified region, so the first lox site is inserted
into the genomic sequence via site-specific homologous
recombination. Then the cell is transfected with a lox-targeting
vector comprising a second lox site suitable for Cre-mediated
recombination with the integrated lox site and a modifying sequence
to convert the region of the immunoglobulin loci to the modified
region. This conversion is performed by interacting the lox sites
with Cre in vivo, so that the modifying sequence inserts into the
genomic sequence via Cre-mediated site-specific recombination of
the lox sites.
[0114] Alternatively, monoclonal antibody fragments can be
synthesized using an automated peptide synthesizer, or by
expression of full-length gene or of gene fragments in E. coli.
[0115] It is further contemplated that monoclonal antibodies may be
further screened or optimized for properties relating to
specificity, avidity, half-life, immunogenicity, binding
association, binding disassociation, or overall functional
properties relative to being a treatment for infection and/or
disease state. Thus, it is contemplated that monoclonal antibodies
may have 1, 2, 3, 4, 5, 6, or more alterations in the amino acid
sequence of 1, 2, 3, 4, 5, or 6 CDRs of monoclonal antibodies
mAnti-ASGPR 49C11, mAnti-ASGPR 4G2.2, mAnti-ASGPR 5F10, mAnti-ASGPR
1H11, mAnti-ASGPR 6.3H9.1D11, mAnti-ASGPR 5H8.1D4. It is
contemplated that the amino acid in position 1, 2, 3, 4, 5, 6, 7,
8, 9, or 10 of CDR1, CDR2, CDR3, CDR4, CDR5, or CDR6 of the VJ or
VDJ region of the light or heavy variable region of monoclonal
antibodies mAnti-ASGPR 49C11, mAnti-ASGPR 4G2.2, mAnti-ASGPR 5F10,
mAnti-ASGPR 1H11, mAnti-ASGPR 6.3H9.1D11, mAnti-ASGPR 5H8.1D4, may
have an insertion, deletion, or substitution with a conserved or
non-conserved amino acid. Such amino acids that can either be
substituted or constitute the substitution are disclosed above.
[0116] Methods of determining CDRs from the sequence of a variable
region are known in the art (see, for example, Zhao and Lu, "A
germline knowledge based computational approach for determining
antibody complementarity determining regions." Mol. Immunol.,
(2010) 47(4):694-700, which is herein incorporated by
reference).
[0117] In some embodiments, fragments of a whole antibody can
perform the function of binding antigens. Examples of binding
fragments are (i) the Fab fragment constituted with the VL, VH, CL
and CHI domains; (ii) the Fd fragment consisting of the VH and CH1
domains; (iii) the Fv fragment constituted with the VL and VH
domains of a single antibody; (iv) the dAb fragment (Ward, 1989;
McCafferty et al., 1990; Holt et al., 2003), which is constituted
with a VH or a VL domain; (v) isolated CDR regions; (vi) F(ab')2
fragments, a bivalent fragment comprising two linked Fab fragments
(vii) single chain Fv molecules (scFv), wherein a VH domain and a
VL domain are linked by a peptide linker which allows the two
domains to associate to form an antigen binding site (Bird et al.,
1988; Huston et al., 1988); (viii) bispecific single chain Fv
dimers (PCT/US92/09965) and (ix) "diabodies", multivalent or
multispecific fragments constructed by gene fusion (WO94/13804;
Holliger et al., 1993). Fv, scFv or diabody molecules may be
stabilized by the incorporation of disulphide bridges linking the
VH and VL domains (Reiter et al., 1996). Minibodies comprising a
scFv joined to a CH3 domain may also be made (Hu et al. 1996). The
citations in this paragraph are all incorporated by reference.
[0118] Antibodies also include bispecific antibodies. Bispecific or
bifunctional antibodies form a second generation of monoclonal
antibodies in which two different variable regions are combined in
the same molecule (Holliger, P. & Winter, G. 1999 Cancer and
metastasis rev. 18:411-419, 1999). Their use has been demonstrated
both in the diagnostic field and in the therapy field from their
capacity to recruit new effector functions or to target several
molecules on the surface of tumor cells. Where bispecific
antibodies are to be used, these may be conventional bispecific
antibodies, which can be manufactured in a variety of ways
(Holliger et al, PNAS USA 90:6444-6448, 1993), e.g. prepared
chemically or from hybrid hybridomas, or may be any of the
bispecific antibody fragments mentioned above. These antibodies can
be obtained by chemical methods (Glennie et al., 1987 J. Immunol.
139, 2367-2375; Repp et al., J. Hemat. 377-382, 1995) or somatic
methods (Staerz U. D. and Bevan M. J. PNAS 83, 1986; et al., Method
Enzymol. 121:210-228, 1986) but likewise by genetic engineering
techniques which allow the heterodimerization to be forced and thus
facilitate the process of purification of the antibody sought
(Merchand et al. Nature Biotech, 16:677-681, 1998). Examples of
bispecific antibodies include those of the BiTE.TM. technology in
which the binding domains of two antibodies with different
specificity can be used and directly linked via short flexible
peptides. This combines two antibodies on a short single
polypeptide chain. Diabodies and scFv can be constructed without an
Fc region, using only variable domains, potentially reducing the
effects of anti-idiotypic reaction. The citations in this paragraph
are all incorporated by reference.
[0119] Bispecific antibodies can be constructed as entire IgG, as
bispecific Fab'2, as Fab'PEG, as diabodies or else as bispecific
scFv. Further, two bispecific antibodies can be linked using
routine methods known in the art to form tetravalent
antibodies.
[0120] Bispecific diabodies, as opposed to bispecific whole
antibodies, may also be particularly useful because they can be
readily constructed and expressed in E. coli. Diabodies (and many
other polypeptides such as antibody fragments) of appropriate
binding specificities can be readily selected using phage display
(WO94/13804) from libraries. If one arm of the diabody is to be
kept constant, for instance, with a specificity directed against a
DC receptor, then a library can be made where the other arm is
varied and an antibody of appropriate specificity selected.
Bispecific whole antibodies may be made by alternative engineering
methods as described in Ridgeway et al, (Protein Eng., 9:616-621,
1996), which is hereby incorporated by reference.
[0121] Antibody and Polypeptide Conjugates
[0122] Embodiments provide antibodies and antibody-like molecules
against DC receptors, polypeptides and peptides that are linked to
at least one agent to form an antibody conjugate or payload or
fusion. Embodiments also provide antibody drug conjugates (ADC). In
order to increase the efficacy of antibody molecules as diagnostic
or therapeutic agents, it is conventional to link or covalently
bind or complex at least one desired molecule or moiety. Such a
molecule or moiety may be, but is not limited to, at least one
effector or reporter molecule. Effector molecules comprise
molecules having a desired activity, e.g., cytotoxic activity.
Non-limiting examples of effector molecules which have been
attached to antibodies include toxins, therapeutic enzymes,
antibiotics, radio-labeled nucleotides and the like. By contrast, a
reporter molecule is defined as any moiety which may be detected
using an assay. Non-limiting examples of reporter molecules which
have been conjugated to antibodies include enzymes, radiolabels,
haptens, fluorescent labels, phosphorescent molecules,
chemiluminescent molecules, chromophores, luminescent molecules,
photoaffinity molecules, colored particles or ligands, such as
biotin.
[0123] Certain examples of antibody conjugates are those conjugates
in which the antibody is linked to a detectable label. "Detectable
labels" are compounds and/or elements that can be detected due to
their specific functional properties, and/or chemical
characteristics, the use of which allows the antibody to which they
are attached to be detected, and/or further quantified if
desired.
[0124] Antibody conjugates are in certain embodiments used as
diagnostic agents. Antibody diagnostics generally fall within two
classes, those for use in in vitro diagnostics, such as in a
variety of immunoassays, and/or those for use in vivo diagnostic
protocols, generally known as "antibody directed imaging". Many
appropriate imaging agents are known in the art, as are methods for
their attachment to antibodies (see, for e.g., U.S. Pat. Nos.
5,021,236; 4,938,948; and 4,472,509, each incorporated herein by
reference). The imaging moieties used can be paramagnetic ions;
radioactive isotopes; fluorochromes; NMR-detectable substances;
X-ray imaging.
[0125] In the case of paramagnetic ions, one might mention by way
of example ions such as chromium (III), manganese (II), iron (III),
iron (II), cobalt (II), nickel (II), copper (II), neodymium (III),
samarium (III), ytterbium (III), gadolinium (III), vanadium (II),
terbium (III), dysprosium (III), holmium (III) and/or erbium (III),
with gadolinium being particularly preferred. Ions useful in other
contexts, such as X-ray imaging, include but are not limited to
lanthanum (III), gold (III), lead (II), and especially bismuth
(III).
[0126] In the case of radioactive isotopes for therapeutic and/or
diagnostic application, one might use astatine.sup.211,
carbon.sup.14, chromium.sup.51, chlorine.sup.36, cobalt.sup.57,
cobalt.sup.58, copper .sup.67, Eu.sup.152, gallium.sup.67,
hydrogen.sup.3, iodine.sup.123, iodine.sup.125, iodine.sup.131,
indium.sup.111, iron.sup.59, phosphorus.sup.32, rhenium.sup.186,
rhenium.sup.188, selenium.sup.75, sulphur.sup.35, technicium.sup.99
and/or yttrium.sup.90 . .sup.125I is often used in certain
embodiments, and technicium.sup.99 and/or indium.sup.111 are also
often used due to their low energy and suitability for long range
detection. Radioactively labeled monoclonal antibodies may be
produced according to well-known methods in the art. For instance,
monoclonal antibodies can be iodinated by contact with sodium
and/or potassium iodide and a chemical oxidizing agent such as
sodium hypochlorite, or an enzymatic oxidizing agent, such as
lactoperoxidase. Monoclonal antibodies may be labeled with
technetium99m by ligand exchange process, for example, by reducing
pertechnate with stannous solution, chelating the reduced
technetium onto a Sephadex column and applying the antibody to this
column. Alternatively, direct labeling techniques may be used,
e.g., by incubating pertechnate, a reducing agent such as
SNCl.sub.2, a buffer solution such as sodium-potassium phthalate
solution, and the antibody. Intermediary functional groups which
are often used to bind radioisotopes which exist as metallic ions
to antibody are diethylenetriaminepentaacetic acid (DTPA) or
ethylene diaminetetracetic acid (EDTA).
[0127] Among the fluorescent labels contemplated for use as
conjugates include Alexa 350, Alexa 430, AMCA, BODIPY 630/650,
BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX,
Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX,
6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514,
Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin,
ROX, TAMRA, TET, Tetramethylrhodamine, and/or Texas Red, among
others.
[0128] Antibody conjugates include those intended primarily for use
in vitro, where the antibody is linked to a secondary binding
ligand and/or to an enzyme (an enzyme tag) that will generate a
colored product upon contact with a chromogenic substrate. Examples
of suitable enzymes include, but are not limited to, urease,
alkaline phosphatase, (horseradish) hydrogen peroxidase or glucose
oxidase. Preferred secondary binding ligands are biotin and/or
avidin and streptavidin compounds. The use of such labels is well
known to those of skill in the art and are described, for example,
in U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345;
4,277,437; 4,275,149 and 4,366,241; each incorporated herein by
reference.
[0129] Yet another known method of site-specific attachment of
molecules to antibodies comprises the reaction of antibodies with
hapten-based affinity labels. Essentially, hapten-based affinity
labels react with amino acids in the antigen binding site, thereby
destroying this site and blocking specific antigen reaction.
However, this may not be advantageous since it results in loss of
antigen binding by the antibody conjugate.
[0130] Molecules containing azido groups may also be used to form
covalent bonds to proteins through reactive nitrene intermediates
that are generated by low intensity ultraviolet light (Potter &
Haley, 1983). In particular, 2- and 8-azido analogues of purine
nucleotides have been used as site-directed photoprobes to identify
nucleotide binding proteins in crude cell extracts (Owens &
Haley, 1987; Atherton et al., 1985). The 2- and 8-azido nucleotides
have also been used to map nucleotide binding domains of purified
proteins (Khatoon et al., 1989; King et al., 1989; and Dholakia et
al., 1989) and may be used as antibody binding agents.
[0131] Several methods are known in the art for the attachment or
conjugation of an antibody to its conjugate moiety. Some attachment
methods involve the use of a metal chelate complex employing, for
example, an organic chelating agent such a
diethylenetriaminepentaacetic acid anhydride (DTPA);
ethylenetriaminetetraacetic acid; N-chloro-p-toluenesulfonamide;
and/or tetrachloro-3 -6-diphenylglycouril-3 attached to the
antibody (U.S. Pat. Nos. 4,472,509 and 4,938,948, each incorporated
herein by reference). Monoclonal antibodies may also be reacted
with an enzyme in the presence of a coupling agent such as
glutaraldehyde or periodate. Conjugates with fluorescein markers
are prepared in the presence of these coupling agents or by
reaction with an isothiocyanate. In U.S. Pat. No. 4,938,948,
imaging of breast tumors is achieved using monoclonal antibodies
and the detectable imaging moieties are bound to the antibody using
linkers such as methyl-p-hydroxybenzimidate or
N-succinimidyl-3-(4-hydroxyphenyl)propionate.
[0132] In some embodiments, derivatization of immunoglobulins by
selectively introducing sulfhydryl groups in the Fc region of an
immunoglobulin, using reaction conditions that do not alter the
antibody combining site are contemplated. Antibody conjugates
produced according to this methodology are disclosed to exhibit
improved longevity, specificity and sensitivity (U.S. Pat. No.
5,196,066, incorporated herein by reference). Site-specific
attachment of effector or reporter molecules, wherein the reporter
or effector molecule is conjugated to a carbohydrate residue in the
Fc region have also been disclosed in the literature (O'Shannessy
et al., 1987). This approach has been reported to produce
diagnostically and therapeutically promising antibodies which are
currently in clinical evaluation.
IV. Dendritic Cell Immunotherapeutics
[0133] As used herein, "Dendritic Cells" (DCs) refers to any member
of a diverse population of morphologically similar cell types found
in lymphoid or non-lymphoid tissues. These cells are characterized
by their distinctive morphology, high levels of surface MHC-class
II expression (Steinman, et al., Ann. Rev. Immunol. 9:271 (1991);
incorporated herein by reference for its description of such
cells). These cells can be isolated from a number of tissue
sources, and conveniently, from peripheral blood, as described
herein.
[0134] Myelin Sheath Proteins and Components as Antigens
[0135] In certain embodiments any myelin sheath protein or
component (including but not limited to myelin sheath protein,
glycoprotein, lipid or glycolipid) may be recombinantly fused or
chemically conjugated to a DC targeting antibody to deliver the
myelin sheath protein or component to a dendritic cell. A myelin
sheath protein or component may be any myelin sheath protein or
component that when fused to a DC targeting antibody is sufficient
to evoke an immune tolerance response in a subject. In certain
embodiments the immune response is sufficient to protect a subject
from multiple sclerosis. In other embodiments protection afforded
by the antigen/targeting antibody fusion is sufficient to depress
or prevent symptoms associated with multiple sclerosis.
[0136] In some embodiments the myelin sheath protein or component
is myelin basic protein (MBP). In other embodiments the myelin
sheath protein or component is myelin oligodendrocyte glycoprotein
(MOG). In yet other embodiments, the myelin sheath protein or
component is proteolipid protein (PLP). In still other embodiments
the myelin sheath protein or component is myelin associated
glycoprotein. In additional embodiments, the myelin sheath protein
or component is any one of peripheral myelin protein (PMP-22),
P.sub.0 protein, connexin 32 protein, Schwann cell myelin protein,
or oligodendrocyte-myelin glycoprotein (OMgp). In still additional
embodiments, the immunotherapeutic comprises multiple different
myelin sheath components as stated above.
[0137] Dendritic Cell Specific Antibodies
[0138] In certain aspects, antibodies used to target myelin sheath
protein or components to dendritic cells are dendritic cell
specific antibodies. Some of the antibodies that may be used for
this purpose are known in the art.
[0139] In some embodiments anti-ASGPR antibodies are used to target
myelin sheath protein or components to dendritic cells. One example
includes anti-dendritic cell immunoreceptor monoclonal antibody
conjugates, wherein the conjugate comprises antigenic peptides that
are loaded or chemically coupled to the antibody. Such antibodies
are described in U.S. Pat. No. 8,236,934, incorporated herein by
reference.
[0140] Peptide Linkers
[0141] In certain aspects, peptide linkers are used to link
dendritic cell specific antibodies and myelin sheath protein or
components to be presented. Peptide linkers may incorporate
glycosylation sites or introduce secondary structure. Additionally
these linkers increase the efficiency of expression or stability of
the fusion protein and as a result the efficiency of antigen
presentation to a dendritic cell. Linkers may include
SSVSPTTSVHPTPTSVPPTPTKSSP (SEQ ID NO :1); PTSTPADSSTITPTATPTATPTIKG
(SEQ ID NO :2); TVTPTATATPSAIVTTITPTATTKP (SEQ ID NO :3); or
TNGSITVAATAPTVTPTVNATPSAA (SEQ ID NO :4). These examples and others
are discussed in WO 2010/104747, the contents of which are
incorporated herein by reference. Additional linkers useful for
this purpose are described in US 2010/291082, the contents of which
are incorporated herein by reference.
[0142] In certain aspects antibody domains, adjuvants antigens or
peptide linkers may be bound by high-affinity interacting protein
domains. In some embodiments a high-affinity interacting protein
domains involves a cohesin-dockerin binding pair. A
cohesin-dockerin binding pair may be recombinantly fused to an
antibody domain, adjuvants, antigens or peptide linkers. In some
aspects the Dockerin is modified such that it is capable of binding
to a cohesin domain when recombinantly encoded in an internal (non
carboxy or non-amino terminal end) portion of a polypeptide. In
certain aspects the linker region is not a peptide linker. An
example of a non-peptide linker region may result as the product of
chemical conjugation wherein the covalent bond that is formed
between molecules is not a peptide bond.
[0143] Adjuvants
[0144] In other embodiments an immune adjuvant is directly fused or
otherwise linked to the dendritic cell specific antibody in order
to enhance the efficacy of the immunotherapeutic. In certain
aspects the immune adjuvant may be a toll-like receptor (TLR)
agonist. TLR agonists comprise flagellins from Salmonella enterica
or Vibrio cholerae. In certain aspects the adjuvant in Flagellin-1
or Flagellin-2. TLR agonists may be specific for certain TLR
classes (i.e., TLR5, TLR7 or TLR9 agonists) and may be presented in
any combination or as any modification. Examples of such immune
adjuvants are described in WO 2012/021834, the contents of which
are incorporated herein by reference. Poly ICLC, a TLR3 ligand is
also contemplated for use with myelin sheath protein or component
DC targeting immunotherapeutic compositions. In some embodiments
the DC targeting immunotherapeutic comprises myelin basic protein
(MBP), myelin oligodendrocyte glycoprotein (MOG), proteolipid
protein (PLP), myelin associated glycoprotein, peripheral myelin
protein (PMP-22), P.sub.0 protein, connexin 32 protein, Schwann
cell myelin protein, or oligodendrocyte-myelin glycoprotein (OMgp)
and Poly ICLC is delivered separately from the antibody antigen
fusion polypeptide. In still additional embodiments, the
immunotherapeutic comprises one or more different myelin sheath
components as stated above. In one embodiment, the Poly ICLC is as
described in U.S. Pat. No. 7,439,349, the contents of which are
incorporated herein by reference. In one embodiment, the Poly ICLC
is Hiltonol.RTM.. Interleukins are also contemplated as adjuvants
that may be fused to a dendritic cell specific antibody or to a
protein domain capable of binding with high affinity to a
corresponding or complementary domain on a dendritic cell specific
antibody. Non-limiting examples of such interleukins are IL-21,
IL-2, IL-9 and IL-10. In some embodiments the interleukin proteins
are human interleukins. In certain aspects the adjuvant is an
HLA-DR antigen-associated invariant chain that augments antigen
processing. In certain aspects the adjuvant is interferon alpha. In
yet other embodiments the adjuvant is a toxin that will deliver a
death signal to cells also receiving an myelin sheath protein or
component, thereby augmenting immunotherapeutic efficiency. One
example of such a toxin is PE38. Any adjuvant may be delivered in
fused or conjugated form with a DC targeting immunotherapeutic or
may be delivered concomitantly as part of the same composition or
preparation without fusion or direct conjugation.
[0145] Tolerogenic Adjuvants
[0146] In certain embodiments the immune adjuvant may be a
tolerogenic adjuvant. In certain instances a tolerogenic adjuvant
may refer to an adjuvant that is utilized for tolerogenic
immunization, where the aim of immunization with an antigen is to
generate an immune response such that the antigen is tolerated by
an immunizaed subject. In certain aspects, the goal of a
tolerogenic adjuvant is to enhance tolerogenic immunization such
that tolerance to an antigen is further enhanced. In certain
embodiments a tolerogenic adjuvant is used to tolerize
autoimmunity. In yet other aspects, a tolerogenic adjuvant is used
to tolerize harmful autoimmunity. In some embodiments the
tolerogenic adjuvant is an immunosuppressant. In yet other
embodiments the tolerogenic adjuvant is dexamethasone, FK506
(Tacrolimus), cholera toxin B subunit, Escherichia coli heat-labile
enterotoxin B subunit, IFN-beta, glucocorticoids, vitamin D3, or
vitamin D3 analogues. In certain aspects the tolerogenic adjuvant
is administered concurrently with a DC targeting immunotherapeutic.
In other apsects a tolerogenic adjuvant is administered before or
after administration of a DC targeting immunotherapeutic. In yet
other embodiments two or more tolerogenic adjuvants are
administered concurrently, before or after administration of a DC
targeting immunotherapeutic. In certain aspects, the tolerogenic
adjuvant may be fused, conjugated or otherwise linked to the DC
targeting immunotherapeutic. In one embodiment, the tolerogenic
adjuvant is interleukin-10 (IL-10). In another embodiment IL-10 is
co-administered with the DC targeting immunotherapeutic. In certain
aspects, IL-10 is fused by recombinant methods. In other aspects
IL-10 is conjugated. In other embodiments IL-10 is linked by
coupling or other modular domains.
[0147] Constructs
[0148] The sequences given below, when presented as antibody H or L
chain or protein secreted by mammalian cells are shown as amino
acids without signal peptide (i.e., as `mature` secreted protein),
while the DNA sequences are the entire coding region including
signal sequences if present.
[0149] All examples of H chain constructs are typically used in
co-transfection of CHO cells with matching L chain vectors. Also,
in some embodiments immunotherapeutics will have humanized variable
regions, which have been described for anti-ASGPR_49C11, anti-CD40
12E12, anti-Langerin 15B10, anti-DCIR 9E8, and anti-LOX-1 15C4.
[0150] Anti-ASGPR heavy chain and light chains may be selected from
the following:
TABLE-US-00002 Anti-DC ASGPR mAbs
[mAnti-ASGPR-49C11-7H-LV-hIgG4H-C] (SEQ ID NO.: 5)
DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYSWHWIRQFPGNKLEWMGYI
LFSGSTNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYFCARSNYGSFASWGQG
TLVTVSAAKTTGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH
TFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPC
PAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN
AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP
REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS. The above
sequence is a chimera between the H chain variable region of the
mAb 49C11 (shown underlined) and the C region of hIgG4.
[mAnti-ASGPR-49C11-7K-LV-hIgGK-C] is the corresponding L chain
chimera (sequence below, variable region underlined) (SEQ ID NO.:
6) QIVLTQSPAIMSASPGEKVTMTCSASSSVSHMHWYQQKSGTSPKRWIYDTSR
LASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSHPWSFGGGTKLEIKRTV
AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[mAnti-ASGPR-4G2.2_Hv-V-hIgG4H-C] (SEQ ID NO.: 7)
QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQVPGKGLRWMGW
MDTFTGEPTYADDFKGRFAFSLETSASTAYLQINSLKNEDTATYFCARGGILRLNYFD
YWGQGTTLTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD
GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS. The above
sequence is a chimera between the H chain variable of the mAb 4G2.2
(shown underlined) and the C region of hIgG4.
[mAnti-ASGPR-4G2.2_Kv-V-hIgGK-C] is the corresponding L chain
chimera (sequence below, variable region underlined) (SEQ ID NO.:
8) DIQMTQSSSSFSVSLGDRVTITCKASEDIYNRLGWYQQKPGNAPRLLISGATSL
ETGVPSRFSGSGSGKDYALSITSLQTEDLATYYCQQCWTSPYTFGGGTKLEIKRTVAA
PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[mAnti-ASGPR-5F10H-LV-hIgG4H-C] is (SEQ ID NO.: 9)
EVQLQQSGPELVKPGASVKMSCKASGYTFTDYYMKWVKQSHGKSLEWIGDI
NPNYGDTFYNQKFEGICATLTVDKSSRTAYMQLNSLTSEDSAVYYCGRGDYGYFDV
WGAGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL
TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG
PPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG
VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK
AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLLSLGKAS. The above
sequence is a chimera between the H chain variable of the mAb 5F10H
(shown underlined) and the C region of hIgG4.
[mAnti-ASGPR-5F10K-LV-hIgGK-C] is the corresponding L chain chimera
(sequence below, variable region underlined) (SEQ ID NO.: 10)
DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWA
STRHTGVPDRFTGSGSGTDFTLTINNVQSEDLADYFCQQYSSNPYMFGGGTKLEIKRT
VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[mAnti-ASGPR1H11H-V-hIgG4H-C] is (SEQ ID NO.: 11)
QLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVRQSHGKSLEWIGGINPIN
GGPTYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARWDYGSRDVMDY
WGQGTSVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL
TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG
PPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG
VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK
AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS. The above
sequence is a chimera between the H chain variable of the mAb 1H11
(shown underlined) and the C region of hIgG4.
[mAnti-ASGPR1H11K-LV-hIgGK-C] is the corresponding L chain chimera
(sequence below, variable region underlined) (SEQ ID NO.: 12)
NIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQRPEQSPKWYGAS
NRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQTYSYIFTFGSGTKLEIKRTV
AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. Examples of full
length DC targeting antibody/antigen constructs are as follows:
mAnti-ASGPR_49C11_7H-LV-hIgG4H-C-Flex-v1-hMBP (LV-hIgG4H-C sequence
underlined, Flex-v1 sequence in bold, hMBP sequence double
underlined) (SEQ ID NO: 13)
ATGAGAGCGCTGATTCTTTTGTGCCTGTTCACAGCCTTTCCTGGTATCCTGTCTGA
TGTGCAGCTTCAGGAGTCAGGACCTGACCTGGTGAAACCTTCTCAGTCACTTTCA
CTCACCTGCACTGTCACTGGCTACTCCATCACCAGTGGTTATAGCTGGCACTGGA
TCCGGCAGTTTCCAGGAAACAAACTGGAATGGATGGGCTACATACTCTTCAGTGG
TAGCACTAACTACAACCCATCTCTGAAAAGTCGAATCTCTATCACTCGAGACACA
TCCAAGAACCAGTTCTTCCTGCAGTTGAATTCTGTGACTACTGAGGACACAGCCA
CATATTTCTGTGCAAGATCTAACTATGGTTCCTTTGCTTCCTGGGGCCAAGGGACT
CTGGTCACTGTCTCTGCAGCCAAAACAACGGGCCCATCCGTCTTCCCCCTGGCGC
CCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCG
GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAG
CGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGT
AGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGG
TCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTC
CTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCA
CGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGT
ACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAG
TTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGC
TGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCA
TCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACA
CCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCC
TGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCT
TCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAG
CCTCTCCCTGTCTCTGGGTAAAGCTAGTCAGACCCCCACCAACACCATCAGCGTG
ACCCCCACCAACAACAGCACCCCCACCAACAACAGCAACCCCAAGCCCAACCCC
GCTAGTGCATCACAAAAGCGGCCTTCACAACGGCACGGATCTAAATATCTGGCG
ACAGCCTCTACCATGGATCACGCCAGGCATGGCTTTCTGCCCAGGCACAGAGATA
CTGGAATCTTGGACTCCATCGGCAGGTTCTTTGGCGGCGACCGAGGGGCTCCCAA
GAGAGGGAGTGGCAAGGATAGCCATCATCCAGCCCGAACAGCCCACTACGGAAG
CCTGCCGCAGAAAAGCCACGGTCGCACGCAGGATGAAAATCCCGTTGTGCACTT
CTTCAAAAACATTGTGACCCCACGAACTCCTCCACCTTCCCAAGGCAAGGGCAGA
GGTCTCAGTCTCAGCCGGTTCAGTTGGGGGGCCGAGGGCCAGAGACCCGGATTT
GGTTATGGGGGAAGGGCTAGCGACTACAAGTCTGCACATAAGGGGTTCAAAGGG
GTCGACGCACAGGGAACCCTGTCCAAAATATTTAAGCTTGGTGGCCGCGACTCCC
GCTCAGGCTCTCCCATGGCTCGGCGCTGA (SEQ ID NO: 14)
DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYSWHWIRQFPGNKLEWMGYILFSGS
TNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYFCARSNYGSFASWGQGTLVTV
SAAKTTGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
LOSSGLYSLSSVVTVPSSSLGTKTYTCNVDHICPSNTKVDKRVESKYGPPCPPCPAPEF
EGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK
PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQ
VYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF
FLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASQTPTNTISVTP
TNNSTPTNNSNPKPNPASASQKRPSQRHGSKYLATASTMDHARHGFLPRHRDTGIL
DSIGRFFGGDRGAPKRGSGKDSHHPARTAHYGSLPQKSHGRTQDENPVVHFFKNIVT
PRTPPPSQGKGRGLSLSRFSWGAEGQRPGFYGGRASDYKSAHKFKGVDAQGTLS
KIFKLGGRDSRSGSPMARR mAnti-ASGPR_49C11_7K-LV-hIgGK-C (LV-hIgGK-C
sequence underlined) (SEQ ID NO: 15)
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAAT
ATCCAGAGGACAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCA
GGGGAGAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTAAGTCACATGCAC
TGGTACCAGCAGAAGTCAGGCACTTCCCCCAAAAGATGGATTTATGACACATCC
AGACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTT
ACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCA
GCAGTGGAGTAGTCACCCATGGTCGTTCGGTGGAGGCACCAAACTCGAGATCAA
ACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG
AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGG
CCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGA
GTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGA
CGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTGCGAAGTCACCC
ATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQ ID NO:
16) QIVLTQSPAIMSASPGEKVTMTCSASSSVSHMHWYQQKSGTSPKRWIYDTSRLASGV
PARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSHPWSFGGGTKLEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
mAnti-ASGPR_49C11_7H-LV-hIgG4H-C-hMOG (LV-hIgG4H-C sequence
underlined; hMOG sequence bold) (SEQ ID NO: 17)
ATGAGAGCGCTGATTCTTTTGTGCCTGTTCACAGCCTTTCCTGGTATCCTGTCTGA
TGTGCAGCTTCAGGAGTCAGGACCTGACCTGGTGAAACCTTCTCAGTCACTTTCA
CTCACCTGCACTGTCACTGGCTACTCCATCACCAGTGGTTATAGCTGGCACTGGA
TCCGGCAGTTTCCAGGAAACAAACTGGAATGGATGGGCTACATACTCTTCAGTGG
TAGCACTAACTACAACCCATCTCTGAAAAGTCGAATCTCTATCACTCGAGACACA
TCCAAGAACCAGTTCTTCCTGCAGTTGAATTCTGTGACTACTGAGGACACAGCCA
CATATTTCTGTGCAAGATCTAACTATGGTTCCTTTGCTTCCTGGGGCCAAGGGACT
CTGGTCACTGTCTCTGCAGCCAAAACAACGGGCCCATCCGTCTTCCCCCTGGCGC
CCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCG
GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAG
CGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGT
AGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGG
TCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTC
CTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCA
CGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGT
ACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAG
TTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGC
TGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCA
TCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACA
CCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCC
TGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCT
TCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAG
CCTCTCCCTGTCTCTGGGTAAAGCTAGTGGTCAGTTTAGAGTCATTGGGCCCAGA
CACCCTATAAGGGCTCTTGTGGGAGACGAGGTCGAGCTGCCGTGTCGCATTAGTC
CAGGCAAAAACGCCACAGGGATGGAAGTGGGGTGGTACAGGCCTCCCTTCTCTA
GGGTTGTGCATCTCTACCGCAACGGCAAAGATCAGGATGGAGATCAAGCTCCTG
AATATCGGGGCCGGACTGAGCTGCTCAAGGACGCGATCGGCGAGGGTAAGGTGA
CCTTGCGCATCCGAAATGTTAGATTCAGCGATGAAGGCGGATTTACGTGCTTCTT
TCGGGACCACTCATACCAGGAGGAAGCCGCAATGGAACTGAAGGTGGAGGACCC
CTTCTATTGGGTATCCCCAGCTAGCTGA (SEQ ID NO: 18)
DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYSWHWIRQFPGNKLEWMGYILFSGS
TNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYFCARSNYGSFASWGQGTLVTV
SAAKTTGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF
EGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK
PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQ
VYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF
FLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASGQFRVIGPRHP
IRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRNGKDQDGDQAPE
YRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQEEAAMELKVEDP FYWVSPAS
mAnti-ASGPR_49C11_7K-LV-hIgGK-C (LV-hIgGK-C sequence underlined)
(SEQ ID NO: 19)
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAAT
ATCCAGAGGACAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCA
GGGGAGAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTAAGTCACATGCAC
TGGTACCAGCAGAAGTCAGGCACTTCCCCCAAAAGATGGATTTATGACACATCC
AGACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTT
ACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCA
GCAGTGGAGTAGTCACCCATGGTCGTTCGGTGGAGGCACCAAACTCGAGATCAA
ACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG
AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGG
CCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGA
GTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGA
CGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTGCGAAGTCACCC
ATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQ ID NO:
20) QIVLTQSPAIMSASPGEKVTMTCSASSSVSHMHWYQQKSGTSPKRWIYDTSRLASGV
PARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSHPWSFGGGTKLEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 6xHis-Cohesin-hMOG (6xHis
underlined; Cohesin in bold; hMOG double underlined) (SEQ ID NO:
21) ATGGATCCCAAAGGATCCCTTTCCTGGAGAATACTTCTGTTTCTCTCCCTGGCTTT
TGAGTTGAGCTACGGACTCGACATCACATCCCACCATCACCATCACCATGACGAT
CTGGATGCAGTAAGGATTAAAGTGGACACAGTAAATGCAAAACCGGGAGACACA
GTAAGAATACCTGTAAGATTCAGCGGTATACCATCCAAGGGAATAGCAAACTGT
GACTTTGTATACAGCTATGACCCGAATGTACTTGAGATAATAGAGATAGAACCG
GGAGACATAATAGTTGACCCGAATCCTGACAAGAGCTTTGATACTGCAGTATATC
CTGACAGAAAGATAATAGTATTCCTGTTTGCAGAAGACAGCGGAACAGGAGCGT
ATGCAATAACTAAAGACGGAGTATTTGCTACGATAGTAGCGAAAGTAAAAGAAG
GAGCACCTAACGGACTCAGTGTAATCAAATTTGTAGAAGTAGGCGGATTTGCGA
ACAATGACCTTGTAGAACAGAAGACACAGTTCTTTGACGGTGGAGTAAATGTTG
GAGATACAACAGAACCTGCAACACCTACAACACCTGTAACAACACCGACAACAA
CAGATGATCTGGATGCAGCTAGTGGTCAGTTTAGAGTCATTGGGCCCAGACACCC
TATAAGGGCTCTTGTGGGAGACGAGGTCGAGCTGCCGTGTCGCATTAGTCCAGGC
AAAAACGCCACAGGGATGGAAGTGGGGTGGTACAGGCCTCCCTTCTCTAGGGTT
GTGCATCTCTACCGCAACGGCAAAGATCAGGATGGAGATCAAGCTCCTGAATAT
CGGGGCCGGACTGAGCTGCTCAAGGACGCGATCGGCGAGGGTAAGGTGACCTTG
CGCATCCGAAATGTTAGATTCAGCGATGAAGGCGGATTTACGTGCTTCTTTCGGG
ACCACTCATACCAGGAGGAAGCCGCAATGGAACTGAAGGTGGAGGACCCCTTCT
ATTGGGTATCCCCAGCTAGCTGA (SEQ ID NO: 22)
LDITSHHHHHHDDLDAVRIKVDTVNAKPGDTVRIPVRFSGIPSKGIANCDFVYSYD
PNVLEIIEIEPGDIIVDPNPDKSFDTAVYPDRKIIVFLFAEDSGTGAYAITKDGVFA
TIVAKVKEGAPNGLSVIKFVEVGGFANNDLVEQKTQFFDGGVNVGDTTEPATPT
TPVTTPTTTDDLDAASGQFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYR
PPFSRVVHLYRNGKDQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTC
FFRDHSYQEEAAMELKVEDPFYWVSPAS 6xHis-Cohesin-hMBP (6xHis underlined;
Cohesin in bold; hMBP double underlined) (SEQ ID NO: 23)
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGC
AGCCATATGGCTAGTATGGATCTGGATGCAGTAAGGATTAAAGTGGACACAGTA
AATGCAAAACCGGGAGACACAGTAAATATACCTGTAAGATTCAGTGGTATACCA
TCCAAGGGAATAGCAAACTGTGACTTTGTATACAGCTATGACCCGAATGTACTTG
AGATAATAGAGATAAAACCGGGAGAATTGATAGTTGACCCGAATCCTACCAAGA
GCTTTGATACTGCAGTATATCCTGACAGAAAGATGATAGTATTCCTGTTTGCGGA
AGACAGCGGAACAGGAGCGTATGCAATAACTAAAGACGGAGTATTTGCTACGAT
AGTAGCGAAAGTAAAAGAAGGAGCACCTAACGGGCTCAGTGTAATCAAATTTGT
AGAAGTAGGCGGATTTGCGAACAATGACCTTGTAGAACAGAAGACACAGTTCTT
TGACGGTGGAGTAAATGTTGGAGATACAACAGAACCTGCAACACCTACAACACC
TGTAACAACACCGACAACAACAGATGATCTAGATGCAGCTAGTGCATCACAAAA
GCGGCCTTCACAACGGCACGGATCTAAATATCTGGCGACAGCCTCTACCATGGAT
CACGCCAGGCATGGCTTTCTGCCCAGGCACAGAGATACTGGAATCTTGGACTCCA
TCGGCAGGTTCTTTGGCGGCGACCGAGGGGCTCCCAAGAGAGGGAGTGGCAAGG
ATAGCCATCATCCAGCCCGAACAGCCCACTACGGAAGCCTGCCGCAGAAAAGCC
ACGGTCGCACGCAGGATGAAAATCCCGTTGTGCACTTCTTCAAAAACATTGTGAC
CCCACGAACTCCTCCACCTTCCCAAGGCAAGGGCAGAGGTCTCAGTCTCAGCCGG
TTCAGTTGGGGGGCCGAGGGCCAGAGACCCGGATTTGGTTATGGGGGAAGGGCT
AGCGACTACAAGTCTGCACATAAGGGGTTCAAAGGGGTCGACGCACAGGGAACC
CTGTCCAAAATATTTAAGCTTGGTGGCCGCGACTCCCGCTCAGGCTCTCCCATGG
CTCGGCGCTGA (SEQ ID NO: 24)
MGSSHHHHHHSSGLVPRGSHMASMDLDAVRIKVDTVNAKPGDTVNIPVRFSGIPS
KGIANCDFVYSYDPNVLEIIEIKPGELIVDPNPTKSFDTAVYPDRKMIVFLFAEDS
GTGAYAITKDGVFATIVAKVKEGAPNGLSVIKFVEVGGFANNDLVEQKTQFFDG
GVNVGDTTEPATPTTPVTTPTTTDDLDAASASQKRPSQRHGSKYLATASTMDHAR
HGFLPRHRDTGILDSIGRFFGGDRGAPKRGSGKDSHHPARTAHYGSLPQKSHGRTQD
ENPVVHFFKNIVTPRTPPPSQGKGRGLSLSRFSWGAEGQRPGFGYGGRASDYKSAHK
GFKGVDAQGTLSKIFKLGGRDSRSGSPMARR
manti-hASGPR_6.3H9.1D11H-LV-hIgG4H-C-hMOG (LV-hIgG4H-C underlined,
variable region bold underline; hMOG in bold) (SEQ ID NO: 25)
ATGGAATGGAGCGGGGTCTTTATCTTTCTCCTGTCAGTAACTGCAGGTGCCCACT
CCCAGGTCCAGCTGCAGCAGTCTGGAGCTGAGCTGGTAAGGCCTGGGACTTCAG
TGAAGATGTCCTGCGAGGCTGCTAGATTCACCTTCAGTAACTACTGGATTGGTTG
GGTAAAGCAGAGGCCTGGACATGGCCTTGAGTGGATTGGAGATATTTTCCCTGG
AGGTGATTATACTAACTACAATAAGAAATTCAAGGACAAGGCCACACTGACTGC
AGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGA
CTCTGCCATCTATTACTGTGCAAGATCGGACTACGGTGGTTACTACGTCTTTGACT
ACTGGGGCCAAGGCACCACTCTCACAGICTCCTCAGCCAAAACAAAGGGCCCAT
CCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCT
GGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGAC
TCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGAC
CTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGT
TGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGG
GGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCC
GGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGG
TCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGC
CGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCT
GCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGG
CCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGA
GCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGT
CAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGAC
TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGC
AGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA
CACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGTGGTCAGTTTAGAGTC
ATTGGGCCCAGACACCCTATAAGGGCTCTTGTGGGAGACGAGGTCGAGCTGCCG
TGTCGCATTAGTCCAGGCAAAAACGCCACAGGGATGGAAGTGGGGTGGTACAGG
CCTCCCTTCTCTAGGGTTGTGCATCTCTACCGCAACGGCAAAGATCAGGATGGAG
ATCAAGCTCCTGAATATCGGGGCCGGACTGAGCTGCTCAAGGACGCGATCGGCG
AGGGTAAGGTGACCTTGCGCATCCGAAATGTTAGATTCAGCGATGAAGGCGGAT
TTACGTGCTTCTTTCGGGACCACTCATACCAGGAGGAAGCCGCAATGGAACTGAA
GGTGGAGGACCCCTTCTATTGGGTATCCCCAGCTAGCTGA (SEQ ID NO: 26)
QVQLQQSGAELVRPGTSVKMSCEAARFTFSNYWIGWVKQRPGHGLEWIGDIFP
GGDYTNYNICKFKDKATLTADTSSSTAYMQLSSLTSEDSAIYYCARSDYGGYYVF
DYWGQGTTLTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES
KYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK
TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKA
SGQFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRN
GKDQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQE
EAAMELKVEDPFYWVSPAS manti-hASGPR 6.3H9.1D11K-LV-hIgGK-C (LV-hIgGK-C
underlined, variable region bold underline) (SEQ ID NO: 27)
ATGGATTCACAGGCCCAGGTTCTTATGTTACTGCTGCTATGGGTATCTGGTACCT
GTGGGGACATTGTGATGTCACAGTCTCCATCCTCCCTAGCTGTGTCAGTTGGAGA
GAAGGTTACTATGAGCTGCAAGTCCAGTCAGAACCTTTTATATAGTAGCAATCAA
AAGAACTACTTGGCCTGGTACCAGCAGAAACCAGGGCAGTCTCCTAAACTGCTG
ATTTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTG
GATCTGGGACAGATTTCACICTCACCATCAGCAGTGTGAAGGCTGAAGACCTGGC
AGTCTATTACTGTCAGCAATATTATAGCTATCCTTACACGTTCGGAGGGGGGACC
AAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCAT
CTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTT
CTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGG
TAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCT
CAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGC
CTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAG
GGGAGAGTGTGCTAGCTGA (SEQ ID NO: 28)
DIVMSQSPSSLAVSVGEKVTMSCKSSQNLLYSSNOKNYLAWYQQKPGQSPKLLI
YWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPYTFGGGT
KLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAS
manti-hASGPR_5H8.1D4H-LV-hIgG4H-C-hMOG (LV-hIgG4H-C underlined,
variable region bold underline; hMOG in bold) (SEQ ID NO: 29)
ATGGCTTGGGTGTGGACCTTGCTATTCCTGATGGCAGCCGCCCAAAGTATCCAAG
CACAGATCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGACAG
TCAAGATCTCCTGCAAGGCTTCTGGTTATACCTTCACAGACTATTCAGTGCACTG
GGTGAAGCAGGCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGGATAAATACTGA
GACTGGTGAGCCAACATATGCAGATGACCTCAAGGGACGGTTTGCCTTCTCTTTG
GAAACCTCTGCCAGCACTGCCTATTTGCAGATCAACAACCTCAAAAATGAGGAC
ACGGCTACATATTTCTGTGCTAAACCTACCTATAGATTTTTTGACTACTGGGGCCA
AGGCACCACTCTCACAGCCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCC
CTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTG
GTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTG
ACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCC
TCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCT
GCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCA
AATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATC
AGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCT
GAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTC
AACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAG
GAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGG
ACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGT
CCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGG
TGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGA
CCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACG
GCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGG
GGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGTGGTCAGTTTAGAGTCATTGGG
CCCAGACACCCTATAAGGGCTCTTGTGGGAGACGAGGTCGAGCTGCCGTGTCGC
ATTAGTCCAGGCAAAAACGCCACAGGGATGGAAGTGGGGTGGTACAGGCCTCCC
TTCTCTAGGGTTGTGCATCTCTACCGCAACGGCAAAGATCAGGATGGAGATCAAG
CTCCTGAATATCGGGGCCGGACTGAGCTGCTCAAGGACGCGATCGGCGAGGGTA
AGGTGACCTTGCGCATCCGAAATGTTAGATTCAGCGATGAAGGCGGATTTACGTG
CTTCTTTCGGGACCACTCATACCAGGAGGAAGCCGCAATGGAACTGAAGGTGGA
GGACCCCTTCTATTGGGTATCCCCAGCTAGCTGA (SEQ ID NO: 30)
AQIQLVQSGPELICKPGETVKISCKASGYTFTDYSVHWVKQAPGKGLKWMGWIN
TETGEPTYADDLKGRFAFSLETSASTAYLQINNLKNEDTATYFCAKPTYRFFDY
WGQGTTLTASSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD
GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASG
QFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRNGK
DQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQEEA
AMELKVEDPFYWVSPAS manti-hASGPR_5H8.1D4K-LV-hIgGK-C (LV-hIgGK-C
underlined, variable region bold underline) (SEQ ID NO: 31)
ATGGATTCACAGGCCCAGGTTCTTATATTGCTGCTGCTATGGGTATCTGGTTCCTG
TGGGGACATTGTGATGTCACAGTCTCCATCCTCCCTGGCTGTGTCAGCAGGAGAG
AAGGTCACTATGAGCTGCAAATCCAGTCAGAGTCTGCTCAACAGTAGAACCCGA
AAGAACTACTTGGCTTGGTACCAGCAGAAACCAGGGCAGTCTCCTAAACTGCTG
ATCTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTG
GATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAGGACCTGGC
AGTTTATTACTGCAAGCAATCTTATAATCTGTGGACGTTCGGTGGAGGCACCAAG
CTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTG
ATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTA
TCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAA
CTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAG
CAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTG
CGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGG
AGAGTGTGCTAGCTGA (SEQ ID NO: 32)
DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRICNYLAWYQQKPGQSPKLLI
YWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLWTFGGGTK
LEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAS
[0151] Modular Domain Description of DC-Targeting Multiple
Sclerosis Immunotherapeutics
[0152] In certain aspects a DC-targeting multiple sclerosis
immunotherapeutic may be assembled by combining polypeptides
domains belonging to various classes of proteins categorized
according to a specific function. In a general sense these domains
may belong to classes comprising antibodies, antibody CDRs,
antibody heavy chains, antibody light chains, linkers, antigens,
coupling domains, adjuvants, purification tags, labelling tags or
reporter tags.
[0153] Non limiting examples of domain categories and specific
examples within each category are illustrated in Table 1. (Flgln is
abbreviation for Flagellin)
TABLE-US-00003 TABLE 1 SEQ SEQ SEQ Peptide ID ID Coupling ID
Linkers NO Antigens NO Domains NO Flex-v1 33 hMBP 36 Cohesin 38
Flexx-v1 34 hMOG 37 Dockerin 39 Flexx-v2 35 Dockerinv2 40 SEQ SEQ
Adju- ID ID vants NO Antibodies NO hIL-10 41 mAnti-ASGPR_49C11_7H
(heavy chain) 42 mAnti-ASGPR_49C11_7K (light chain) 43
manti-hASGPR_6.3H9.1D11H (heavy chain) 44 manti-hASGPR_6.3H9.1D11K
(light chain) 45 manti-hASGPR_5H8.1D4H (heavy chain) 46
manti-hASGPR_5H8.1D4K (light chain) 47 mAnti-ASGPR_4G2.2_(heavy
chain) 48 mAnti-ASGPR_4G2.2_(light chain) 49
mAnti-ASGPR-5F10H(heavy chain) 50 mAnti-ASGPR-5F10H(light chain) 51
mAnti-ASGPR1H11(heavy chain) 52 mAnti-ASGPR1H11(light chain) 53
[0154] In some embodiments, components of a DC-targeting
immunotherapeutic may be constructed as illustrated below (For the
schematic representations that follow, the following abbreviations
apply: Peptide Linker (PL); Antigen (Ag); Tag (Tg); Coupling Domain
(CD); Adjuvant (Adj); Antibody (Ab). A number following an
abbreviation differentiates between different types of that domain
within a construct. A hyphen ("-") used may represent a covalent
bond, such as a peptide bond between two domains of a polypeptide
that is formed during translation of, for example, a fusion
protein. The covalent bond may also be formed by, but is not
limited to, known chemical coupling means. A hyphen may also
represent a high-affinity, intermediate affinity, or low affinity
non-covalent interaction. Examples of these types of non-covalent
interactions are known to those skilled in the art and include, but
are not limited to, antibody/antigen interaction, receptor/ligand
interaction, avidin/biotin interaction, cohesin/dockerin
interaction and barnase/barstar interaction.)
[0155] CD-Ag-Tg;
[0156] Ab-Ag-Tg;
[0157] Ab-CD-Ag-Tg;
[0158] Ab-PL-Ag;
[0159] Ab-PL-Ag-Tg;
[0160] Ab-PL-Ag(1)-Ag(2)-Tg;
[0161] Ab-CD-PL;
[0162] Ab-Ag;
[0163] Tg-CD-Ag;
[0164] Tg-CD-Ag-Tg;
[0165] Ab-Adj;
[0166] Ab-Adj-Adj;
[0167] Tg-CD-Adj;
[0168] Tg-CD-Adj(1)-Adj(2);
[0169] CD-Adj;
[0170] Ab-PL-Ag-PL-Ag;
[0171] PL includes but is not limited to peptide linkers. Linkers
with non-peptide bonds are also contemplated. In some embodiments
the tag is absent from the construct or has been removed.
[0172] In one particular embodiment, an antibody-antigen fusion
protein (Ab.Ag) comprises the following formula:
[0173] Ab-(PL-Ag)x;
[0174] Ab-(Ag-PL)x;
[0175] Ab-(PL-Ag-PL)x;
[0176] Ab-(Ag-PL-Ag)x;
[0177] Ab-(PL-Ag)x-PL; or
[0178] Ab-(Ag-PL)x-Ag;
[0179] wherein Ab is an DC targeting antibody or a fragment
thereof; wherein PL is a peptide linker; wherein Ag is an myelin
sheath protein or component; and, wherein x is an integer from 1 to
20, or any range derivable therein. PL includes but is not limited
to peptide linkers. Linkers with non-peptide bonds are also
contemplated.
[0180] In one embodiment, the -(PL-Ag)x, -(Ag-PL)x, -(PL-Ag-PL)x,
or -(Ag-PL-Ag)x are located at the carboxy terminus of the Ab heavy
chain or fragment thereof.
[0181] In another embodiment, the -(PL-Ag)x, -(Ag-PL)x,
-(PL-Ag-PL)x, or -(Ag-PL-Ag)x are located at the carboxy terminus
of the Ab light chain or fragment thereof.
[0182] In one embodiment, the antibody-antigen complex (Ab:Ag)
comprises the following formula
[0183] Ab.Doc:Coh.Ag;
[0184] Ab.Coh:Doc.Ag;
[0185] Ab.(Coh)x:(Doc.Ag)x;
[0186] Ab.(Doc)x:(Coh.Ag)x;
[0187] Ab.(Coh.Doc)x:(Doc.Ag.sup.1)(Coh.Ag.sup.2); or
[0188] Ab.(Coh)x(Doc)x:(Doc.Ag.sup.1)x(Coh.Ag.sup.2)x;
[0189] wherein Ab is a DC targeting antibody or a fragment thereof;
wherein Ag is an
[0190] Myelin sheath protein or component (Ag.sup.1 and Ag.sup.2
being two distinct Myelin sheath protein or components); wherein
Doc is Dockerin; wherein Coh is Cohesin and wherein x is an integer
from 1 to 10, or any range derivable therein, denoting the number
of molecules or domains in the parentheses immediately preceding
it. A period (".") is used to denote a covalent bond between two
molecules or domains (examples of these covalent bonds include, but
are not limited to, a peptide bond between two domains of a
polypeptide that is formed during translation of, for example, a
fusion protein. The covalent bond may also be formed by, but is not
limited to, known chemical coupling means). A colon (":") is used
to denote a non-covalent interaction between a cohesin and dockerin
domain.
IV. Methods of Treatment
[0191] As discussed above, the compositions and methods of using
these compositions can treat a subject (e.g., prevent multiple
sclerosis or evoke a robust immune tolerance to a multiple
sclerosis autoimmune bout) having, suspected of having, or at risk
of developing an autoimmune disorder or related disease,
particularly those related to multiple sclerosis.
[0192] As used herein the phrase "immune response" or its
equivalent "immunological response" refers to a humoral (antibody
mediated), cellular (mediated by antigen-specific T cells or their
secretion products) or both humoral and cellular response directed
against a protein, peptide, or polypeptide of the embodiments in a
recipient patient. Treatment or therapy can be an active immune
response induced by administration of immunogen or a passive
therapy effected by administration of antibody, antibody containing
material, or primed T-cells.
[0193] For purposes of this specification and the accompanying
claims the terms "epitope" and "antigenic determinant" are used
interchangeably to refer to a site on an antigen to which B and/or
T cells respond or recognize. B-cell epitopes can be formed both
from contiguous amino acids or noncontiguous amino acids juxtaposed
by tertiary folding of a protein. Epitopes formed from contiguous
amino acids are typically retained on exposure to denaturing
solvents whereas epitopes formed by tertiary folding are typically
lost on treatment with denaturing solvents. An epitope typically
includes at least 3, and more usually, at least 5 or 8-10 amino
acids in a unique spatial conformation. Methods of determining
spatial conformation of epitopes include those methods described in
Epitope Mapping Protocols (1996). T cells recognize continuous
epitopes of about nine amino acids for CD8 cells or about 13-15
amino acids for CD4 cells. T cells that recognize the epitope can
be identified by in vitro assays that measure antigen-dependent
proliferation, as determined by 3H-thymidine incorporation by
primed T cells in response to an epitope (Burke et al., 1994), by
antigen-dependent killing (cytotoxic T lymphocyte assay, Tigges et
al., 1996) or by cytokine secretion.
[0194] The presence of a cell-mediated immunological response can
be determined by proliferation assays (CD4 (+) T cells) or CTL
(cytotoxic T lymphocyte) assays. The relative contributions of
humoral and cellular responses to the protective or therapeutic
effect of an immunogen can be distinguished by separately isolating
IgG and T-cells from an immunized syngeneic animal and measuring
protective or therapeutic effect in a second subject. As used
herein and in the claims, the terms "antibody" or "immunoglobulin"
are used interchangeably.
[0195] Optionally, an antibody or preferably an immunological
portion of an antibody, can be chemically conjugated to, or
expressed as, a fusion protein with other proteins. For purposes of
this specification and the accompanying claims, all such fused
proteins are included in the definition of antibodies or an
immunological portion of an antibody.
[0196] In one embodiment a method includes treatment for a disease
or condition caused by an autoimmune disorder. In certain aspects
embodiments include methods of treatment of multiple sclerosis. In
some embodiments, the treatment is administered in the presence of
myelin sheath protein or components. Furthermore, in some examples,
treatment comprises administration of other agents commonly used
against autoimmune disorders, such as one or more immunosuppressant
compounds.
[0197] The therapeutic compositions are administered in a manner
compatible with the dosage formulation, and in such amount as will
be therapeutically effective. The quantity to be administered
depends on the subject to be treated. Precise amounts of active
ingredient required to be administered depend on the judgment of
the practitioner. Suitable regimes for initial administration and
boosters are also variable, but are typified by an initial
administration followed by subsequent administrations.
[0198] Compositions of the current methods may be administered to
patients via any route used to introduce vaccines or antibodies to
patients. Such routes include, but are not limited to, mucosal or
intramuscular delivery. In particular embodiments, a composition is
administered to a patient intranasally or by inhalation. In other
embodiments, a composition is administered intravenously or by
intravenous injection. In additional embodiments, the
administration of compositions includes, but is not limited to
oral, parenteral, subcutaneous, intramuscular, intravenous
administration, or various combinations thereof.
[0199] The manner of application may be varied widely. Any of the
conventional methods for administration of a polypeptide
therapeutic are applicable. These are believed to include oral
application on a solid physiologically acceptable base or in a
physiologically acceptable dispersion, parenterally, by injection
and the like. The dosage of the composition will depend on the
route of administration and will vary according to the size and
health of the subject. In one treatment scheme, the patient
receives a subcutaneous dose of the immunotherapeutic every week
for three weeks and then every first week for an additional 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.
[0200] In certain instances, it will be desirable to have multiple
administrations of the composition, e.g., 2, 3, 4, 5, 6 or more
administrations. The administrations can be at 1, 2, 3, 4, 5, 6, 7,
8, to 5, 6, 7, 8, 9 ,10, 11, 12 twelve week intervals, including
all ranges there between.
[0201] Combination Therapy
[0202] The compositions and related methods, particularly
administration of an antibody that binds DC receptor and delivers a
myelin sheath protein or component or a peptide to a
patient/subject, may also be used in combination with the
administration of multiple sclerosis effective strategies or
traditional immunomodulatory therapies. Such strategies or
therapies may be directed, among other aims, to modify the disease
course, treat exacerbations, manage symptoms or improve a
compromised function. Examples of disease-modifying agents include,
but are not limited to, Aubagio (teriflunomide), Avonex (interferon
beta-1a), Betaseron and Extavia (interferon beta-lb), Copaxone
(glatiramer acetate), Extavia (interferon beta-1b), Gilenya
(fingolimod), Novantrone (mitoxantrone), Rebif (interferon
beta-1a), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab).
In other embodiments the disease-modifying therapeutic to be used
in combination therapy include, but are not limited to, Fingolimod
(Gilenya), Methotrexate, azathioprine (Imuran), intravenous
immunoglobulin (IVIg) and cyclophosphamide (Cytoxan).
[0203] In some instances the combination therapeutic may be used to
control symptoms. Examples of medications or pharmaceuticals that
may be used to control multiple sclerosis symptoms include, but are
not limited to, dalfamipridine (Ampyra), tizanidine (Zanaflex),
diazepam (Valium), clonazepam (Klonopin), dantrolene (Dantrium),
baclofen (Lioresal), or any benzodiazepine, cholinergic
medications, or amantadine.
[0204] In one aspect, it is contemplated that a therapy is used in
conjunction with immunosuppressants. In other aspects, a therapy is
used in conjunction with disease-modifying agents, symptom
controlling agents, or agents to improve compromised function.
Alternatively, the therapy may precede or follow the other agent
treatment by intervals ranging from minutes to weeks. In
embodiments where the other agents and/or a proteins or
polynucleotides are administered separately, one would generally
ensure that a significant period of time did not expire between the
time of each delivery, such that the therapeutic composition would
still be able to exert an advantageously combined effect on the
subject. In such instances, it is contemplated that one may
administer both modalities within about 12-24 h of each other and,
more preferably, within about 6-12 h of each other. In some
situations, it may be desirable to extend the time period for
administration significantly, however, where several days (2, 3, 4,
5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse
between the respective administrations.
[0205] Various combinations of therapy may be employed, for example
immunosuppressant therapy, disease-modifying agents, symptom
controlling agents, or agents to improve compromised function is
"A" and an antibody immunotherapeutic that comprises an antibody
that binds a DC receptor and delivers an myelin sheath protein or
component or a peptide or consensus peptide thereof is "B":
TABLE-US-00004 A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B
B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B
A/A/A/B B/A/A/A A/B/A/A A/A/B/A
[0206] Administration of the antibody compositions to a
patient/subject will follow general protocols for the
administration of such compounds, taking into account the toxicity,
if any, of the composition. It is expected that the treatment
cycles would be repeated as necessary. It is also contemplated that
various standard therapies, such as hydration, may be applied in
combination with the described therapy.
[0207] General Pharmaceutical Compositions
[0208] In some embodiments, pharmaceutical compositions are
administered to a subject. Different aspects may involve
administering an effective amount of a composition to a subject. In
some embodiments, an antibody that binds DC receptor and delivers a
myelin sheath protein or component or a peptide or consensus
peptide thereof may be administered to the patient to protect
against or treat against multiple sclerosis. Alternatively, an
expression vector encoding one or more such antibodies or
polypeptides or peptides may be given to a patient as a
preventative treatment. Additionally, such compositions can be
administered in combination with an immunosuppressant. Such
compositions will generally be dissolved or dispersed in a
pharmaceutically acceptable carrier or aqueous medium.
[0209] The phrases "pharmaceutically acceptable" or
"pharmacologically acceptable" refer to molecular entities and
compositions that do not produce an adverse, allergic, or other
untoward reaction when administered to an animal or human. As used
herein, "pharmaceutically acceptable carrier" includes any and all
solvents, dispersion media, coatings, antibacterial and antifungal
agents, isotonic and absorption delaying agents, and the like. The
use of such media and agents for pharmaceutical active substances
is well known in the art. Except insofar as any conventional media
or agent is incompatible with the active ingredients, its use in
immunogenic and therapeutic compositions is contemplated.
Supplementary active ingredients, such as other anti-infective
agents, immunosuppressants and immunotherapeutics, can also be
incorporated into the compositions.
[0210] The active compounds can be formulated for parenteral
administration, e.g., formulated for injection via the intravenous,
intramuscular, sub-cutaneous, or even intraperitoneal routes.
Typically, such compositions can be prepared as either liquid
solutions or suspensions; solid forms suitable for use to prepare
solutions or suspensions upon the addition of a liquid prior to
injection can also be prepared; and, the preparations can also be
emulsified.
[0211] The pharmaceutical forms suitable for injectable use include
sterile aqueous solutions or dispersions; formulations including
sesame oil, peanut oil, or aqueous propylene glycol; and sterile
powders for the extemporaneous preparation of sterile injectable
solutions or dispersions. In all cases the form must be sterile and
must be fluid to the extent that it may be easily injected. It also
should be stable under the conditions of manufacture and storage
and must be preserved against the contaminating action of
microorganisms, such as bacteria and fungi.
[0212] The proteinaceous compositions may be formulated into a
neutral or salt form. Pharmaceutically acceptable salts, include
the acid addition salts (formed with the free amino groups of the
protein) and which are formed with inorganic acids such as, for
example, hydrochloric or phosphoric acids, or such organic acids as
acetic, oxalic, tartaric, mandelic, and the like. Salts formed with
the free carboxyl groups can also be derived from inorganic bases
such as, for example, sodium, potassium, ammonium, calcium, or
ferric hydroxides, and such organic bases as isopropylamine,
trimethylamine, histidine, procaine and the like.
[0213] A pharmaceutical composition can include a solvent or
dispersion medium containing, for example, water, ethanol, polyol
(for example, glycerol, propylene glycol, and liquid polyethylene
glycol, and the like), suitable mixtures thereof, and vegetable
oils. The proper fluidity can be maintained, for example, by the
use of a coating, such as lecithin, by the maintenance of the
required particle size in the case of dispersion, and by the use of
surfactants. The prevention of the action of microorganisms can be
brought about by various antibacterial and antifungal agents, for
example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal,
and the like. In many cases, it will be preferable to include
isotonic agents, for example, sugars or sodium chloride. Prolonged
absorption of the injectable compositions can be brought about by
the use in the compositions of agents delaying absorption, for
example, aluminum monostearate and gelatin.
[0214] Sterile injectable solutions are prepared by incorporating
the active compounds in the required amount in the appropriate
solvent with various of the other ingredients enumerated above, as
required, followed by filtered sterilization or an equivalent
procedure. Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle which
contains the basic dispersion medium and the required other
ingredients from those enumerated above. In the case of sterile
powders for the preparation of sterile injectable solutions, the
preferred methods of preparation are vacuum-drying and
freeze-drying techniques, which yield a powder of the active
ingredient, plus any additional desired ingredient from a
previously sterile-filtered solution thereof.
[0215] Administration of the compositions will typically be via any
common route. This includes, but is not limited to oral, nasal, or
buccal administration. Alternatively, administration may be by
orthotopic, intradermal, subcutaneous, intramuscular,
intraperitoneal, intranasal, or intravenous injection. In certain
embodiments, a immunotherapeutic composition may be inhaled (e.g.,
U.S. Pat. No. 6,651,655, which is specifically incorporated by
reference). Such compositions would normally be administered as
pharmaceutically acceptable compositions that include
physiologically acceptable carriers, buffers or other
excipients.
[0216] An effective amount of therapeutic or prophylactic
composition is determined based on the intended goal. The term
"unit dose" or "dosage" refers to physically discrete units
suitable for use in a subject, each unit containing a predetermined
quantity of the composition calculated to produce the desired
responses discussed above in association with its administration,
i.e., the appropriate route and regimen. The quantity to be
administered, both according to number of treatments and unit dose,
depends on the protection desired.
[0217] Precise amounts of the composition also depend on the
judgment of the practitioner and are peculiar to each individual.
Factors affecting dose include physical and clinical state of the
subject, route of administration, intended goal of treatment
(alleviation of symptoms versus cure), and potency, stability, and
toxicity of the particular composition.
[0218] Upon formulation, solutions will be administered in a manner
compatible with the dosage formulation and in such amount as is
therapeutically or prophylactically effective. The formulations are
easily administered in a variety of dosage forms, such as the type
of injectable solutions described above.
IV. EXAMPLES
[0219] The following examples are included to demonstrate preferred
embodiments. It should be appreciated by those of skill in the art
that the techniques disclosed in the examples which follow
represent techniques discovered by the inventors to function well
in the practice of the embodiments, and thus can be considered to
constitute preferred modes for their practice. However, those of
skill in the art should, in light of the present disclosure,
appreciate that many changes can be made in the specific
embodiments which are disclosed and still obtain a like or similar
result without departing from the spirit and scope of the
invention.
Example 1
Characterization and Response to Anti-DC-ASGPR Antibodies
[0220] All animals (total 12 animals: 6 animals per group) were
pre-immunized with live influenza viruses (H1N1, PR8). Sera from
all animals displayed HA1-specific IgG (data not shown). Four
months after priming, animals were immunized i.d. with either
anti-LOX-1-HA1 (right arm) and anti-LOX-1-PSA (left arm) or
anti-DC-ASGPR-HA1 (right arm) and anti-DC-ASGPR-PSA (left arm).
After three immunizations at 40 days intervals with the same
recombinant fusion proteins, blood was collected as indicated.
PBMCs from animals immunized with anti-DC-ASGPR-HA1 secreted higher
levels of IL-10 in response to HA1 peptide pool when compared to
those immunized with anti-LOX-1-HA1 (FIG. 2B, upper panel).
Conversely, PBMCs from animals immunized with anti-LOX-1-HA1
secreted significantly higher levels of IFNy than animals immunized
with anti-DC-ASGPR-HA1 (FIG. 2B, lower panel). The same findings
were made with animals that were primed and boosted twice with PSA
fusion proteins. PSA-specific IL-10-producing cellular responses
were preferentially mounted in animals immunized with
anti-DC-ASGPR-PSA (FIG. 1B, upper panel). Animals immunized with
anti-LOX-1-PSA mounted higher PSA-specific IFN.gamma.-producing
cellular responses than animals immunized with anti-DC-ASGPR-PSA
(FIG. 1B, lower panel). For both HAI and PSA, the peak of
IL-10-producing cellular responses was obtained at week one, but
the peak of IFNy-producing cellular responses was obtained at week
three. Taken together, the data show that targeting antigens to in
vivo DCs via DC-ASGPR can establish antigen-specific
IL-10-producing T cells in vivo.
[0221] Monocyte-derived IFNDCs were cultured overnight in the
plates coated with indicated monoclonal antibodies. Cells were
harvested and RNA expression levels of IL-10, IL-6 and TNFalpha was
assessed by real time PCR using commercially available PCR primers.
Compared to other clones of anti-DC-ASGPR antibodies, 5H8 and 49C11
resulted in increased expression of IL-10. They also induced
increased levels of IL-6 and TNFa (FIG. 3A).
[0222] The amount of IL-10 in the culture supernatants were
assessed by Luminex assay. Consistent with the data in the left
panel, 5H8 and 49C11 induced IFNDCs to secrete increased amount of
IL-10 (FIG. 3B).
[0223] CD11c+ blood DCs from healthy donors (n=6) and MS patients
(n=25) were stained with 5H8, 4G2 and 49C11. CD11c+ DCs from both
healthy and patient donors displayed two distinct patterns of
anti-DC-ASGPR antibody bindings: all of the anti-DC-ASGPR
antibodies bound well to CD11c+ DCs from approximately 50% of the
donors, while CD11c+ DCs from the other 50% of donors were weakly
stained with the three clones of anti-DC-ASGPR antibodies. However,
49C11 was able to bind to CD11c+ DCs better than the other two
clones. In addition to its (49C11) ability to induce IL-10, 49C11
can bind well to DCs. Thus 49C11 was selected as a clone to be
fused to MS antigens (FIG. 4).
[0224] CD11c+ DCs from healthy donors were stained with different
concentrations (0, 3, 10, and 30 ug/ml) of anti-DC-ASGPR-MBP or MBP
alone. The data indicate that anti-DC-ASGPR-MBP binds well to the
DCs (FIG. 6B, upper panels).
[0225] PBMCs from healthy and MS patient donors were loaded with 5
ug/ml anti-DC-ASGPR-MBP fusion protein or MBP alone. Cells were
incubated for 7 days and then T cells were restimulated for 48 h in
the presence of MBP-derived peptide clusters. IFNg and IL-10
secreted from T cells were assessed by the Luminex. Compared to
MBP, anti-DC-ASGPR-MBP resulted in increased MBP-specific IL-10
producing T cell responses in both healthy and patient donors (FIG.
6B, lower panels).
[0226] CD1 1 c+ DCs from healthy donors were stained with different
concentrations (0, 3, 10, and 30 ug/ml) of anti-DC-ASGPR-MOG or MOG
alone. The data indicate that anti-DC-ASGPR-MOG binds well to the
DCs (FIG. 7A).
[0227] (Lower panels) PBMCs from MS patient donor were loaded with
5 ug/ml anti-DC-ASGPR-MOG fusion protein or MBP alone. Cells were
incubated for 7 days and then T cells were restimulated for 48 h in
the presence of MBP-derived peptide clusters. IFNg and IL-10
secreted from T cells were assessed by the Luminex. Compared to
MOG, anti-DC-ASGPR-MOG resulted in increased MBP-specific IL-10
producing T cell responses in both healthy and patient donors (FIG.
7B).
Example 2
Effect of Anti-DC-ASGPR-MOG on EAE Induction/Progression in NHP
[0228] The following experimental results were kindly provided by
Dr. Roger Le Grand, who worked with the inventors.
[0229] To test the effects of anti-DC-ASGPR-MOG on the
development/progression of EAE in non-human primates (NHP), an EAE
model in cynomolgus macaques was used.
[0230] Experimental autoimmune encephalomyelitis (EAE), sometimes
referred to as experimental allergic encephalomyelitis, is an
animal model of brain inflammation. It is an inflammatory
demyelinating disease of the central nervous system (CNS).
Originally used with rodents, it is widely studied as an animal
model of human CNS demyelinating diseases, including multiple
sclerosis and acute disseminated encephalomyelitis (ADEM). EAE is
also the prototype for T-cell-mediated autoimmune disease in
general. Animals are scored according to the following clinical
signs and duration of symptoms:
TABLE-US-00005 Maximal EAE cumulative score Clinical signs duration
0 Asymptomatic End of the study 1 Discrete behavioral disorder with
stereotypia, 20 weeks ptosis, nystagmus, discrete paresis, rubbing.
2 Moderate behavioral disorders 4 weeks (shaking, oculomotor
paralysis, paresis with compensation). 3 Walking disorders (ataxia,
lameness) without 2 weeks social or feeding behavior impact. 4
Severe behavioral disorders (paralysis, paresis) <18 h leading
to lack of self feeding. 5 Coma. <6 h 6 Moribund. <1 h
[0231] Experimental Design. The Experimental Design is summarized
in FIG. 8. Group 1 (Experimental group: consisting of 3 cynomolgus
macaques) and Group 2 (Control group: consisting of 3 cynomolgus
macaques) were injected with hMOG in incomplete Freund's adjuvant
on days 0, 28 and 56. Experimental Group 1 animals received
anti-ASGPR-hMOG injections on days 7, 14, 21, 35, and 63. Control
group 2 animals received anti-ASGPR-hPSA injections on days 7, 14,
21, 35, and 63.
[0232] Anti-DC-ASGPR-MOG suppresses the development/progression of
EAE in NHP. During the entire period of the experiment, animals
were monitored daily to measure EAE score. None of the animals (ID
numbers AP607, CB385, and CB457) treated with anti-DC-ASGPR-MOG
showed any clinical signs of disease. These animals did not show
escalated EAE disease scores. However, two (AM637 and CB207) out of
three animals (AM637, CB207, and 21983) in the control group
displayed escalated EAE scores between days 20 and 37 (when both
animals died; FIGS. 9 and 10). Taken together, the inventors
conclude that anti-DC-ASGPR-MOG is able to suppress the
development/progression of EAE in NHP.
[0233] To further confirm whether the clinical signs observed
(FIGS. 9 and 10) in the animals in the control group (Group 2 in
FIG. 8) were due to inflammation in the brain, magnetic resonance
imaging (MRI) of the brain of animal AM637 on day 22 was performed.
FIG. 11 shows that i.v. administered gadolinium is dispersed,
indicating that there was leakage in the blood vessels into the
brain. A T2 image also shows the accumulation of water in several
spots, indicating that myelin in this animal was damaged and thus
less able to exclude water. Considering Flair data along with T2
and gadolinium data, it was concluded that this animal had severe
inflammation in the brain, along with demyelination, which is a
typical sign of EAE.
[0234] In summary, the inventors demonstrated that 1) cynomolgus
macaques develop EAE by immunizing with MOG peptide and an adjuvant
and 2) anti-DC-ASGPR-MOG, but not anti-DC-ASGPR-hPSA, suppressed
the development/progression of EAE in cynomolgus macaques.
[0235] All of the methods disclosed and claimed herein can be made
and executed without undue experimentation in light of the present
disclosure. While the compositions and methods of this invention
have been described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the methods and in the steps or in the sequence of steps
of the method described herein without departing from the concept,
spirit and scope of the invention. More specifically, it will be
apparent that certain agents which are both chemically and
physiologically related may be substituted for the agents described
herein while the same or similar results would be achieved. All
such similar substitutes and modifications apparent to those
skilled in the art are deemed to be within the spirit, scope and
concept of the invention as defined by the appended claims.
Sequence CWU 1
1
53125PRTArtificial SequenceSynthetic sequence 1Ser Ser Val Ser Pro
Thr Thr Ser Val His Pro Thr Pro Thr Ser Val 1 5 10 15 Pro Pro Thr
Pro Thr Lys Ser Ser Pro 20 25 225PRTArtificial SequenceSynthetic
sequence 2Ser Ser Val Ser Pro Thr Thr Ser Val His Pro Thr Pro Thr
Ser Val 1 5 10 15 Pro Pro Thr Pro Thr Lys Ser Ser Pro 20 25
325PRTArtificial SequenceSynthetic sequence 3Thr Val Thr Pro Thr
Ala Thr Ala Thr Pro Ser Ala Ile Val Thr Thr 1 5 10 15 Ile Thr Pro
Thr Ala Thr Thr Lys Pro 20 25 425PRTArtificial SequenceSynthetic
sequence 4Thr Asn Gly Ser Ile Thr Val Ala Ala Thr Ala Pro Thr Val
Thr Pro 1 5 10 15 Thr Val Asn Ala Thr Pro Ser Ala Ala 20 25
5446PRTArtificial SequenceSynthetic sequence 5Asp Val Gln Leu Gln
Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser
Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly 20 25 30 Tyr
Ser Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40
45 Met Gly Tyr Ile Leu Phe Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln
Phe Phe 65 70 75 80 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala
Thr Tyr Phe Cys 85 90 95 Ala Arg Ser Asn Tyr Gly Ser Phe Ala Ser
Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ala Ala Lys Thr
Thr Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170
175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro
Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly
Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly
Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg
Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295
300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe
Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420
425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 435
440 445 6213PRTArtificial SequenceSynthetic sequence 6Gln Ile Val
Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu
Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser His Met 20 25
30 His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
35 40 45 Asp Thr Ser Arg Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser
Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
Ser Ser His Pro Trp Ser 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155
160 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
Tyr Ala 180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
Thr Lys Ser Phe 195 200 205 Asn Arg Gly Glu Cys 210
7449PRTArtificial SequenceSynthetic sequence 7Gln Ile Gln Leu Val
Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys
Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly
Met Asn Trp Val Lys Gln Val Pro Gly Lys Gly Leu Arg Trp Met 35 40
45 Gly Trp Met Asp Thr Phe Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr
Ala Tyr 65 70 75 80 Leu Gln Ile Asn Ser Leu Lys Asn Glu Asp Thr Ala
Thr Tyr Phe Cys 85 90 95 Ala Arg Gly Gly Ile Leu Arg Leu Asn Tyr
Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser
Ala Lys Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170
175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp
His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser
Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe
Glu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys
Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr
Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295
300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly
Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420
425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
Ala 435 440 445 Ser 8214PRTArtificial SequenceSynthetic sequence
8Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 1
5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn
Arg 20 25 30 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg
Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Ala Leu
Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Leu Ala Thr Tyr Tyr
Cys Gln Gln Cys Trp Thr Ser Pro Tyr 85 90 95 Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val
Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135
140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu
Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210
9445PRTArtificial SequenceSynthetic sequence 9Glu Val Gln Leu Gln
Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr
Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40
45 Gly Asp Ile Asn Pro Asn Tyr Gly Asp Thr Phe Tyr Asn Gln Lys Phe
50 55 60 Glu Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg Thr
Ala Tyr 65 70 75 80 Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala
Val Tyr Tyr Cys 85 90 95 Gly Arg Gly Asp Tyr Gly Tyr Phe Asp Val
Trp Gly Ala Gly Thr Thr 100 105 110 Val Thr Val Ser Ser Ala Lys Thr
Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170
175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro
Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly
Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly
Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg
Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295
300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe
Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420
425 430 Tyr Thr Gln Lys Ser Leu Leu Ser Leu Gly Lys Ala Ser 435 440
445 10214PRTArtificial SequenceSynthetic sequence 10Asp Ile Val Met
Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg
Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala 20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35
40 45 Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn
Val Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr
Ser Ser Asn Pro Tyr 85 90 95 Met Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165
170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210
11447PRTArtificial SequenceSynthetic sequence 11Gln Leu Gln Gln Ser
Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val 1 5 10 15 Lys Ile Ser
Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met 20 25 30 His
Trp Val Arg Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly 35 40
45 Ile Asn Pro Ile Asn Gly Gly Pro Thr Tyr Asn Gln Lys Phe Lys Gly
50 55 60 Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
Met Glu 65 70 75 80 Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr Cys Ala Arg 85 90 95 Trp Asp Tyr Gly Ser Arg Asp Val Met Asp
Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser Ala Lys
Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Cys Ser Arg
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155
160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
Ser Ser 180 185 190 Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp
His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Ser
Lys Tyr Gly Pro Pro Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Phe
Glu Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys
Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 260 265 270 Phe
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280
285 Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu
290 295 300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys 305 310 315 320 Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
Lys Thr Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser 340 345 350 Gln Glu Glu Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400
Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln 405
410 415 Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn 420 425 430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
Ala Ser 435 440 445 12214PRTArtificial SequenceSynthetic sequence
12Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly 1
5 10 15 Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr
Tyr 20 25 30 Val Ser Trp Tyr Gln Gln Arg Pro Glu Gln Ser Pro Lys
Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro
Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Ala Thr Asp Phe Thr Leu
Thr Ile Ser Ser Val Gln Ala 65 70 75 80 Glu Asp Leu Ala Asp Tyr His
Cys Gly Gln Thr Tyr Ser Tyr Ile Phe 85 90 95 Thr Phe Gly Ser Gly
Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val
Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135
140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu
Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210
131992DNAArtificial SequenceSynthetic sequence 13atgagagcgc
tgattctttt gtgcctgttc acagcctttc ctggtatcct gtctgatgtg 60cagcttcagg
agtcaggacc tgacctggtg aaaccttctc agtcactttc actcacctgc
120actgtcactg gctactccat caccagtggt tatagctggc actggatccg
gcagtttcca 180ggaaacaaac tggaatggat gggctacata ctcttcagtg
gtagcactaa ctacaaccca 240tctctgaaaa gtcgaatctc tatcactcga
gacacatcca agaaccagtt cttcctgcag 300ttgaattctg tgactactga
ggacacagcc acatatttct gtgcaagatc taactatggt 360tcctttgctt
cctggggcca agggactctg gtcactgtct ctgcagccaa aacaacgggc
420ccatccgtct tccccctggc gccctgctcc aggagcacct ccgagagcac
agccgccctg 480ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg
tgtcgtggaa ctcaggcgcc 540ctgaccagcg gcgtgcacac cttcccggct
gtcctacagt cctcaggact ctactccctc 600agcagcgtgg tgaccgtgcc
ctccagcagc ttgggcacga agacctacac ctgcaacgta 660gatcacaagc
ccagcaacac caaggtggac aagagagttg agtccaaata tggtccccca
720tgcccaccct gcccagcacc tgagttcgaa gggggaccat cagtcttcct
gttcccccca 780aaacccaagg acactctcat gatctcccgg acccctgagg
tcacgtgcgt ggtggtggac 840gtgagccagg aagaccccga ggtccagttc
aactggtacg tggatggcgt ggaggtgcat 900aatgccaaga caaagccgcg
ggaggagcag ttcaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc
tgcaccagga ctggctgaac ggcaaggagt acaagtgcaa ggtctccaac
1020aaaggcctcc cgtcctccat cgagaaaacc atctccaaag ccaaagggca
gccccgagag 1080ccacaggtgt acaccctgcc cccatcccag gaggagatga
ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctaccccagc
gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa
gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca
ggctaaccgt ggacaagagc aggtggcagg aggggaatgt cttctcatgc
1320tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc
cctgtctctg 1380ggtaaagcta gtcagacccc caccaacacc atcagcgtga
cccccaccaa caacagcacc 1440cccaccaaca acagcaaccc caagcccaac
cccgctagtg catcacaaaa gcggccttca 1500caacggcacg gatctaaata
tctggcgaca gcctctacca tggatcacgc caggcatggc 1560tttctgccca
ggcacagaga tactggaatc ttggactcca tcggcaggtt ctttggcggc
1620gaccgagggg ctcccaagag agggagtggc aaggatagcc atcatccagc
ccgaacagcc 1680cactacggaa gcctgccgca gaaaagccac ggtcgcacgc
aggatgaaaa tcccgttgtg 1740cacttcttca aaaacattgt gaccccacga
actcctccac cttcccaagg caagggcaga 1800ggtctcagtc tcagccggtt
cagttggggg gccgagggcc agagacccgg atttggttat 1860gggggaaggg
ctagcgacta caagtctgca cataaggggt tcaaaggggt cgacgcacag
1920ggaaccctgt ccaaaatatt taagcttggt ggccgcgact cccgctcagg
ctctcccatg 1980gctcggcgct ga 199214645PRTArtificial
SequenceSynthetic sequence 14Asp Val Gln Leu Gln Glu Ser Gly Pro
Asp Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Thr
Val Thr Gly Tyr Ser Ile Thr Ser Gly 20 25 30 Tyr Ser Trp His Trp
Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr
Ile Leu Phe Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu 50 55 60 Lys
Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70
75 80 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Phe
Cys 85 90 95 Ala Arg Ser Asn Tyr Gly Ser Phe Ala Ser Trp Gly Gln
Gly Thr Leu 100 105 110 Val Thr Val Ser Ala Ala Lys Thr Thr Gly Pro
Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu
Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190
Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195
200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys
Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val
Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser
Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln
Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315
320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser Gln Thr 435 440
445 Pro Thr Asn Thr Ile Ser Val Thr Pro Thr Asn Asn Ser Thr Pro Thr
450 455 460 Asn Asn Ser Asn Pro Lys Pro Asn Pro Ala Ser Ala Ser Gln
Lys Arg 465 470 475 480 Pro Ser Gln Arg His Gly Ser Lys Tyr Leu Ala
Thr Ala Ser Thr Met 485 490 495 Asp His Ala Arg His Gly Phe Leu Pro
Arg His Arg Asp Thr Gly Ile 500 505 510 Leu Asp Ser Ile Gly Arg Phe
Phe Gly Gly Asp Arg Gly Ala Pro Lys 515 520 525 Arg Gly Ser Gly Lys
Asp Ser His His Pro Ala Arg Thr Ala His Tyr 530 535 540 Gly Ser Leu
Pro Gln Lys Ser His Gly Arg Thr Gln Asp Glu Asn Pro 545 550 555 560
Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro 565
570 575 Ser Gln Gly Lys Gly Arg Gly Leu Ser Leu Ser Arg Phe Ser Trp
Gly 580 585 590 Ala Glu Gly Gln Arg Pro Gly Phe Gly Tyr Gly Gly Arg
Ala Ser Asp 595 600 605 Tyr Lys Ser Ala His Lys Gly Phe Lys Gly Val
Asp Ala Gln Gly Thr 610 615 620 Leu Ser Lys Ile Phe Lys Leu Gly Gly
Arg Asp Ser Arg Ser Gly Ser 625 630 635 640 Pro Met Ala Arg Arg 645
15708DNAArtificial SequenceSynthetic sequence 15atggattttc
aagtgcagat tttcagcttc ctgctaatca gtgcctcagt cataatatcc 60agaggacaaa
ttgttctcac ccagtctcca gcaatcatgt ctgcatctcc aggggagaag
120gtcaccatga cctgcagtgc cagctcaagt gtaagtcaca tgcactggta
ccagcagaag 180tcaggcactt cccccaaaag atggatttat gacacatcca
gactggcttc tggagtccct 240gctcgcttca gtggcagtgg gtctgggacc
tcttactctc tcacaatcag cagcatggag 300gctgaagatg ctgccactta
ttactgccag cagtggagta gtcacccatg gtcgttcggt 360ggaggcacca
aactcgagat caaacgaact gtggctgcac catctgtctt catcttcccg
420ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct
gaataacttc 480tatcccagag aggccaaagt acagtggaag gtggataacg
ccctccaatc gggtaactcc 540caggagagtg tcacagagca ggacagcaag
gacagcacct acagcctcag cagcaccctg 600acgctgagca aagcagacta
cgagaaacac aaagtctatg cctgcgaagt cacccatcag 660ggcctgagct
cgcccgtcac aaagagcttc aacaggggag agtgttag 70816213PRTArtificial
SequenceSynthetic sequence 16Gln Ile Val Leu Thr Gln Ser Pro Ala
Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys
Ser Ala Ser Ser Ser Val Ser His Met 20 25 30 His Trp Tyr Gln Gln
Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 35 40 45 Asp Thr Ser
Arg Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly
Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 65 70
75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser His Pro Trp
Ser 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val
Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu Leu Asn Asn
Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys Val Asp Asn
Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser Val Thr Glu
Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 Thr Leu
Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195
200 205 Asn Arg Gly Glu Cys 210 171773DNAArtificial
SequenceSynthetic sequence 17atgagagcgc tgattctttt gtgcctgttc
acagcctttc ctggtatcct gtctgatgtg 60cagcttcagg agtcaggacc tgacctggtg
aaaccttctc agtcactttc actcacctgc 120actgtcactg gctactccat
caccagtggt tatagctggc actggatccg gcagtttcca 180ggaaacaaac
tggaatggat gggctacata ctcttcagtg gtagcactaa ctacaaccca
240tctctgaaaa gtcgaatctc tatcactcga gacacatcca agaaccagtt
cttcctgcag 300ttgaattctg tgactactga ggacacagcc acatatttct
gtgcaagatc taactatggt 360tcctttgctt cctggggcca agggactctg
gtcactgtct ctgcagccaa aacaacgggc 420ccatccgtct tccccctggc
gccctgctcc aggagcacct ccgagagcac agccgccctg 480ggctgcctgg
tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc
540ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact
ctactccctc 600agcagcgtgg tgaccgtgcc ctccagcagc ttgggcacga
agacctacac ctgcaacgta 660gatcacaagc ccagcaacac caaggtggac
aagagagttg agtccaaata tggtccccca 720tgcccaccct gcccagcacc
tgagttcgaa gggggaccat cagtcttcct gttcccccca 780aaacccaagg
acactctcat gatctcccgg acccctgagg tcacgtgcgt ggtggtggac
840gtgagccagg aagaccccga ggtccagttc aactggtacg tggatggcgt
ggaggtgcat 900aatgccaaga caaagccgcg ggaggagcag ttcaacagca
cgtaccgtgt ggtcagcgtc 960ctcaccgtcc tgcaccagga ctggctgaac
ggcaaggagt acaagtgcaa ggtctccaac 1020aaaggcctcc cgtcctccat
cgagaaaacc atctccaaag ccaaagggca gccccgagag 1080ccacaggtgt
acaccctgcc cccatcccag gaggagatga ccaagaacca ggtcagcctg
1140acctgcctgg tcaaaggctt ctaccccagc gacatcgccg tggagtggga
gagcaatggg 1200cagccggaga acaactacaa gaccacgcct cccgtgctgg
actccgacgg ctccttcttc 1260ctctacagca ggctaaccgt ggacaagagc
aggtggcagg aggggaatgt cttctcatgc 1320tccgtgatgc atgaggctct
gcacaaccac tacacacaga agagcctctc cctgtctctg 1380ggtaaagcta
gtggtcagtt tagagtcatt gggcccagac accctataag ggctcttgtg
1440ggagacgagg tcgagctgcc gtgtcgcatt agtccaggca aaaacgccac
agggatggaa 1500gtggggtggt acaggcctcc cttctctagg gttgtgcatc
tctaccgcaa cggcaaagat 1560caggatggag atcaagctcc tgaatatcgg
ggccggactg agctgctcaa ggacgcgatc 1620ggcgagggta aggtgacctt
gcgcatccga aatgttagat tcagcgatga aggcggattt 1680acgtgcttct
ttcgggacca ctcataccag gaggaagccg caatggaact gaaggtggag
1740gaccccttct attgggtatc cccagctagc tga 177318572PRTArtificial
SequenceSynthetic sequence 18Asp Val Gln Leu Gln Glu Ser Gly Pro
Asp Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Thr
Val Thr Gly Tyr Ser Ile Thr Ser Gly 20 25 30 Tyr Ser Trp His Trp
Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr
Ile Leu Phe Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu 50 55 60 Lys
Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70
75 80 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Phe
Cys 85 90 95 Ala Arg Ser Asn Tyr Gly Ser Phe Ala Ser Trp Gly Gln
Gly Thr Leu 100 105 110 Val Thr Val Ser Ala Ala Lys Thr Thr Gly Pro
Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu
Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190
Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn
195
200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys
Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val
Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser
Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln
Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315
320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser Gly Gln 435 440
445 Phe Arg Val Ile Gly Pro Arg His Pro Ile Arg Ala Leu Val Gly Asp
450 455 460 Glu Val Glu Leu Pro Cys Arg Ile Ser Pro Gly Lys Asn Ala
Thr Gly 465 470 475 480 Met Glu Val Gly Trp Tyr Arg Pro Pro Phe Ser
Arg Val Val His Leu 485 490 495 Tyr Arg Asn Gly Lys Asp Gln Asp Gly
Asp Gln Ala Pro Glu Tyr Arg 500 505 510 Gly Arg Thr Glu Leu Leu Lys
Asp Ala Ile Gly Glu Gly Lys Val Thr 515 520 525 Leu Arg Ile Arg Asn
Val Arg Phe Ser Asp Glu Gly Gly Phe Thr Cys 530 535 540 Phe Phe Arg
Asp His Ser Tyr Gln Glu Glu Ala Ala Met Glu Leu Lys 545 550 555 560
Val Glu Asp Pro Phe Tyr Trp Val Ser Pro Ala Ser 565 570
19708DNAArtificial SequenceSynthetic sequence 19atggattttc
aagtgcagat tttcagcttc ctgctaatca gtgcctcagt cataatatcc 60agaggacaaa
ttgttctcac ccagtctcca gcaatcatgt ctgcatctcc aggggagaag
120gtcaccatga cctgcagtgc cagctcaagt gtaagtcaca tgcactggta
ccagcagaag 180tcaggcactt cccccaaaag atggatttat gacacatcca
gactggcttc tggagtccct 240gctcgcttca gtggcagtgg gtctgggacc
tcttactctc tcacaatcag cagcatggag 300gctgaagatg ctgccactta
ttactgccag cagtggagta gtcacccatg gtcgttcggt 360ggaggcacca
aactcgagat caaacgaact gtggctgcac catctgtctt catcttcccg
420ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct
gaataacttc 480tatcccagag aggccaaagt acagtggaag gtggataacg
ccctccaatc gggtaactcc 540caggagagtg tcacagagca ggacagcaag
gacagcacct acagcctcag cagcaccctg 600acgctgagca aagcagacta
cgagaaacac aaagtctatg cctgcgaagt cacccatcag 660ggcctgagct
cgcccgtcac aaagagcttc aacaggggag agtgttag 70820213PRTArtificial
SequenceSynthetic sequence 20Gln Ile Val Leu Thr Gln Ser Pro Ala
Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys
Ser Ala Ser Ser Ser Val Ser His Met 20 25 30 His Trp Tyr Gln Gln
Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 35 40 45 Asp Thr Ser
Arg Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly
Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 65 70
75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser His Pro Trp
Ser 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val
Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu Leu Asn Asn
Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys Val Asp Asn
Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser Val Thr Glu
Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 Thr Leu
Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195
200 205 Asn Arg Gly Glu Cys 210 211002DNAArtificial
SequenceSynthetic sequence 21atggatccca aaggatccct ttcctggaga
atacttctgt ttctctccct ggcttttgag 60ttgagctacg gactcgacat cacatcccac
catcaccatc accatgacga tctggatgca 120gtaaggatta aagtggacac
agtaaatgca aaaccgggag acacagtaag aatacctgta 180agattcagcg
gtataccatc caagggaata gcaaactgtg actttgtata cagctatgac
240ccgaatgtac ttgagataat agagatagaa ccgggagaca taatagttga
cccgaatcct 300gacaagagct ttgatactgc agtatatcct gacagaaaga
taatagtatt cctgtttgca 360gaagacagcg gaacaggagc gtatgcaata
actaaagacg gagtatttgc tacgatagta 420gcgaaagtaa aagaaggagc
acctaacgga ctcagtgtaa tcaaatttgt agaagtaggc 480ggatttgcga
acaatgacct tgtagaacag aagacacagt tctttgacgg tggagtaaat
540gttggagata caacagaacc tgcaacacct acaacacctg taacaacacc
gacaacaaca 600gatgatctgg atgcagctag tggtcagttt agagtcattg
ggcccagaca ccctataagg 660gctcttgtgg gagacgaggt cgagctgccg
tgtcgcatta gtccaggcaa aaacgccaca 720gggatggaag tggggtggta
caggcctccc ttctctaggg ttgtgcatct ctaccgcaac 780ggcaaagatc
aggatggaga tcaagctcct gaatatcggg gccggactga gctgctcaag
840gacgcgatcg gcgagggtaa ggtgaccttg cgcatccgaa atgttagatt
cagcgatgaa 900ggcggattta cgtgcttctt tcgggaccac tcataccagg
aggaagccgc aatggaactg 960aaggtggagg accccttcta ttgggtatcc
ccagctagct ga 100222309PRTArtificial SequenceSynthetic sequence
22Leu Asp Ile Thr Ser His His His His His His Asp Asp Leu Asp Ala 1
5 10 15 Val Arg Ile Lys Val Asp Thr Val Asn Ala Lys Pro Gly Asp Thr
Val 20 25 30 Arg Ile Pro Val Arg Phe Ser Gly Ile Pro Ser Lys Gly
Ile Ala Asn 35 40 45 Cys Asp Phe Val Tyr Ser Tyr Asp Pro Asn Val
Leu Glu Ile Ile Glu 50 55 60 Ile Glu Pro Gly Asp Ile Ile Val Asp
Pro Asn Pro Asp Lys Ser Phe 65 70 75 80 Asp Thr Ala Val Tyr Pro Asp
Arg Lys Ile Ile Val Phe Leu Phe Ala 85 90 95 Glu Asp Ser Gly Thr
Gly Ala Tyr Ala Ile Thr Lys Asp Gly Val Phe 100 105 110 Ala Thr Ile
Val Ala Lys Val Lys Glu Gly Ala Pro Asn Gly Leu Ser 115 120 125 Val
Ile Lys Phe Val Glu Val Gly Gly Phe Ala Asn Asn Asp Leu Val 130 135
140 Glu Gln Lys Thr Gln Phe Phe Asp Gly Gly Val Asn Val Gly Asp Thr
145 150 155 160 Thr Glu Pro Ala Thr Pro Thr Thr Pro Val Thr Thr Pro
Thr Thr Thr 165 170 175 Asp Asp Leu Asp Ala Ala Ser Gly Gln Phe Arg
Val Ile Gly Pro Arg 180 185 190 His Pro Ile Arg Ala Leu Val Gly Asp
Glu Val Glu Leu Pro Cys Arg 195 200 205 Ile Ser Pro Gly Lys Asn Ala
Thr Gly Met Glu Val Gly Trp Tyr Arg 210 215 220 Pro Pro Phe Ser Arg
Val Val His Leu Tyr Arg Asn Gly Lys Asp Gln 225 230 235 240 Asp Gly
Asp Gln Ala Pro Glu Tyr Arg Gly Arg Thr Glu Leu Leu Lys 245 250 255
Asp Ala Ile Gly Glu Gly Lys Val Thr Leu Arg Ile Arg Asn Val Arg 260
265 270 Phe Ser Asp Glu Gly Gly Phe Thr Cys Phe Phe Arg Asp His Ser
Tyr 275 280 285 Gln Glu Glu Ala Ala Met Glu Leu Lys Val Glu Asp Pro
Phe Tyr Trp 290 295 300 Val Ser Pro Ala Ser 305 231098DNAArtificial
SequenceSynthetic sequence 23atgggcagca gccatcatca tcatcatcac
agcagcggcc tggtgccgcg cggcagccat 60atggctagta tggatctgga tgcagtaagg
attaaagtgg acacagtaaa tgcaaaaccg 120ggagacacag taaatatacc
tgtaagattc agtggtatac catccaaggg aatagcaaac 180tgtgactttg
tatacagcta tgacccgaat gtacttgaga taatagagat aaaaccggga
240gaattgatag ttgacccgaa tcctaccaag agctttgata ctgcagtata
tcctgacaga 300aagatgatag tattcctgtt tgcggaagac agcggaacag
gagcgtatgc aataactaaa 360gacggagtat ttgctacgat agtagcgaaa
gtaaaagaag gagcacctaa cgggctcagt 420gtaatcaaat ttgtagaagt
aggcggattt gcgaacaatg accttgtaga acagaagaca 480cagttctttg
acggtggagt aaatgttgga gatacaacag aacctgcaac acctacaaca
540cctgtaacaa caccgacaac aacagatgat ctagatgcag ctagtgcatc
acaaaagcgg 600ccttcacaac ggcacggatc taaatatctg gcgacagcct
ctaccatgga tcacgccagg 660catggctttc tgcccaggca cagagatact
ggaatcttgg actccatcgg caggttcttt 720ggcggcgacc gaggggctcc
caagagaggg agtggcaagg atagccatca tccagcccga 780acagcccact
acggaagcct gccgcagaaa agccacggtc gcacgcagga tgaaaatccc
840gttgtgcact tcttcaaaaa cattgtgacc ccacgaactc ctccaccttc
ccaaggcaag 900ggcagaggtc tcagtctcag ccggttcagt tggggggccg
agggccagag acccggattt 960ggttatgggg gaagggctag cgactacaag
tctgcacata aggggttcaa aggggtcgac 1020gcacagggaa ccctgtccaa
aatatttaag cttggtggcc gcgactcccg ctcaggctct 1080cccatggctc ggcgctga
109824365PRTArtificial SequenceSynthetic sequence 24Met Gly Ser Ser
His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly
Ser His Met Ala Ser Met Asp Leu Asp Ala Val Arg Ile Lys 20 25 30
Val Asp Thr Val Asn Ala Lys Pro Gly Asp Thr Val Asn Ile Pro Val 35
40 45 Arg Phe Ser Gly Ile Pro Ser Lys Gly Ile Ala Asn Cys Asp Phe
Val 50 55 60 Tyr Ser Tyr Asp Pro Asn Val Leu Glu Ile Ile Glu Ile
Lys Pro Gly 65 70 75 80 Glu Leu Ile Val Asp Pro Asn Pro Thr Lys Ser
Phe Asp Thr Ala Val 85 90 95 Tyr Pro Asp Arg Lys Met Ile Val Phe
Leu Phe Ala Glu Asp Ser Gly 100 105 110 Thr Gly Ala Tyr Ala Ile Thr
Lys Asp Gly Val Phe Ala Thr Ile Val 115 120 125 Ala Lys Val Lys Glu
Gly Ala Pro Asn Gly Leu Ser Val Ile Lys Phe 130 135 140 Val Glu Val
Gly Gly Phe Ala Asn Asn Asp Leu Val Glu Gln Lys Thr 145 150 155 160
Gln Phe Phe Asp Gly Gly Val Asn Val Gly Asp Thr Thr Glu Pro Ala 165
170 175 Thr Pro Thr Thr Pro Val Thr Thr Pro Thr Thr Thr Asp Asp Leu
Asp 180 185 190 Ala Ala Ser Ala Ser Gln Lys Arg Pro Ser Gln Arg His
Gly Ser Lys 195 200 205 Tyr Leu Ala Thr Ala Ser Thr Met Asp His Ala
Arg His Gly Phe Leu 210 215 220 Pro Arg His Arg Asp Thr Gly Ile Leu
Asp Ser Ile Gly Arg Phe Phe 225 230 235 240 Gly Gly Asp Arg Gly Ala
Pro Lys Arg Gly Ser Gly Lys Asp Ser His 245 250 255 His Pro Ala Arg
Thr Ala His Tyr Gly Ser Leu Pro Gln Lys Ser His 260 265 270 Gly Arg
Thr Gln Asp Glu Asn Pro Val Val His Phe Phe Lys Asn Ile 275 280 285
Val Thr Pro Arg Thr Pro Pro Pro Ser Gln Gly Lys Gly Arg Gly Leu 290
295 300 Ser Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro Gly
Phe 305 310 315 320 Gly Tyr Gly Gly Arg Ala Ser Asp Tyr Lys Ser Ala
His Lys Gly Phe 325 330 335 Lys Gly Val Asp Ala Gln Gly Thr Leu Ser
Lys Ile Phe Lys Leu Gly 340 345 350 Gly Arg Asp Ser Arg Ser Gly Ser
Pro Met Ala Arg Arg 355 360 365 251785DNAArtificial
SequenceSynthetic sequence 25atggaatgga gcggggtctt tatctttctc
ctgtcagtaa ctgcaggtgc ccactcccag 60gtccagctgc agcagtctgg agctgagctg
gtaaggcctg ggacttcagt gaagatgtcc 120tgcgaggctg ctagattcac
cttcagtaac tactggattg gttgggtaaa gcagaggcct 180ggacatggcc
ttgagtggat tggagatatt ttccctggag gtgattatac taactacaat
240aagaaattca aggacaaggc cacactgact gcagacacat cctccagcac
agcctacatg 300cagctcagca gcctgacatc tgaggactct gccatctatt
actgtgcaag atcggactac 360ggtggttact acgtctttga ctactggggc
caaggcacca ctctcacagt ctcctcagcc 420aaaacaaagg gcccatccgt
cttccccctg gcgccctgct ccaggagcac ctccgagagc 480acagccgccc
tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg
540aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca
gtcctcagga 600ctctactccc tcagcagcgt ggtgaccgtg ccctccagca
gcttgggcac gaagacctac 660acctgcaacg tagatcacaa gcccagcaac
accaaggtgg acaagagagt tgagtccaaa 720tatggtcccc catgcccacc
ctgcccagca cctgagttcg aagggggacc atcagtcttc 780ctgttccccc
caaaacccaa ggacactctc atgatctccc ggacccctga ggtcacgtgc
840gtggtggtgg acgtgagcca ggaagacccc gaggtccagt tcaactggta
cgtggatggc 900gtggaggtgc ataatgccaa gacaaagccg cgggaggagc
agttcaacag cacgtaccgt 960gtggtcagcg tcctcaccgt cctgcaccag
gactggctga acggcaagga gtacaagtgc 1020aaggtctcca acaaaggcct
cccgtcctcc atcgagaaaa ccatctccaa agccaaaggg 1080cagccccgag
agccacaggt gtacaccctg cccccatccc aggaggagat gaccaagaac
1140caggtcagcc tgacctgcct ggtcaaaggc ttctacccca gcgacatcgc
cgtggagtgg 1200gagagcaatg ggcagccgga gaacaactac aagaccacgc
ctcccgtgct ggactccgac 1260ggctccttct tcctctacag caggctaacc
gtggacaaga gcaggtggca ggaggggaat 1320gtcttctcat gctccgtgat
gcatgaggct ctgcacaacc actacacaca gaagagcctc 1380tccctgtctc
tgggtaaagc tagtggtcag tttagagtca ttgggcccag acaccctata
1440agggctcttg tgggagacga ggtcgagctg ccgtgtcgca ttagtccagg
caaaaacgcc 1500acagggatgg aagtggggtg gtacaggcct cccttctcta
gggttgtgca tctctaccgc 1560aacggcaaag atcaggatgg agatcaagct
cctgaatatc ggggccggac tgagctgctc 1620aaggacgcga tcggcgaggg
taaggtgacc ttgcgcatcc gaaatgttag attcagcgat 1680gaaggcggat
ttacgtgctt ctttcgggac cactcatacc aggaggaagc cgcaatggaa
1740ctgaaggtgg aggacccctt ctattgggta tccccagcta gctga
178526575PRTArtificial SequenceSynthetic sequence 26Gln Val Gln Leu
Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 1 5 10 15 Ser Val
Lys Met Ser Cys Glu Ala Ala Arg Phe Thr Phe Ser Asn Tyr 20 25 30
Trp Ile Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35
40 45 Gly Asp Ile Phe Pro Gly Gly Asp Tyr Thr Asn Tyr Asn Lys Lys
Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser
Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser
Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Ser Asp Tyr Gly Gly Tyr Tyr
Val Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser
Ser Ala Lys Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro
Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165
170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu
Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu
Phe Glu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr
Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr
Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly
Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375
380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu
Ser Leu Ser Leu Gly Lys Ala 435 440 445 Ser Gly Gln Phe Arg Val Ile
Gly Pro Arg His Pro Ile Arg Ala Leu 450 455 460 Val Gly Asp Glu Val
Glu Leu Pro Cys Arg Ile Ser Pro Gly Lys Asn 465 470 475 480 Ala Thr
Gly Met Glu Val Gly Trp Tyr Arg Pro Pro Phe Ser Arg Val 485 490 495
Val His Leu Tyr Arg Asn Gly Lys Asp Gln Asp Gly Asp Gln Ala Pro 500
505 510 Glu Tyr Arg Gly Arg Thr Glu Leu Leu Lys Asp Ala Ile Gly Glu
Gly 515 520 525 Lys Val Thr Leu Arg Ile Arg Asn Val Arg Phe Ser Asp
Glu Gly Gly 530 535 540 Phe Thr Cys Phe Phe Arg Asp His Ser Tyr Gln
Glu Glu Ala Ala Met 545 550 555 560 Glu Leu Lys Val Glu Asp Pro Phe
Tyr Trp Val Ser Pro Ala Ser 565 570 575 27729DNAArtificial
SequenceSynthetic sequence 27atggattcac aggcccaggt tcttatgtta
ctgctgctat gggtatctgg tacctgtggg 60gacattgtga tgtcacagtc tccatcctcc
ctagctgtgt cagttggaga gaaggttact 120atgagctgca agtccagtca
gaacctttta tatagtagca atcaaaagaa ctacttggcc 180tggtaccagc
agaaaccagg gcagtctcct aaactgctga tttactgggc atccactagg
240gaatctgggg tccctgatcg cttcacaggc agtggatctg ggacagattt
cactctcacc 300atcagcagtg tgaaggctga agacctggca gtctattact
gtcagcaata ttatagctat 360ccttacacgt tcggaggggg gaccaagctc
gagatcaaac gaactgtggc tgcaccatct 420gtcttcatct tcccgccatc
tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc 480ctgctgaata
acttctatcc cagagaggcc aaagtacagt ggaaggtgga taacgccctc
540caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag
cacctacagc 600ctcagcagca ccctgacgct gagcaaagca gactacgaga
aacacaaagt ctatgcctgc 660gaagtcaccc atcagggcct gagctcgccc
gtcacaaaga gcttcaacag gggagagtgt 720gctagctga 72928222PRTArtificial
SequenceSynthetic sequence 28Asp Ile Val Met Ser Gln Ser Pro Ser
Ser Leu Ala Val Ser Val Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys
Lys Ser Ser Gln Asn Leu Leu Tyr Ser 20 25 30 Ser Asn Gln Lys Asn
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Ser Pro Lys
Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro
Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70
75 80 Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln
Gln 85 90 95 Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys
Leu Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser
Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys
Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190
Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195
200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ala Ser 210
215 220 291776DNAArtificial SequenceSynthetic sequence 29atggcttggg
tgtggacctt gctattcctg atggcagccg cccaaagtat ccaagcacag 60atccagttgg
tgcagtctgg acctgagctg aagaagcctg gagagacagt caagatctcc
120tgcaaggctt ctggttatac cttcacagac tattcagtgc actgggtgaa
gcaggctcca 180ggaaagggtt taaagtggat gggctggata aatactgaga
ctggtgagcc aacatatgca 240gatgacctca agggacggtt tgccttctct
ttggaaacct ctgccagcac tgcctatttg 300cagatcaaca acctcaaaaa
tgaggacacg gctacatatt tctgtgctaa acctacctat 360agattttttg
actactgggg ccaaggcacc actctcacag cctcctcagc caaaacgaag
420ggcccatccg tcttccccct ggcgccctgc tccaggagca cctccgagag
cacagccgcc 480ctgggctgcc tggtcaagga ctacttcccc gaaccggtga
cggtgtcgtg gaactcaggc 540gccctgacca gcggcgtgca caccttcccg
gctgtcctac agtcctcagg actctactcc 600ctcagcagcg tggtgaccgt
gccctccagc agcttgggca cgaagaccta cacctgcaac 660gtagatcaca
agcccagcaa caccaaggtg gacaagagag ttgagtccaa atatggtccc
720ccatgcccac cctgcccagc acctgagttc gaagggggac catcagtctt
cctgttcccc 780ccaaaaccca aggacactct catgatctcc cggacccctg
aggtcacgtg cgtggtggtg 840gacgtgagcc aggaagaccc cgaggtccag
ttcaactggt acgtggatgg cgtggaggtg 900cataatgcca agacaaagcc
gcgggaggag cagttcaaca gcacgtaccg tgtggtcagc 960gtcctcaccg
tcctgcacca ggactggctg aacggcaagg agtacaagtg caaggtctcc
1020aacaaaggcc tcccgtcctc catcgagaaa accatctcca aagccaaagg
gcagccccga 1080gagccacagg tgtacaccct gcccccatcc caggaggaga
tgaccaagaa ccaggtcagc 1140ctgacctgcc tggtcaaagg cttctacccc
agcgacatcg ccgtggagtg ggagagcaat 1200gggcagccgg agaacaacta
caagaccacg cctcccgtgc tggactccga cggctccttc 1260ttcctctaca
gcaggctaac cgtggacaag agcaggtggc aggaggggaa tgtcttctca
1320tgctccgtga tgcatgaggc tctgcacaac cactacacac agaagagcct
ctccctgtct 1380ctgggtaaag ctagtggtca gtttagagtc attgggccca
gacaccctat aagggctctt 1440gtgggagacg aggtcgagct gccgtgtcgc
attagtccag gcaaaaacgc cacagggatg 1500gaagtggggt ggtacaggcc
tcccttctct agggttgtgc atctctaccg caacggcaaa 1560gatcaggatg
gagatcaagc tcctgaatat cggggccgga ctgagctgct caaggacgcg
1620atcggcgagg gtaaggtgac cttgcgcatc cgaaatgtta gattcagcga
tgaaggcgga 1680tttacgtgct tctttcggga ccactcatac caggaggaag
ccgcaatgga actgaaggtg 1740gaggacccct tctattgggt atccccagct agctga
177630573PRTArtificial SequenceSynthetic sequence 30Ala Gln Ile Gln
Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly 1 5 10 15 Glu Thr
Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp 20 25 30
Tyr Ser Val His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp 35
40 45 Met Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp
Asp 50 55 60 Leu Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala
Ser Thr Ala 65 70 75 80 Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp
Thr Ala Thr Tyr Phe 85 90 95 Cys Ala Lys Pro Thr Tyr Arg Phe Phe
Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Ala Ser Ser Ala
Lys Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Cys Ser
Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165
170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
Ser 180 185 190 Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His
Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
Tyr Gly Pro Pro Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Phe Glu
Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val
Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 260 265 270 Phe Asn
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285
Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290
295 300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Lys 305 310 315 320 Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys
Thr Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser 340 345 350 Gln Glu Glu Met Thr Lys Asn Gln
Val Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 Ser
Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410
415 Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
420 425 430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala
Ser Gly 435 440 445 Gln Phe Arg Val Ile Gly Pro Arg His Pro Ile Arg
Ala Leu Val Gly 450 455 460 Asp Glu Val Glu Leu Pro Cys Arg Ile Ser
Pro Gly Lys Asn Ala Thr 465 470 475 480 Gly Met Glu Val Gly Trp Tyr
Arg Pro Pro Phe Ser Arg Val Val His 485 490 495 Leu Tyr Arg Asn Gly
Lys Asp Gln Asp Gly Asp Gln Ala Pro Glu Tyr 500 505 510 Arg Gly Arg
Thr Glu Leu Leu Lys Asp Ala Ile Gly Glu Gly Lys Val 515 520 525 Thr
Leu Arg Ile Arg Asn Val Arg Phe Ser Asp Glu Gly Gly Phe Thr 530 535
540 Cys Phe Phe Arg Asp His Ser Tyr Gln Glu Glu Ala Ala Met Glu Leu
545 550 555 560 Lys Val Glu Asp Pro Phe Tyr Trp Val Ser Pro Ala Ser
565 570 31726DNAArtificial SequenceSynthetic sequence 31atggattcac
aggcccaggt tcttatattg ctgctgctat gggtatctgg ttcctgtggg 60gacattgtga
tgtcacagtc tccatcctcc ctggctgtgt cagcaggaga gaaggtcact
120atgagctgca aatccagtca gagtctgctc aacagtagaa cccgaaagaa
ctacttggct 180tggtaccagc agaaaccagg gcagtctcct aaactgctga
tctactgggc atccactagg 240gaatctgggg tccctgatcg cttcacaggc
agtggatctg ggacagattt cactctcacc 300atcagcagtg tgcaggctga
ggacctggca gtttattact gcaagcaatc ttataatctg 360tggacgttcg
gtggaggcac caagctcgag atcaaacgaa ctgtggctgc accatctgtc
420ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt
tgtgtgcctg 480ctgaataact tctatcccag agaggccaaa gtacagtgga
aggtggataa cgccctccaa 540tcgggtaact cccaggagag tgtcacagag
caggacagca aggacagcac ctacagcctc 600agcagcaccc tgacgctgag
caaagcagac tacgagaaac acaaagtcta tgcctgcgaa 660gtcacccatc
agggcctgag ctcgcccgtc acaaagagct tcaacagggg agagtgtgct 720agctga
72632221PRTArtificial SequenceSynthetic sequence 32Asp Ile Val Met
Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly 1 5 10 15 Glu Lys
Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30
Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35
40 45 Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly
Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val
Tyr Tyr Cys Lys Gln 85 90 95 Ser Tyr Asn Leu Trp Thr Phe Gly Gly
Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser
Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165
170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
Ala Ser 210 215 220 3327PRTArtificial SequenceSynthetic sequence
33Gln Thr Pro Thr Asn Thr Ile Ser Val Thr Pro Thr Asn Asn Ser Thr 1
5 10 15 Pro Thr Asn Asn Ser Asn Pro Lys Pro Asn Pro 20 25
34123PRTArtificial SequenceSynthetic sequence 34Pro Ser Glu Thr Pro
Glu Glu Pro Ile Pro Thr Asp Thr Pro Ser Asp 1 5 10 15 Glu Pro Thr
Pro Ser Asp Glu Pro Thr Pro Ser Asp Glu Pro Thr Pro 20 25 30 Ser
Asp Glu Pro Thr Pro Ser Asp Glu Pro Thr Pro Ser Asp Glu Pro 35 40
45 Thr Pro Ser Asp Glu Pro Thr Pro Ser Glu Thr Pro Glu Glu Pro Thr
50 55 60 Pro Thr Thr Thr Pro Thr Pro Thr Pro Ser Thr Thr Pro Thr
Ser Gly 65 70 75 80 Ser Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Gly 85 90 95 Thr Val Pro Thr Ser Pro Thr Pro Thr Pro
Thr Ser Lys Pro Thr Ser 100 105 110 Thr Pro Ala Pro Thr Glu Ile Glu
Glu Pro Thr 115 120 35124PRTArtificial SequenceSynthetic sequence
35Asp Glu Pro Ile Pro Thr Asp Thr Pro Ser Asp Glu Pro Thr Pro Ser 1
5 10 15 Asp Glu Pro Thr Pro Ser Asp Glu Pro Thr Pro Ser Asp Glu Pro
Thr 20 25 30 Pro Ser Asp Glu Pro Thr Pro Ser Glu Thr Pro Glu Glu
Pro Ile Pro 35 40 45 Thr Asp Thr Pro Ser Asp Glu Pro Thr Pro Ser
Asp Glu Pro Thr Pro 50 55 60 Ser Asp Glu Pro Thr Pro Ser Asp Glu
Pro Thr Pro Ser Asp Glu Pro 65 70 75 80 Thr Pro Ser Glu Thr Pro Glu
Glu Pro Ile Pro Thr Asp Thr Pro Ser 85 90 95 Asp Glu Pro Thr Pro
Ser Asp Glu Pro Thr Pro Ser Asp Glu Pro Thr 100 105 110 Pro Ser Asp
Glu Pro Thr Pro Ser Asp Glu Pro Thr 115 120 36168PRTArtificial
SequenceSynthetic sequence 36Gln Lys Arg Pro Ser Gln Arg His Gly
Ser Lys Tyr Leu Ala Thr Ala 1 5 10 15 Ser Thr Met Asp His Ala Arg
His Gly Phe Leu Pro Arg His Arg Asp 20 25 30 Thr Gly Ile Leu Asp
Ser Ile Gly Arg Phe Phe Gly Gly Asp Arg Gly 35 40 45 Ala Pro Lys
Arg Gly Ser Gly Lys Asp Ser His His Pro Ala Arg Thr 50 55 60 Ala
His Tyr Gly Ser Leu Pro Gln Lys Ser His Gly Arg Thr Gln Asp 65 70
75 80 Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg
Thr 85 90 95 Pro Pro Pro Ser Gln Gly Lys Gly Arg Gly Leu Ser Leu
Ser Arg Phe 100 105 110 Ser Trp Gly Ala Glu Gly Gln Arg Pro Gly Phe
Gly Tyr Gly Gly Arg 115 120 125 Ala Ser Asp Tyr Lys Ser Ala His Lys
Gly Phe Lys Gly Val
Asp Ala 130 135 140 Gln Gly Thr Leu Ser Lys Ile Phe Lys Leu Gly Gly
Arg Asp Ser Arg 145 150 155 160 Ser Gly Ser Pro Met Ala Arg Arg 165
37124PRTArtificial SequenceSynthetic sequence 37Gly Gln Phe Arg Val
Ile Gly Pro Arg His Pro Ile Arg Ala Leu Val 1 5 10 15 Gly Asp Glu
Val Glu Leu Pro Cys Arg Ile Ser Pro Gly Lys Asn Ala 20 25 30 Thr
Gly Met Glu Val Gly Trp Tyr Arg Pro Pro Phe Ser Arg Val Val 35 40
45 His Leu Tyr Arg Asn Gly Lys Asp Gln Asp Gly Asp Gln Ala Pro Glu
50 55 60 Tyr Arg Gly Arg Thr Glu Leu Leu Lys Asp Ala Ile Gly Glu
Gly Lys 65 70 75 80 Val Thr Leu Arg Ile Arg Asn Val Arg Phe Ser Asp
Glu Gly Gly Phe 85 90 95 Thr Cys Phe Phe Arg Asp His Ser Tyr Gln
Glu Glu Ala Ala Met Glu 100 105 110 Leu Lys Val Glu Asp Pro Phe Tyr
Trp Val Ser Pro 115 120 38169PRTArtificial SequenceSynthetic
sequence 38Asp Leu Asp Ala Val Arg Ile Lys Val Asp Thr Val Asn Ala
Lys Pro 1 5 10 15 Gly Asp Thr Val Arg Ile Pro Val Arg Phe Ser Gly
Ile Pro Ser Lys 20 25 30 Gly Ile Ala Asn Cys Asp Phe Val Tyr Ser
Tyr Asp Pro Asn Val Leu 35 40 45 Glu Ile Ile Glu Ile Glu Pro Gly
Asp Ile Ile Val Asp Pro Asn Pro 50 55 60 Asp Lys Ser Phe Asp Thr
Ala Val Tyr Pro Asp Arg Lys Ile Ile Val 65 70 75 80 Phe Leu Phe Ala
Glu Asp Ser Gly Thr Gly Ala Tyr Ala Ile Thr Lys 85 90 95 Asp Gly
Val Phe Ala Thr Ile Val Ala Lys Val Lys Glu Gly Ala Pro 100 105 110
Asn Gly Leu Ser Val Ile Lys Phe Val Glu Val Gly Gly Phe Ala Asn 115
120 125 Asn Asp Leu Val Glu Gln Lys Thr Gln Phe Phe Asp Gly Gly Val
Asn 130 135 140 Val Gly Asp Thr Thr Glu Pro Ala Thr Pro Thr Thr Pro
Val Thr Thr 145 150 155 160 Pro Thr Thr Thr Asp Asp Leu Asp Ala 165
3963PRTArtificial SequenceSynthetic sequence 39Gly Asp Val Asn Asp
Asp Gly Lys Val Asn Ser Thr Asp Leu Thr Leu 1 5 10 15 Leu Lys Arg
Tyr Val Leu Lys Ala Val Ser Thr Leu Pro Ser Ser Lys 20 25 30 Ala
Glu Lys Asn Ala Asp Val Asn Arg Asp Gly Arg Val Asp Val Thr 35 40
45 Ile Leu Ser Arg Tyr Leu Ile Arg Val Ile Glu Lys Leu Pro Ile 50
55 60 40230PRTArtificial SequenceSynthetic sequence 40Ile Glu Arg
Leu Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp 1 5 10 15 Ala
Ala Gly Gln Ala Ile Ala Asn Arg Phe Thr Ala Asn Ile Lys Gly 20 25
30 Leu Thr Gln Ala Ser Arg Asn Ala Asn Asp Gly Ile Ser Ile Ala Gln
35 40 45 Thr Thr Glu Gly Ala Leu Asn Glu Ile Asn Asn Asn Leu Gln
Arg Val 50 55 60 Arg Glu Leu Ala Val Gln Ser Ala Asn Ser Thr Asn
Ser Gln Ser Asp 65 70 75 80 Leu Asp Ser Ile Gln Ala Glu Ile Thr Gln
Arg Leu Asn Glu Ile Asp 85 90 95 Arg Val Ser Gly Gln Thr Gln Phe
Asn Gly Val Lys Val Leu Ala Gln 100 105 110 Asp Asn Thr Leu Thr Ile
Gln Val Gly Ala Asn Asp Gly Glu Thr Ile 115 120 125 Asp Ile Asp Leu
Lys Gln Ile Asn Ser Gln Thr Leu Gly Leu Asp Ser 130 135 140 Leu Asn
Val Gln Ala Ser Gln Pro Glu Leu Ala Glu Ala Ala Ala Lys 145 150 155
160 Thr Thr Glu Asn Pro Leu Gln Lys Ile Asp Ala Ala Leu Ala Gln Val
165 170 175 Asp Ala Leu Arg Ser Asp Leu Gly Ala Val Gln Asn Arg Phe
Asn Ser 180 185 190 Ala Ile Thr Asn Leu Gly Asn Thr Val Asn Asn Leu
Ser Glu Ala Arg 195 200 205 Ser Arg Ile Glu Asp Ser Asp Tyr Ala Thr
Glu Val Ser Asn Met Ser 210 215 220 Arg Ala Gln Ile Leu Gln 225 230
41159PRTArtificial SequenceSynthetic sequence 41Pro Gly Gln Gly Thr
Gln Ser Glu Asn Ser Cys Thr His Phe Pro Gly 1 5 10 15 Asn Leu Pro
Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg Val 20 25 30 Lys
Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu Lys 35 40
45 Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala Leu
50 55 60 Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln
Ala Glu 65 70 75 80 Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser
Leu Gly Glu Asn 85 90 95 Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg
Cys His Arg Phe Leu Pro 100 105 110 Cys Glu Asn Lys Ser Lys Ala Val
Glu Gln Val Lys Asn Ala Phe Asn 115 120 125 Lys Leu Gln Glu Lys Gly
Ile Tyr Lys Ala Met Ser Glu Phe Asp Ile 130 135 140 Phe Ile Asn Tyr
Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 145 150 155
42446PRTArtificial SequenceSynthetic sequence 42Asp Val Gln Leu Gln
Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser
Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly 20 25 30 Tyr
Ser Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40
45 Met Gly Tyr Ile Leu Phe Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln
Phe Phe 65 70 75 80 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala
Thr Tyr Phe Cys 85 90 95 Ala Arg Ser Asn Tyr Gly Ser Phe Ala Ser
Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ala Ala Lys Thr
Thr Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170
175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro
Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly
Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly
Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg
Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295
300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe
Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420
425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 435
440 445 43213PRTArtificial SequenceSynthetic sequence 43Gln Ile Val
Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu
Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser His Met 20 25
30 His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
35 40 45 Asp Thr Ser Arg Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser
Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
Ser Ser His Pro Trp Ser 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155
160 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
Tyr Ala 180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
Thr Lys Ser Phe 195 200 205 Asn Arg Gly Glu Cys 210
44446PRTArtificial SequenceSynthetic sequence 44Val Gln Leu Gln Gln
Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser 1 5 10 15 Val Lys Met
Ser Cys Glu Ala Ala Arg Phe Thr Phe Ser Asn Tyr Trp 20 25 30 Ile
Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly 35 40
45 Asp Ile Phe Pro Gly Gly Asp Tyr Thr Asn Tyr Asn Lys Lys Phe Lys
50 55 60 Asp Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala
Tyr Met 65 70 75 80 Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile
Tyr Tyr Cys Ala 85 90 95 Arg Ser Asp Tyr Gly Gly Tyr Tyr Val Phe
Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser Ala
Lys Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Cys Ser
Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170
175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190 Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His
Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
Tyr Gly Pro Pro 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu
Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val
Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 260 265 270 Gln Phe Asn
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys
Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val 290 295
300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305 310 315 320 Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys
Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro 340 345 350 Ser Gln Glu Glu Met Thr Lys Asn Gln
Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser
Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 405 410 415
Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420
425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435
440 445 45220PRTArtificial SequenceSynthetic sequence 45Asp Ile Val
Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly 1 5 10 15 Glu
Lys Val Thr Met Ser Cys Lys Ser Ser Gln Asn Leu Leu Tyr Ser 20 25
30 Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45 Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser
Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Lys Ala Glu Asp Leu Ala
Val Tyr Tyr Cys Gln Gln 85 90 95 Tyr Tyr Ser Tyr Pro Tyr Thr Phe
Gly Gly Gly Thr Lys Leu Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155
160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His
Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly
Glu Cys 210 215 220 46445PRTArtificial SequenceSynthetic sequence
46Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly 1
5 10 15 Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
Asp 20 25 30 Tyr Ser Val His Trp Val Lys Gln Ala Pro Gly Lys Gly
Leu Lys Trp 35 40 45 Met Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro
Thr Tyr Ala Asp Asp 50 55 60 Leu Lys Gly Arg Phe Ala Phe Ser Leu
Glu Thr Ser Ala Ser Thr Ala 65 70 75 80 Tyr Leu Gln Ile Asn Asn Leu
Lys Asn Glu Asp Thr Ala Thr Tyr Phe 85 90 95 Cys Ala Lys Pro Thr
Tyr Arg Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr
Ala Ser Ser Ala Lys Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val
His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser
Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr
Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 195 200 205 Asn Thr
Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys 210 215 220
Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu 225
230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu 245 250 255 Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp
Pro Glu Val Gln 260 265 270 Phe Asn Trp Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys 275 280 285 Pro Arg Glu Glu Gln Phe Asn Ser
Thr Tyr Arg Val Val Ser Val Leu 290 295 300 Thr Val Leu His Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320 Val Ser Asn
Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys 325 330 335 Ala
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 340 345
350 Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly 385 390 395 400 Ser Phe Phe Leu Tyr Ser Arg Leu Thr
Val Asp Lys Ser Arg Trp Gln 405 410 415 Glu Gly Asn Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 47219PRTArtificial
SequenceSynthetic sequence 47Asp Ile Val Met Ser Gln Ser Pro Ser
Ser Leu Ala Val Ser Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys
Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Arg Thr Arg Lys Asn
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Ser Pro Lys
Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro
Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70
75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys
Gln 85 90 95 Ser Tyr Asn Leu Trp Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val
Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val
Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser
Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr
Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195
200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215
48449PRTArtificial SequenceSynthetic sequence 48Gln Ile Gln Leu Val
Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys
Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly
Met Asn Trp Val Lys Gln Val Pro Gly Lys Gly Leu Arg Trp Met 35 40
45 Gly Trp Met Asp Thr Phe Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr
Ala Tyr 65 70 75 80 Leu Gln Ile Asn Ser Leu Lys Asn Glu Asp Thr Ala
Thr Tyr Phe Cys 85 90 95 Ala Arg Gly Gly Ile Leu Arg Leu Asn Tyr
Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser
Ala Lys Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170
175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp
His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser
Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe
Glu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys
Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr
Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295
300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly
Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420
425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
Ala 435 440 445 Ser 49214PRTArtificial SequenceSynthetic sequence
49Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 1
5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn
Arg 20 25 30 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg
Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Ala Leu
Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Leu Ala Thr Tyr Tyr
Cys Gln Gln Cys Trp Thr Ser Pro Tyr 85 90 95 Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val
Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135
140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu
Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210
50445PRTArtificial SequenceSynthetic sequence 50Glu Val Gln Leu Gln
Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr
Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40
45 Gly Asp Ile Asn Pro Asn Tyr Gly Asp Thr Phe Tyr Asn Gln Lys Phe
50 55 60 Glu Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg Thr
Ala Tyr 65 70 75 80 Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala
Val Tyr Tyr Cys 85 90 95 Gly Arg Gly Asp Tyr Gly Tyr Phe Asp Val
Trp Gly Ala Gly Thr Thr 100 105 110 Val Thr Val Ser Ser Ala Lys Thr
Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170
175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro
Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly
Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly
Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg
Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295
300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe
Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420
425 430 Tyr Thr Gln Lys Ser Leu Leu Ser Leu Gly Lys Ala Ser 435 440
445 51214PRTArtificial SequenceSynthetic sequence 51Asp Ile Val Met
Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg
Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala 20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35
40 45 Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn
Val Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr
Ser Ser Asn Pro Tyr 85 90 95 Met Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165
170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210
52447PRTArtificial SequenceSynthetic sequence 52Gln Leu Gln Gln Ser
Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val 1 5 10 15 Lys Ile Ser
Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met 20 25 30 His
Trp Val Arg Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly 35 40
45 Ile Asn Pro Ile Asn Gly Gly Pro Thr Tyr Asn Gln Lys Phe Lys Gly
50 55 60 Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
Met Glu 65 70 75 80 Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr Cys Ala Arg 85 90 95 Trp Asp Tyr Gly Ser Arg Asp Val Met Asp
Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser Ala Lys
Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Cys Ser Arg
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170
175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
180 185 190 Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr
Gly Pro Pro Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly
Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys Asp
Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val
Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 260 265 270 Phe Asn Trp
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro
Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295
300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
305 310 315 320 Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr
Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser 340 345 350 Gln Glu Glu Met Thr Lys Asn Gln Val
Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 Ser Phe
Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415
Glu Gly Asn Val Phe Ser Cys Ser
Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys Ser
Leu Ser Leu Ser Leu Gly Lys Ala Ser 435 440 445 53214PRTArtificial
SequenceSynthetic sequence 53Asn Ile Val Met Thr Gln Ser Pro Lys
Ser Met Ser Met Ser Val Gly 1 5 10 15 Glu Arg Val Thr Leu Ser Cys
Lys Ala Ser Glu Asn Val Gly Thr Tyr 20 25 30 Val Ser Trp Tyr Gln
Gln Arg Pro Glu Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala
Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser
Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala 65 70
75 80 Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Thr Tyr Ser Tyr Ile
Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Thr
Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn
Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp
Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr
Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr
Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195
200 205 Phe Asn Arg Gly Glu Cys 210
* * * * *